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ABSTRACT
Besides	malignant	 cells,	 tumours	 are	 composed	 of	 vascular,	 hematopoietic	 and	
mesenchymal	cells,	amongst	which	in	particular	macrophages	can	be	found	numer-
ously	within	the	tumour	infiltrate.	So	called	tumour-associated	macro	phages	(TAM)	
exert	 important	 tumour-supportive	roles	and	are	 involved	 in	tumour	 initiation,	
progression	 and	 metastasis	 as	 providers	 of	 angiogenic,	 anti-	inflammatory	 and	
matrix	remodelling	factors.	In	numerous	different	cancers,	high	TAM	density	cor-
relates	with	poor	patient	prognosis.	The	plasticity	of	gene	regulation	allows	macro-
phages	to	adapt	their	phenotype	to	local	requirements.	Therefore	TAM	populations	
are	highly	heterogeneous	and	adapt	to	the	corresponding	microenvironment	of	
the	particular	tumour	region.	The	identification	of	further	TAM	macrophage	mar-
kers	is	indispensable	regarding	the	necessity	of	functional	characterization	of	dis-
tinct	TAM	subsets.	
In	 the	past	 years,	 our	 group	has	 identified	Ms4a8a,	 Stabilin-1	 and	Lyve-1	 as	
novel	markers	 of	murine	 TAM.	 In vitro,	 Lyve-1	 expression	 could	 be	 induced	 in	
murine	bone	marrow	derived	macrophages	by	the	stimulation	with	tumour	condi-
tioned	medium,	dexamethasone	and	IL-4.	In	this	thesis	the	main	aim	was	to	com-
prehensively	characterize	expression	and	processing	of	Lyve-1	in	macrophages	in 
vitro	and	in vivo.	The	type I	transmembrane	glycoprotein	Lyve-1	is	part	of	the	link	
	domain	 superfamily	with	 43	%	 sequence	 homology	 to	 the	 hyaluronan	 receptor	
CD44.	Lyve-1	has	first	been	identified	as	a	lymphatic	endothelial	cell	specific	HA	
receptor	which	also	binds	different	growth	factors	like	FGF-2	and	VEGF.	Lyve-1	is	
involved	in	lymphangiogenesis	in	endothelial	cells.
By	immunohistological	analyses	we	could	demonstrate	the	presence	of		Lyve-1+	
macrophages	 in	 human	 melanoma	 specimen	 and	 in	 murine	 B16	 transplant	
tumours.	In	human	peripheral	blood	mononuclear	cells	(pBMC),	which	were	iso-
lated	from	buffy	coats,	seven	days	of	stimulation	with	M-CSF	/	dexa	/	IL-4	(MDI)	led	
to	the	induction	of	Lyve-1	in	25	%	of	the	stimulated	cells.	Expression	analysis	of	
combinations	of	macrophage	marker	revealed	that	Lyve-1+	pBMC	were	more	ori-
ented	towards	a	M2-like	phenotype.	In	addition,	we	found	that	the	induction	of	
Lyve-1	in vitro	is	crucially	dependent	on	the	activation	of	the	glucocorticoid	recep-
tor	(GR)	and	can	be	impaired	by	inhibition	of	the	p	38	MAPK	signalling	cascade.	In 
vivo,	the	activation	of	GR	seems	to	play	a	secondary	role	for	Lyve-1	induction,	as	
Lyve-1+	macrophages	were	detected	in	murine	B16F10	tumours	derived	from	mice	
with	a	myeloid	specific	deletion	of	the	GR.
Functional	 analyses	 were	 accomplished	 using	 genetically	 engineered	 Lyve-1	
overexpressing	 cell	 lines.	 In	 the	human	macrophage	 like	 cell	 line	U937	 Lyve-1	
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was	expressed	in	a	highly	glycosylated	state.	Even	though	binding	to	HA	could	be	
demonstrated,	ligand	binding	did	not	induce	proliferation	as	it	has	been	reported	
for	Lyve-1+	endothelial	cells.	In	an	adhesion	assay	we	identified	fibronectin	as	a	
further	binding	partner	of	Lyve-1.
In	analogy	to	CD44,	which	is	shedded	from	the	cell	surface	by	proteolytic	cleav-
age,	we	supply	evidence	for	the	existence	of	a	soluble	form	of	Lyve-1	in	the	cell	
culture	supernatant	of	transgenic	U937.	Soluble	Lyve-1	(sLyve-1)	 is	produced	by	
a	 me	talloproteinase	 mediated	 shedding	 process	 in	 macrophages	 and	 endothe-
lial	cells	in	a	comparable	fashion.	To	address	our	hypothesis	that	sLyve-1	might	
function	as	a	decoy	receptor,	we	incubated	melanoma	cell	lines	with	macrophage	
derived	 and	 synthetic	 sLyve-1	 and	 observed	 reduced	 tumour	 cell	 proliferation.	
Physiological	 relevance	of	Lyve-1	 shedding	was	demonstrated	by	 the	quantifica-
tion	of	sLyve-1	in	human	plasma.	The	concentration	of	sLyve-1	was	significantly	
increased	in	plasma	samples	derived	from	psoriasis	patients.
To	 examine	 the	 relevance	 of	 Lyve-1+	 macrophages	 for	 tumour	 growth	 we	
injected	 B16	melanoma	 tumour	 cells	 subcutaneously	 into	 the	 flank	 of	 Lyve-1-/-	
mice.	After	ten	days	enhanced	tumour	growth	due	to	increased	tumour	cell	pro-
liferation	was	observed	in	the	knockout	mice	in	comparison	to	wild	type	controls.	
The	exact	contribution	of	Lyve-1+	macrophages	 to	 this	effect	still	needs	 further	
clarification.
Therefore,	we	could	demonstrate	that	Lyve-1	is	a	marker	of	a	M2-like	macro-
phage	subpopulation	in	human	and	murine	melanoma.	By	proteolytic	cleavage	of	
the	ectodomain	the	function	of	Lyve-1	is	modulated	and	thus	plays	also	an	impor-
tant	role	for	tumour	growth	and	progression.
XV
ZUSAMMENFASSUNG
Tumore	 sind	 komplexe	 organ-ähnliche	 Strukturen,	 die	 neben	malignen	 Zellen	
von	vaskulären,	hämatopoetischen	und	mesenchymalen	Zellen	gebildet	werden,	
wobei	insbesondere	Makrophagen	zahlreich	im	Tumorinfiltrat	zu	finden	sind.	So	
genannte	 Tumor-assoziierte	Makrophagen	 (TAM)	 führen	 wichtige	 tumor-unter-
stützende	 Funktionen	 aus.	 Als	Quelle	 von	 angiogenen,	 anti-inflammatorischen	
und	Matrix-umbauenden	Faktoren	beeinflussen	TAM	maßgeblich	die	Tumoriniti-
ierung,	 die	 Progression	 und	 auch	 die	Metastasierung.	 In	 diversen	Krebserkran-
kungen	korreliert	eine	hohe	TAM	Dichte	im	Tumor	mit	einer	schlechten	Prognose	
für	die	Patienten.	Aufgrund	der	Plastizität	der	Gen-Regulation	können	Makropha-
gen	sich	funktionell	auf	lokale	Bedingungen	einstellen.	Daher	bilden	auch	TAM	
eine	stark	heterogene	Zellpopulation,	da	sie	ihren	Phänotyp	an	das	sie	umgebende	
Mikromillieu	der	jeweiligen	Tumorregion	anpassen.	Zur	funktionellen	Charakte-
risierung	von	TAM	Subpopulationen	ist	die	Identifizierung	weiterer	TAM	Marker	
somit	unabdingbar.
In	den	 letzten	 Jahren	hat	unsere	Gruppe	Ms4a8a,	 Stablilin-1	und	Lyve-1	 als	
neue	Marker	für	murine	TAM	identifiziert.	Die	Expression	von	Lyve-1	konnte	in 
vitro	 in	Knochenmarkmakrophagen	durch	die	 Stimulation	mit	 Tumor-konditio-
niertem	Medium,	Dexamethason	und	IL-4	induziert	werden.	Das	Hauptziel	der	
vorliegenden	Arbeit	war	es	die	Expression	und	die	Prozessierung	von	Lyve-1	in	
Makrophagen	 in vitro	und	 in vivo	umfassend	zu	charakterisieren.	Das	Typ I	trans-
membrane	Glykoprotein	Lyve-1	gehört	zu	der	Link-Domäne	Superfamilie	und	teilt	
43	%	Sequenzhomologie	mit	dem	Hyaluronsäure	 (HS)	Rezeptor	CD44.	Zunächst	
wurde	Lyve-1	als	spezifischer	HS	Rezeptor	des	lymphatischen	Endotheliums	iden-
tifiziert.	Zusätzlich	wurden	Interaktionen	zwischen	Lyve-1	und	Wachstumsfakto-
ren	wie	FGF-2	und	VEGF	nachgewiesen.	Im	lymphatischen	Endothelium	ist	Lyve-1	
in	der	Regulation	der	Lymphangiogenese	involviert.
Mittels	immunohistochemischer	Analysen	konnten	wir	die	Existenz	von		Lyve-1+	
Makrophagen	in	humanen	Melanomen	und	in	murinen	B16	Tumoren	nachweisen.	
Im	Menschen	führt	eine	sieben	tägige	Stimulation	mit	M-CSF,	Dexamethason	und	
IL-4	(MDI)	von	peripheren	Blutmonozyten	(pBMZ)	aus	Buffy	Coats	zu	einer	Lyve-1	
Induktion	 in	 25	%	 der	 Zellen.	 Expressionsanalysen	 einer	Kombination	 von	 ver-
schiedenen	Makrophagenmarkern	zeigten,	dass	Lyve-1+	pBMZ	mehr	in	Richtung	
M2	differenziert	sind.	Außerdem	hat	sich	herausgestellt,	dass	die	Lyve-1	Induktion	
in vitro	maßgeblich	von	der	Aktivierung	des	Glukokortikoidrezeptors	(GR)	abhängt	
und	durch	 Inhibition	des	p	38	MAPK	Signalwegs	beeinträchtig	werden	kann.	 In 
vivo	scheint	die	GR	Aktivierung	eine	untergeordnete	Rolle	zu	spielen,	da	Lyve-1+	
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Makrophagen	in	murinen	B16F10	Tumoren,	welche	von	Mäusen	mit	einer	mye-
loid-spezifischen	Deletion	des	GR	stammten,	nachgewiesen	werden	konnten.	
Funktionelle	Analysen	wurden	mit	 transgen	modifizierten	Lyve-1	überexpri-
mierenden	 Zelllinien	 durchgeführt.	 In	 der	 humanen	 Makrophagen-ähnlichen	
Zelllinie	U937	wird	Lyve-1	in	einer	stark	glykosylierten	Form	exprimiert.	Obwohl	
die	Bindung	an	HS	nachgewiesen	werden	konnte,	hatte	die	Interaktion	mit	Ligan-
den	keinen	Einfluss	 auf	die	Proliferationsrate	der	U937-Zellen.	Mit	Hilfe	 eines	
Adhäsionsassays	 konnten	 wir	 Fibronektin	 als	 weiteren	 Bindungspartner	 von	
Lyve-1	identifizieren.	
In	 Analogie	 zu	 CD44,	 dessen	 Ectodomäne	 proteolytisch	 abgespalten	 wird,	
konnten	wir	eine	lösliche	Form	von	Lyve-1	(sLyve-1)	im	Zellkulturüberstand	von	
transgenen	U937	Zellen	nachweisen.	sLyve-1	wird	in	Makrophagen	und	Endothel-
zellen	 in	 ähnlicher	Weise	 durch	Metalloproteinase	 vermitteltes	 Shedding	 pro-
duziert.	Unsere	Hypothese,	 dass	 sLyve-1	 als	Decoy-Rezeptor	 fungiert,	 überprüf-
ten	wir	durch	Inkubation	von	Melanomzellen	mit	synthetisiertem	sLyve-1	und	
	sLyve-1,	welches	von	Makrophagen	stammte,	und	stellten	eine	verminderte	Pro-
liferationsrate	der	Krebszellen	fest.	Die	physiologische	Relevanz	des	Lyve-1	Shed-
dings	belegten	wir	mit	der	Quantifizierung	von	Lyve-1	in	humanem	Plasma.	Die	
Konzentration	von	löslichem	Lyve-1	war	hierbei	im	Plasma	von	Psoriasis	Patien-
ten	signifikant	erhöht.
Um	die	Bedeutung	von	Lyve-1+	Makrophagen	für	das	Tumorwachstum	zu	klä-
ren,	injizierten	wir	B16	Melanomzellen	subkutan	in	die	Flanke	von	Lyve-1	Knock-
out	Mäusen.	Nach	zehn	Tagen	Tumorwachstum	konnten	wir	im	Vergleich	zu	den	
Wildtyp	Mäusen	 in	 den	Knockout	 Tieren	 ein	 verstärktes	 Tumorwachstum	 fest-
stellen,	welches	durch	eine	 erhöhte	Tumorzellproliferation	bedingt	wurde.	Der	
genaue	Beitrag	von	Lyve-1+	Makrophagen	zu	diesem	Effekt	muss	im	Detail	noch	
weiter	untersucht	werden.	
Wir	konnten	 somit	 zeigen,	dass	Lyve-1	 ein	Marker	von	einer	M2-ähnlichen	
Makrophagen	Subpopulation	im	humanen	und	murinen	Melanom	ist.	Durch	pro-
teolytische	Abspaltung	der	Ectodomaine	wird	die	Funktion	von	Lyve-1	maßgeb-
lich	beeinflusst	und	spielt	daher	auch	für	das	Tumorwachstum	eine	wichtige	Rolle.
11 .  INTRODUCTION
1.1 Macrophages
Macrophages	 are	 innate	 immune	 cells	 of	myeloid	 hematopoietic	 origin,	which	
can	be	found	in	all	body	tissues,	where	they	exert	important	homeostatic,	tissue-	
specific	functions	and	provide	a	first	line	defence	against	health	threatening	path-
ogens.	Macrophages	were	first	described	by	the	comparative	zoologist	Elie	Metch-
nikoff.	His	studies	on	larvae	of	starfish	(Hydra)	in	1883	allowed	him	to	observe	
phagocytosis	of	foreign	material	by	specific	migratory	cells	of	mesodermal	origin,	
at	which	he	noted	distinct	similarities	to	vertebrate	blood	cells.	Further	experi-
ments	lead	Elie	Metchnikoff	to	the	discovery	of	the	mechanism	of	cellular	innate	
immune	response	for	which	he	was	awarded	with	the	Nobel	Prize	in	1908	together	
with	Paul	Ehrlich	for	his	findings	in	humoral	immunity	[1].	
The	identification	of	further	phagocytic	active	cells	and	the	efficient	clearance	
function	of	 tissue-specific	macrophages	 (histiocytes)	 led	 to	 the	 introduction	of	
the	concept	of	 the	 reticulo-endothelial	 system	by	Aschoff	 in	 1924.	He	grouped	
cells	of	different	origins	and	ranked	them	in	ascending	order	according	to	their	
phagocytic	capacity	which	was	evaluated	by	experiments	with	vital	dyes	[2].	This	
concept	was	challenged	by	van	der	Furth	and	his	colleagues	in	the	1970	s,	when	
they	presented	the	mononuclear	phagocyte	system	(MPS),	which	comprises	mono-
cytes	and	macrophages	as	well	as	their	bone-marrow	derived	progenitor	cells.	MPS	
included	cells	were	related	in	morphology,	function	and	origin.	However,	van	der	
Furth	et	al.	assumed	that	tissue-macrophages	are	non-proliferative	terminally	dif-
ferentiated	cells,	which	are	steadily	replenished	by	circulating	monocytes	which	
originate	from	the	bone	marrow	[2,	3].	
Even	though	the	definition	of	the	MPS	holds	true	for	dermal	and	gut	macro-
phages,	which	are	constantly	replaced	by	monocytes,	fate	mapping	experiments	
demonstrated	 that	 early	 embryonic	 haematopoiesis	 contributes	 to	 the	 pool	 of	
tissue-resident	macrophages.	Thus,	most	of	the	macrophages	are	established	pre-
natally	and	persist	through	adulthood	by	local	proliferation	independently	from	
monocytic	input.	During	embryogenesis	first	hematopoietic	cells	can	be	detected	
in	blood	islands	of	the	extraembryonic	yolk-sac	(YS).	These	cells	are	progenitors	
of	 erythrocytes	 and	 so-called	primitive	macrophages,	which	develop	without	 a	
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monocytic	 intermediate.	During	 a	 second	wave	of	haematopoiesis,	 erythromye-
loid	(EMP)	and	lymphoid-myeloid	progenitors	emerge	in	the	YS.	After	the	estab-
lishment	of	blood	circulation,	 EMP	 seed	 the	 fetal	 liver	 and	 further	 tissues.	 Sub-
sequently,	 the	 haematogenic	 endothelium	 of	 the	 aorto-gonadal-mesonephros	
vessels	give	rise	to	hematopoietic	stem	cells	(HSC),	which	translocate	to	the	fetal	
liver	to	establish	definitive	haematopoiesis	[4,	5].	
In vivo	 lineage	tracing	experiments	provided	first	hints	of	the	embryonic	ori-
gin	of	microglia,	which	are	specific	macrophages	of	the	central	nervous	system.	
The	direct	origin	of	microglia	from	YS	derived	progenitors	could	be	demonstrated,	
whereas	postnatal	monocytes	are	not	involved	significantly	in	the	maintenance	
of	the	adult	microglia	population	[6].	In	contrast	to	microglia,	Langerhans	cells	
of	the	epidermis	where	found	to	derive	mainly	from	fetal	 liver	monocytes	that	
replace	YS-derived	Langerhans	cells	during	embryogenesis	[7].	The	contribution	
of	 YS	macrophages	 to	 adult	 tissue	 resident	macrophages	 was	 further	 substanti-
ated	by	a	study	with	Myb-/-	mice.	The	transcription	factor	Myb	is	required	for	the	
development	of	HSC	in	the	fetal	liver,	but	primitive	macrophages	can	develop	in	
the	YS	independently	from	Myb	activity	and	give	later	rise	to	F4	/	80bright	CD11	blow	
macrophages.	Lineage	tracing	of	these	macrophages	demonstrated	that	YS-derived	
progenitors	give	rise	to	microglia,	liver	Kupffer	cells	and	epidermal	Langerhans	
cells,	whereas	a	part	of	the	F4	/	80bright	CD11	blow	macrophages	in	lung	and	kidney	
and	the	majority	of	these	macrophages	in	pancreas	and	spleen	were	replaced	in	
the	adult	organism	by	bone	marrow	derived	progenitors	[8].	
1.1.1 Tissue-specific functions of macrophages in homeostasis
Macrophages	constitute	a	highly	heterogeneous	population	of	cells	with	a	wide	
range	of	various	functions.	They	do	not	only	play	a	major	role	in	host	defence,	but	
are	also	involved	in	developmental	processes,	systemic	metabolism,	clearance	of	
apoptotic	cells,	extracellular	matrix	 (ECM)	remodelling	and	homeostasis.	Tissue	
specialization	enables	resident	macrophages	to	adapt	to	their	local	environment	
and	to	exert	particular	functions.	The	Immunological	Genome	Project	was	able	to	
demonstrate	the	transcriptomal	diversity	of	different	tissue-resident	macrophage	
subsets	as	only	few	transcripts	are	in	fact	shared	amongst	different	macrophage	
populations	[9].	The	distinct	macrophage	phenotype	is	formed	by	a	combination	
of	differentiation	and	polarization	signals,	which	regulate	epigenetic	modifications	
and	the	accessibility	of	gene	expression	regulatory	elements.	In	this	connection,	
the	hierarchically	organized	control	of	gene	expression	by	transcriptional	regula-
tors	leads	to	the	shaping	of	tissue-specific	macrophage	characteristics	[10].	First	of	
all,	 lineage	determining	transcription	factors	enable	the	expression	of	common	
macrophage	associated	genes.	The	ETS	family	member	PU.1	acts	as	such	a	so-called	
pioneer	transcription	factor	in	early	myeloid	differentiation	by	opening	long	seg-
ments	of	chromatin	around	enhancer	and	promoter	regions,	 thus	controlling	a	
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wide	range	of	macrophage-specific	regulatory	regions,	which	are	then	amenable	
for	 interactions	with	 further	 transcription	factors.	PU.1	 regulatory	elements	can	
be	found	in	nearly	all	expression	regulatory	elements	of	myeloid	specific	genes.	
Myeloid	lineage	differentiation	is	further	influenced	by	CCAAT	/	enhancer-binding	
protein	(CEBP)	controlling	the	development	of	 	granulocyte	/	monocyte	progeni-
tor	cells	and	MAF	/	MAFB,	which	is	involved	in	terminal	differentiation	of	macro-
phages	 [4,	 11].	On	 the	next	 level	 of	 transcriptional	 control,	 tissue-specific	 tran-
scription	factors	like	e.	g.	peroxisome	proliferator-activated	receptor	γ	(PPARγ)	in	
alveolar	macrophages	or	GATA6	in	peritoneal	cavity	macrophages,	further	remodel	
chromatin	structures	such	that	local	differentiation	of	tissue	resident	macrophages	
is	 achieved.	 The	 corresponding	 local	microenvironment	made	 up	 of	 cytokines,	
chemokines	and	metabolites	leads	to	further	specialization	and	maintenance	of	
macrophages	[4].	
Under	homeostatic	conditions	the	different	macrophage	subpopulations	vary	
greatly	in	their	functions	depending	on	their	anatomical	location;	examples	are	
described	 in	 the	 following.	Bone	marrow	osteoclasts	 are	multinucleated	macro-
phage-derived	 cells	which	 are	 involved	 in	 bone	 remodelling	 processes	 [12].	 So	
called	alveolar	macrophages	are	located	in	the	lungs	where	they	are	exposed	to	
the	alveolar	lumen.	Besides	phagocytosis	and	clearance	of	inhaled	particles,	these	
macrophages	 also	 recycle	 surfactant	molecules	 of	 epithelial	 cells	 [13].	 The	 sinu-
soidal	vessels	of	 the	 liver	 are	 lined	by	Kupffer	cells.	The	 stellate-shaped	phago-
cytes	are	mainly	involved	in	local	immune	response	to	blood-borne	antigens	[14].	
Microglia	on	the	other	hand	carry	out	tissue	remodelling	functions	by	synaptic	
pruning	and	are	important	sources	of	neurotrophic	factors,	additionally	they	are	
key	components	of	the	immune	response	in	the	central	nervous	system	[15].	In	
other	organs	like	the	gut,	diverse	macrophage	subpopulations	exist	that		co	operate	
to	 ensure	 tolerance	 to	 gut	flora	 and	 food	 [16].	 In	 second	 lymphoid	 tissues	 too,	
heterogeneous	populations	of	macrophage	subsets	can	be	found,	like	lymph	node	
subcapsular	 sinus	 (SCS)	macrophages.	By	presenting	 lymph	derived	 antigens	 to	
B cells	the	SCS	macrophages	promote	the	induction	of	antiviral	humoral	responses	
[17].	Many	further	subpopulations	of	macrophages	with	particular	functions	exist,	
which	contribute	to	maintenance	of	tissue	homeostasis.	
1.1.2 Macrophages in the inflammatory response
When	microorganisms	succeed	in	overcoming	the	physical	barriers	of	our	body,	
macrophages	build	the	first	cellular	defence	against	the	invading	pathogens.	Their	
abundant	occurrence	in	the	connective	tissue	facilitates	the	immediate	combat	of	
microorganisms,	at	which	macrophages	play	also	an	important	role	in	the	recruit-
ment	of	further	inflammatory	cells	to	the	site	of	infection	and	the	induction	of	an	
inflammatory	response.	The	distinct	functions	of	macrophages	during	challenge	
with	pathogens	are	described	in	the	following	in	more	detail.
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Pathogen recognition Macrophages	 express	 numerous	 invariable	 pattern-	
recognition-receptors	 (PRR)	 on	 their	 surface,	which	 allow	 them	 to	 detect	 path-
ogens	by	recognition	of	pathogen	associated	molecular	patterns	(PAMP),	such	as	
bacterial	and	fungi	cell	wall	components	and	viral	nucleic	acids.	PRR	are	able	to	
discriminate	between	self	and	non-self,	as	PAMP	are	not	present	in	higher	eukary-
otes	and	thus	are	unique	to	disease	causing	pathogens.	PRR	can	serve	as	phagocytic	
receptors,	 membrane-bound	 signalling	 receptors	 or	 cytosolic	 signalling	 recep-
tors	[18].	The	recognition	of	cytosolic	pathogens	is	mediated	by	intracellular	PRR,	
like	NOD	 (nucleotide-binding	 oligomerization	 domain)	 and	NRL	 (leucine-riche	
repeat-containing	receptors)	that	act	as	sensors	for	viral	nucleotides	and	nucleic	
acids	and	operate	 in	all	cells.	Exogenous	pathogenic	stimuli	on	 the	other	hand	
are	sensed	by	PRR	in	the	plasma	membrane	of	macrophages	and	dendritic	cells	
(DC)	[19].	PRR	expressed	on	macrophages	are	for	example	members	of	the	C-type	
lectin	-like	family	like	Dectin-1	and	mannose	receptor	(MR).	One	important	family	
of	signal	transducing	PRR	in	macrophages	are	the	Toll-like	receptors	(TLR)	which	
comprise	at	least	11	members	in	mammals,	amongst	which	some	are	expressed	on	
the	cellular	surface	and	others	are	located	intracellular	in	endosomal	membranes.	
TLR	 signalling	 activates	 transcription	 factors	 like	 nuclear	 factor	 κ-light-chain-	
enhancer	of	activated	B	cells	(NFκB)	and	AP-1	which	in	turn	induce	the	expres-
sion	of	pro-	inflammatory	genes	orchestrating	both	innate	and	adaptive	immune	
response	[20].
Phagocytosis and resPiratory burst	 Phagocytosis	is	defined	as	the	process	of	
uptake	of	large	particles	(>	0.5	µm).	Macrophages	are	so-called	professional	phago-
cytes	which	 are	 characterized	by	 a	high	phagocytic	 capacity	 and	efficiency	due	
to	expression	of	numerous	phagocytic	receptors.	By	phagocytosis,	macrophages	
mediate	 clearance	 from	 pathogens,	microorganisms	 and	 apoptotic	 cells.	 Phago-
cytic	receptors	can	be	PRR,	like	e.	g.	MR.	Hence	binding	of	macrophage	to	a	patho-
gen	via	its	phagocytic	receptors	triggers	the	polymerization	of	actin.	This	facilitates	
the	formation	of	membrane	extensions	leading	to	the	engulfment	of	the	bound	
particle.	The	ingested	particle	is	enclosed	in	a	membranous	vesicle	called	phago-
some.	After	its	formation	the	phagosome	experiences	a	step-wise	maturation.	In	
the	course	of	the	endocytic	pathway	the	phagosome	is	subsequently	fused	with	
early	and	late	endosomes.	The	maturation	process	is	terminated	by	a	final	fusion	
with	preformed	 lysosomes	which	contain	 large	amounts	of	hydrolytic	enzymes	
and	defensins	in	an	acidic	milieu.	The	formation	of	the	so-called	phagolysosome	
results	in	the	destruction	of	the	pathogen	and	its	digestion	for	antigen	presenta-
tion	[21-23].	Phagocytosis	can	also	be	initiated	and	enhanced	by	interaction	with	
opsonized	particles,	which	means	loading	of	pathogens	with	complement	compo-
nents	(opsonins)	or	antibodies.	In	the	latter	case	for	example,	an	antibody	binds	
in	a	highly	specific	manner	to	its	corresponding	antigen	on	the	pathogen	surface,	
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subsequently	the	constant	region	of	the	antibody	is	bound	to	Fc	receptor	(FcR)	
expressed	by	phagocytes	and	again	phagocytosis	 is	 induced	[24].	Microbial	con-
tact	also	has	an	influence	on	the	plastic	phenotype	of	macrophages	and	induces	
an	activated	status	of	the	cells.	Interestingly,	phagocytosis	induced	by	FcR	inter-
actions	 leads	 to	 a	 pro-inflammatory	 phenotype,	 whereas	 complement-receptor	
mediated	phagocytosis	is	rather	non-inflammatory	[25].	Phagocytosis	is	a	funda-
mental	mechanism	of	the	microbicidal	activity	of	macrophages.
Pathogen-receptor	 interactions	 further	 increase	 the	 defensive	 properties	
of	macrophages	by	 stimulating	 the	production	of	microbicidal	 agents	 like	 reac-
tive	nitrogen	 species	 (NOS)	 and	 reactive	 oxygen	 species	 (ROS).	 NOS	 production	
is	mediated	by	inducible	nitric	oxide	synthase	(iNOS)	by	conversion	of	arginine	
and	oxygen.	Moreover,	PRR	signalling	activates	protein	kinase	C	(PKC)	which	in	
turn	phosphorylates	cytosolic	subunits	of	NADPH	oxidase	which	translocates	to	
the	phagolysosomal	plasma	membrane	and	assembles	with	its	corresponding	sub-
units	to	form	the	active	multiunit	complex	NADPH	oxidase.	The	enzyme	uses	oxy-
gen	to	convert	cytosolic	NADPH	to	superoxide	anion.	The	superoxide	anion	either	
converts	 spontaneously	 to	 hydrogen	 peroxide	 or	 is	 converted	 by	 peroxide	 dis-
mutase.	The	production	of	ROS,	like	peroxide	and	superoxide,	and	NOS	increases	
the	microbicidal	activity	of	macrophages.	Besides	this	induction	of	an	additional	
potent	killing	mechanism,	hydrogen	peroxide	can	also	act	as	a	second	messenger	
by	inducing	pro-inflammatory	signalling	pathways	via	the	activation	of	NFκB	and	
AP-1	transcription	factors	[26].
chemotaxis  Macrophages	 play	 an	 essential	 role	 in	 host	 defence	 as	mediators	
of	innate	immunity.	However,	in	many	infections	the	number	of	tissue-resident	
macrophages	is	insufficient	to	overcome	the	pathogenic	burden.	Activated	tissue-	
resident	 macrophages	 produce	 chemoattractant	 cytokines	 in	 order	 to	 recruit	
blood	 stream	 circulating	 monocytes	 to	 the	 site	 of	 infection	 or	 inflammation,	
where	they	differentiate	into	distinct	subsets	of	dendritic	cell	and	macrophages.	
Monocytes	 are	 divided	 into	 two	 subsets	 according	 to	 their	 expression	 of	 sur-
face	 receptors.	 Classical	 human	monocytes	 are	 characterized	 by	 the	 expression	
of	CD14++CD16-	 (mice:	 lymphocyte	antigen	6	complex;	Ly6Chigh	monocytes)	and	
are	rapidly	recruited	to	the	inflammatory	site	by	chemotaxis	[27].	A	key	regulator	
of	monocyte	 recruitment	produced	by	macrophages	 is	monocyte	 chemoattract-
ing	protein-1	(MCP-1,	also	known	as	CCL2).	Interactions	with	the	corresponding	
G-protein	coupled	receptor	CCR2,	expressed	on	classical	monocytes,	promotes	the	
migration	of	monocytes	along	the	chemokine	gradient	to	the	inflamed	foci	[28].	
Recruitment	of	phagocytes	 from	 the	blood	 stream	 requires	 transendothelial	
migration,	 a	 process	 also	 known	 as	 leukocyte	 extravasation.	 Pro-inflammatory	
cytokines	 activate	 the	endothelium	 to	express	 selectins	on	 the	 luminal	 surface	
which	 allows	 the	 binding	 to	 their	 carbohydrate	 ligands	 on	 leukocytes.	 Due	 to	
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weak	interactions	the	binding	to	the	endothelium	is	only	transient	and	the	mono-
cytes	roll	along	the	blood	vessel	wall	as	a	result	of	the	shearing	force	of	the	blood	
flow.	However,	stronger	linking	to	the	endothelial	cells	is	induced	upon	binding	
of	 chemo	kine	 receptors	 to	 their	 corresponding	 ligands	 that	 are	present	on	 the	
endothelial	surface.	Activation	of	the	chemokine	receptor	leads	to	conformational	
changes	of	 integrins	on	monocytes,	 thus	 leading	 to	enhanced	adhesion	via	 the	
interaction	with	endothelial	intercellular	adhesion	molecule	(ICAM).	The	mono-
nuclear	phagocyte	is	now	able	to	pass	between	endothelial	cells	to	enter	the	sub-	
endothelial	 tissue	 along	 the	 chemokine	 gradient	 and	 begins	 to	 differentiate	
according	to	the	stimuli	of	the	local	microenvironment	[18].
The	 second	 subset	 of	 human	 monocytes	 is	 marked	 by	 the	 expression	 of	
CD14low CD16+ (mice:	Ly6Clow)	[27].	These	cells	do	not	respond	to	chemotaxis	and	
thus	are	not	recruited	during	an	inflammatory	response.	Their	primary	function	
seems	to	be	patrolling,	as	microscopic	studies	 in	mice	demonstrated	that	 these	
cells	continuously	migrate	along	the	luminal	surface	of	endothelial	cells	[29].	
In	general,	 activation	of	macrophages	 induces	 the	production	 and	 secretion	
of	a	broad	array	of	different	substances	including	chemokines,	cytokines,	growth	
factors,	matrix	remodelling	proteases,	protease	inhibitors	and	further	mediators	
of	inflammation	[30].	
the  interface  between  innate  and  adaPtive  immunity  Macrophages	 and	
dendritic	cells	are	phagocytic	antigen	presenting	cells	(APC)	which	are	crucial	for	
the	activation	of	the	adaptive	immune	response.	In	order	to	activate	naïve	T	cells	
APC	must	generate	pathogen	derived	antigenic	peptides	and	associate	them	with	
specialized	 surface	 glycoproteins	 called	major	histocompability	 complex	 (MHC)	
class I	and	class II.	Priming	of	T	cells	with	their	corresponding	antigen	presented	
via	MHC	occurs	in	a	highly	specific	manner	and	results	in	the	clonal	expansion	of	
T cells	and	their	subsequent	differentiation	into	particular	T cell	effector	subsets	
[18].	Intracellular	antigens	of	e.	g.	viral	origin	are	assembled	with	MHC class I,	which	
is	expressed	on	all	nucleated	cells,	to	induce	activation	of	CD8+	cytotoxic	T	cells.	
In	contrast,	extracellular	antigens	are	presented	via	MHC	class II	expressed	only	
on	APC.	 The	phagocytes	 internalize	 extracellular	pathogens,	 like	bacteria,	 fungi	
or	parasites	and	present	phagosomal	derived	antigens	to	activate	CD4+	T	helper	
cells.	A	particular	property	of	APC	is	cross	presentation	which	implies	presenta-
tion	of	exogenous	antigens	via	MHC	class I	and	cytosolic	antigens	via	MHC	class II,	
respectively	 [31].	 The	 former	 occurs	 in	 a	 time-dependent	manner.	After	 phago-
cytosis	of	 the	extracellular	pathogen	the	production	of	antigen	peptides	occurs	
during	the	maturation	of	 the	phagolysosome.	The	activation	of	NADPH	oxidase	
and	the	successive	ROS	production	create	an	alkylating	milieu	which	impedes	the	
activation	of	lysosomal	proteases.	Consequently,	antigenic	peptides	remain	avail-
able	 for	assembly	with	MHC	class I	molecules.	The	time-dependent	decrease	of	
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ROS	production	leads	to	an	acidification	of	the	phagolysosme.	Proteolysis	is	initi-
ated	and	antigens	that	are	derived	from	the	late	lysosome	are	presented	via	MHC	
class II	molecules.	Cross	presentation	of	soluble	antigens	is	localization-depend-
ent,	at	which	the	route	of	internalization	determines	association	with	MHC	class I	
or	MHC	class II	[32].
1.1.3 Macrophage polarization and activation
As	 described	 above	 macrophages	 constitute	 a	 highly	 heterogenic	 population.	
Macro	phages	are	distributed	throughout	the	body	and	can	be	found	in	nearly	all	
tissues,	where	they	are	exposed	to	distinct	microenvironments.	Due	to	their	plas-
ticity	of	gene	expression,	macrophages	are	capable	of	functional	adaption	during	
steady	state	and	disease.
In	 1964,	 Mackaness	 and	 colleagues	 performed	 studies	 on	 macrophage	 acti-
vation	by	 infecting	mice	with	 the	 intracellular	pathogens	mycobacterium	bovis	
bacillus	Calmette-Guerin	(BCG)	or	Listeria monocytogenes.	They	were	able	to	observe	
diverse	morphological	and	functional	changes	regarding	the	microbicidal	activity	
of	macrophages.	Enhanced	anti-microbial	functions	of	the	macrophages	occurred	
in	a	non-specific	although	antigen	dependent	manner	 [33].	The	 following	find-
ings	 that	 lymphocytes	 are	 the	 key	 antigen	 specific	 cells	 wich	 are	 involved	 in	
macro	phage	activation	paved	the	way	for	the	identification	of	the	pro-inflamma-
tory	cytokine	 interferon-γ	(IFN-γ),	which	is	produced	by	CD4+	T	helper	1	 (Th	1)	
cells,	CD8+	cytotoxic	T cells	and	natural	killer	(NK)	cells,	as	an	inducer	of	oxidative	
metabolism	and	microbicidal	activity	of	macrophages	[34].	Thus,	 IFN-γ	was	the	
first	identified	stimulus	of	macrophage	activation	which	was	therefore	designated	
as	classical	activation.	In	contrast	to	that,	T	helper	2	(Th	2)	cell	derived	cytokines	
interleukine-4	(IL-4)	and	IL-13	were	described	to	induce	alternative	activation	of	
macrophages	which	was	marked	by	enhanced	expression	of	the	scavenger	recep-
tor	MR,	increased	expression	of	MHC	class II	proteins	and	decreased	expression	
of	 pro-inflammatory	 cytokines	 [35,	 36].	 Continuative	 research	 in	 the	 field	 of	
macro	phage	activation	manifested	the	plasticity	of	these	cells,	whereupon	several	
	models	of	macrophage	classification	were	developed	in	order	to	comprehensively	
illustrate	macrophage	diversity.
S.	Gordon	and	colleagues	proposed	the	first	model	of	macrophage	classification.	
Mirroring	the	Th	1	/	Th	2	dichotomy,	macrophages	are	divided	into	pro-inflamma-
tory	M1	macrophages	or	classically	activated	macrophages	and	anti-inflammatory	
M2	macrophages	or	alternatively	activated	macrophages.	The	classical	activation	
profile	is	induced	by	pro-inflammatory	cytokines	like	mediators	of	Th	1	response,	
e.	g.	IFN-γ	and	tumour	necrosis	factor-α	(TNF-α),	granulocyte	macrophage-colony	
stimulating	factor	(GM-CSF)	and	microbial	antigens	like	lipopolysaccharide	(LPS).	
The	main	functions	of	M1	polarized	macrophages	are	the	combat	of	intracellular	
bacteria	and	virus	 infections,	 immune	stimulation	and	tumour	resistance.	Char-
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acteristically,	M1	macrophages	are	potent	APC	with	abundant	expression	of	MHC	
molecules	and	promote	immune	response	by	the	secretion	of	inflammatory	medi-
ators	such	as	IL-12,	IL-23	and	TNF-α.	In	the	murine	system	expression	of	iNOS	and	
the	concomitant	production	of	NOS	is	a	further	hallmark	of	classically	activated	
M1	macrophages.	 In	 contrast	 to	 that,	 Th	2	 cytokines	 IL-4	 and	 IL-13	 and	 further	
anti-inflammatory	 agents	 like	glucocorticoids	 (GC)	 and	 IL-10	 induce	 alternative	
activation	 of	 macrophages.	M2	macrophages	 are	 primarily	 involved	 in	 homeo-
static	processes	such	as	angiogenesis,	tissue-remodelling,	wound	healing	as	well	
as	regulation	of	immune	suppression	and	killing	of	parasites.	M2	macrophages	are	
poor	antigen	presenters	due	to	reduced	expression	of	MHC	class II	proteins.	Alter-
natively	activated	macrophages	secrete	 low	amounts	of	 IL-12	and	high	amounts	
of	anti-inflammatory	cytokines	and	chemokines	like	IL-10,	transforming	growth	
factor-β	(TGF-β)	and	CCL18.	In	murine	M2	macrophages	the	arginine	metabolism	
is	shifted	towards	the	arginase	mediated	conversion	to	ornithine	and	urea,	thus	
lower	levels	of	NOS	are	produced.	Markers	of	M2	macrophages	are	diverse	scaven-
ger	receptors	like	CD163,	Stabilin-1	and	MR	(also	known	as	CD206)	[37-39].	How-
ever,	it	is	important	to	note	that	M1-M2	polarization	is	an	oversimplification	of	
the	in vivo	situation	and	only	represents	two	extremes	of	a	wide	spectrum	of	inter-
mediate	macrophage	activation	stages.
In	order	to	differentiate	the	broad	range	of	alternatively	activated	macrophages	
in	more	detail,	Mantovani	et	al.	suggested	in	2002	the	subdivision	of	M2	into	M2	a,	
M2	b	and	M2	c.	At	which	M2	a	polarization	is	induced	by	IL-4	and	IL-13,	and	M2	b	
by	immune	complexes	or	agonists	of	TLR	and	IL-1R.	These	two	subclasses	execute	
immune-regulatory	functions	and	drive	type II	responses.	The	M2	c	subset	on	the	
other	site	is	induced	in	response	to	IL-10	and	glucocorticoids	and	is	overridingly	
involved	in	immunosuppression	and	tissue	remodelling	[40].
To	paint	 a	more	 realistic	picture	of	 the	 in vivo	 situation	Moser	 and	Edwards	
developed	 a	 further	model	 of	 classification	which	 groups	macrophages	 accord-
ing	to	their	three	primary	functions:	host	defence,	wound	healing	and	immune	
regulation.	The	functional	groups	are	associated	with	the	three	primary	colours	
that	were	arranged	in	the	colour	wheel	of	macrophage	activation.	The	different	
hues	blending	the	primary	colours	represent	the	various	macrophage	subsets	with	
mixed	phenotypes	[41].	
However,	macrophages	are	highly	dynamic	cells,	which	easily	adapt	to	different	
signals	from	their	environment	and	thus	are	subjected	to	constant	changes	in	their	
phenotype	indicating	that	all	classification	models	are	still	insufficient	to	reflect	
the	enormous	plasticity	and	diversity	of	macrophage	phenotypes.	The	limitation	
of	classification	models	led	Murray	and	further	leading	researchers	in	the	field	of	
macrophage	activation	to	recommend	guidelines	concerning	 the	description	of	
properties	of	the	specific	macrophage	population	under	investigation.	Most	impor-
tantly,	they	recommend	the	exact	definition	of	the	stimulus	such	as	M(IL-4)	or	
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M(IL-10)	of	macrophage	activation	to	avoid	unprecise	term	of	M1	or	M2	activation,	
whose	definition	might	be	dissimilar	in	between	different	labs.	Moreover,	the	acti-
vation	profile	of	macrophages	should	be	examined	by	expression	analysis	of	com-
binations	of	macrophage	markers	to	define		specific	macrophage	subsets	[42].
Figure 1: The	microenvironment	determines	the	functional	phenotype	of	macro	phages. 
Inflammatory conditions (e. g. IFN-γ) induce the formation of an inflammation promoting M1-like phe-
notype, whereas anti-inflammatory mediators (e. g. dexa, IL-4) shape an immunosuppressive, trophic M2 
like phenotype. Depending on the composition of the micromilieu, macrophages with a mixed phenotype 
develop.
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1.2 Tumour immunology
The	growth	of	a	tumour	is	a	multistep	process	in	which	normal	cells	evolve	pro-
gressively	 to	 become	malignant.	 The	 transformation	 is	 caused	 by	 genetic	 insta-
bility,	by	which	genetic	heterogeneity	of	neoplastic	cells	is	formed.	Hanahan	and	
Weinberg	conceptualized	common	traits	of	neoplastic	cells	as	the	six	hallmarks	of	
cancer	in	2000,	and	based	on	prevailing	research	subjoined	two	further	hallmarks	
in	2013,	namely:
1)	 Sustained	proliferative	signalling
2)	 Evasion	of	growth	suppression
3)	 Resistance	to	cell	death
4)	 Replicative	immortality
5)	 Invasion	and	formation	of	metastasis
6)	 Induction	of	angiogenesis
Newly	added	hallmarks:
7)	 Reprogramming	of	energy	metabolism	
8)	 Tumour	promoting	inflammation
The	acquirement	of	these	characteristics	of	self-sufficiency	enables	transformed	
cancer	cells	to	form	tumours.	Tumours	are	complex	tissues	which	are	composed	of	
several	cell	types	–	besides	neoplastic	cells	and	non-malignant	stromal	cells,	infil-
trating	 leukocytes	 represent	a	 further	 important	 integrant,	which	can	be	 found	
during	all	tumour	stages	[43].	First	links	between	cancer	and	inflammation	were	
already	made	 in	 the	 late	 19	th	 century,	when	Rudolph	Virchow	discovered	 that	
chronic	 inflammations	may	 promote	 tumour	 growth	 already	 pointing	 towards	
macrophages	 as	 key	 players	 of	 cancer-related	 inflammation	 [44].	 Accumulating	
evidence	by	continuative	studies	of	the	past	years	revealed	the	close	relationship	
between	local	inflammation	and	tumour	growth.	Epidemiological	studies	revealed	
that	 the	 regular	 use	 of	 non-steroidal	 anti-inflammatory	 drugs	 (NSAID)	 such	 as	
aspirin	reduces	the	risk	of	developing	colorectal	cancer	and	adenoma	by	inhibi-
ting	cyclooxygenase	(COX),	which	is	overexpressed	in	numerous	cancers	[45].	In	
2008	approximately	16	%	of	malignancies	worldwide	were	attributable	to	infectious	
agents	[46].	Designative	features	of	cancer-related	inflammation	are	the	presence	
of	inflammatory	cells	and	mediators,	also	in	tumours	arising	without	inflamma-
tory	predisposition,	as	well	as	tissue	remodelling	and	induction	of	angiogenesis.	
The	promoting	 effects	 of	 inflammation	 to	 tumour	development	 can	be	 sub-
divided	into	intrinsic	and	extrinsic	pathway.	The	intrinsic	pathway	requires	the	
occurrence	 of	 a	 genetic	 event.	 Mutations	 in	 oncogenes	 or	 tumour	 suppressor	
genes	in	neoplastic	cells	establish	the	activation	of	signalling	pathways	that	cre-
ate	an	inflammatory	tumour	promoting	microenvironment	[47].	One	of	the	most	
common	cancer	related	mutations	affects	the	proto-oncogenes	RAS.	Aberrant	reg-
ulated	 activation	of	GTPases	of	 the	RAS	 family	 facilitates	 increased	proliferative	
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potential	and	reduced	susceptibility	to	apoptosis	of	neoplastic	cells	through	acti-
vation	of	mitogen	activated	protein	kinase	 (MAPK)	downstream	signalling	 [48].	
In	approximately	50	%	of	melanoma	a	mutation	in	the	BRAF	gene,	a	downstream	
target	of	RAS	belonging	to	the	RAF	family,	leads	to	its	continuative	activation	inde-
pendent	from	extracellular	stimuli	[49].	BRAF	mutated	melanoma	cells	create	and	
anti-	inflammatory	and	pro-angiogenic	microenvironment	due	to	increased	secre-
tion	of	IL-6,	IL-10	and	vascular	endothelial	growth	factor	(VEGF)	facilitating	the	
immune	evasion	of	the	neoplastic	cells	[50].
On	the	other	hand	infections,	autoimmune	disease	and	further	inflammatory	
conditions,	which	can	occur	before	or	during	carcinogenesis,	contribute	to	tumour	
development	via	the	extrinsic	pathway	[47].	Excessive	production	of	ROS	and	NOS	
by	 inflammatory	 cells,	 especially	macrophages	 in	 the	 course	 of	 the	 respiratory	
burst	(described	in	1.1.2)	may	result	in	the	formation	of	mutagenic	peroxynitrite.	
Hence,	activated	inflammatory	cells	facilitate	genomic	alterations	by	interactions	
with	the	DNA	in	the	proliferating	epithelium	during	tissue	regeneration	[51,	52].	
Chronic	inflammations	like	Crohn’s	disease	and	inflammatory	bowel	disease	pre-
Figure 2: Inflammation	related	tumourigenesis. Cancer promoting effects of inflammation 
can be conceptualized by the concurrence of an intrinsic and an extrinsic pathway. The intrinsic pathway 
comprises mutations in oncogenes and tumour suppressor genes which create an inflammatory tumour 
promoting environment. The extrinsic pathway promotes tumourigenesis via the presence of a smouldering 
inflamma tion due to an infection or chronic inflammation. Both pathways converge to promote tumour 
initiation [55].
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dispose	to	development	of	colon	carcinoma.	Virus	infections	like	Hepatitis	B	/	C	
are	associated	with	liver	carcinoma	and	infection	with	the	gram	negative	bacte-
rium	Helicobacter pylori	is	a	major	cause	of	gastric	cancer,	to	give	just	a	few	examples	
that	link	inflammatory	conditions	to	cancer	[51,	53].	The	extrinsic	and	intrinsic	
pathways	contribute	simultaneously	to	the	formation	of	a	so	called	smouldering	
inflammation,	which	is	described	as	a	subclinical	 inflammation	where	the	reso-
lution	reaction	of	inflammation	failed	and	thus	creates	a	mutagenic	environment	
that	 promotes	 cancer	 initiation	 [54].	 Numerous	 inflammatory	 cytokines	 and	
chemokines	recruit	and	activate	immune	cells,	such	as	T	cells	and	macrophages	to	
the	site	of	the	smouldering	inflammation	which	in	turn	promote	immune	evasion,	
tumour	cell	proliferation	and	angiogenesis.
1.3 Tumour associated macrophages
Tumours	constitute	complex	organ	like	structures	which	are	composed	of	proli-
ferating	malignant	cells,	mesenchymal	cells	and	cells	of	hematopoietic	origin	like	
endothelial	cells	and	leukocytes,	amongst	which	in	particular	macrophages	can	be	
found	numerously	within	the	tumour	infiltrate.	The	macrophages	are	shaped	by	
the	tumour	microenvironment	resulting	in	a	phenotype	which	promotes	tumour	
growth.	So	called	tumour	associated	macrophages	(TAM)	can	be	found	during	all	
stages	of	tumour	development.	In	general,	TAM	are	involved	in	tumour	initiation,	
progression	 and	 metastasis	 as	 providers	 of	 angiogenic,	 anti-inflammatory	 and	
matrix	remodelling	factors	[56].	The	important	tumour	supportive	functions	of	
macrophages	are	reflected	by	the	findings	that	in	many	different	cancers	high	TAM	
density	 correlates	with	poor	patient	prognosis	 [57,	 58].	 In	melanoma	 for	 exam-
ple	significantly	increased	numbers	of	TAM	have	been	found	in	thick	melanomas	
which	 correlated	 with	 increased	 invasiveness	 and	 the	 formation	 of	 metastasis	
[59].	Further	evidence	for	the	tumour	promoting	effect	of	macrophages	was	pro-
vided	by	a	murine	model	of	breast	cancer;	monocyte	recruitment	was	genetically	
prevented,	resulting	in	delayed	tumour	development	and	decreased	formation	of	
metastasis	[60].	
TAM	 originate	 from	 recruited	 Ly6Chigh	 monocytes	 which	 are	 derived	 from	
the	bone	marrow	where	 their	release	 is	augmented	during	tumour	growth	[61].	
The	recruitment	of	the	monocytes	is	mediated	by	various	chemokines,	cytokines	
and	growth	factor.	One	major	chemoattractant	is	the	C-C	chemokine	CCL2,	also	
known	as	MCP-1.	Already	in	1992	researchers	demonstrated	that	CCL2	overexpres-
sion	in	murine	melanoma	promoted	monocyte	infiltration [62].	Furthermore,	the	
relevance	of	CCL2	has	been	substantiated	by	the	finding	that	non-tumourigenic	
melanoma	cells	which	were	genetically	engineered	to	express	CCL2	give	rise	to	
tumours	due	to	modest	monocyte	/	macrophage	infiltration	[63].	Further	chemo-
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kines	involved	in	monocytes	recruitment	are	CCL5,	CCL7,	CXCL8	as	well	as	CXCL12	
[64].	 Besides	 chemokines,	 different	 cytokines	 and	most	 importantly	 CSF-1	 are	
involved	in	the	tumour	mediated	recruitment	of	monocytes.	Similar	to	the	pre-
viously	described	CCL2	tumour	model,	Dorsch	et	al.	generated	a	CSF-1	transgenic	
plasmacytoma	cell	line	and	observed	augmented	monocyte	infitration	in	a	trans-
plant	tumour	model	using	BALB	/	C	mice	[65].	In	addition,	VEGF	has	been	shown	to	
be	implicated	in	the	recruitment	of	TAM	into	beast	carcinoma	[66,	67].
A	hallmark	of	macrophages	is	their	plastic	gene	expression	profile.	While	in	
early	stages	of	tumour	development	M1-like	macrophages	prevail,	M2-like	TAM	are	
predominantly	found	in	fully	developed	solid	tumours	[68].	As	already	described	
above,	a	pro-inflammatory	milieu	 fostered	by	M1-like	macrophages	and	further	
immune	cells	promotes	tumour	development.	Suppression	of	anti-inflammatory	
functions	 of	macrophages	 by	 ablation	 of	 IL-10	 or	 its	 downstream	 target	 signal	
transducer	and	activator	of	transcription	3	(STAT3)	supports	the	generation	of	a	
smouldering	 inflammation	which	 in	 turn	 is	 associated	with	 tumourigenesis	 in	
the	colon	[69,	70].	Besides	STAT3,	NFκB	constitutes	an	important	transcriptional	
regulator	of	innate	immune	response	by	acting	downstream	of	TLR	to	regulate	the	
expression	of	pro-inflammatory	cytokines	such	as	IL-1	and	TNF-α	[71].	Targeted	
deletion	of	 inhibitor	of	NFκB	kinase	 subunit	β	 (IKKβ)	and	 thus	 impaired	NFκB	
signalling	in	LysM+	myeloid	cells	in	a	murine	mouse	model	of	colitis-associated	
cancer	led	to	significant	reduction	of	tumour	size	[72].	In	the	course	of	immuno-
editing,	 tumour	 cells	 create	 an	 anti-inflammatory	 environment	by	 secretion	of	
anti-inflammatory	cytokines	like	IL-4	and	TGF-β	that	promotes	M1	/	M2	transition	
thus	in	developed	solid	tumours	macrophages	are	trophic	M2-like.
In	 tumours	 discrete	 TAM	 subpopulations	 with	 site	 specific	 functions	 exist.	
In	 hypoxic	 regions	 TAM	 characteristically	 express	MHC  II low	 and	 exhibit	 a	 pro-	
angiogenic	M2-like	phenotype,	while	in	well	oxygenated	tumour	regions	TAM	are	
MHC IIhigh	[73,	74].	In	these	hypoxic	areas	TAM	secrete	growth	factors	like	VEGF	and	
platelet	derived	growth	factor	(PDGF)	to	induce	angiogenic	sprouting	of	blood	and	
lymph	vessels,	which	in	turn	facilitates	tumour	cell	intravasation	and	the	develop-
ment	of	metastasis.	In	perivascular	areas,	TAM	are	sources	of	growth	factors	like	
epidermal	growth	factor	(EGF)	and	hepatocyte	growth	factor	(HGF)	which	induce	
tumour	cell	proliferation.	By	secretion	of	metalloproteinases	(MMPs)	TAM	mediate	
matrix	remodelling	which	is	important	both	for	angiogenesis	and	tumour	tissue	
invasion.	In	addition,	TAM	inhibit	an	efficient	anti-tumour	immune	response	by	
producing	 anti-inflammatory	mediators	 like	 IL-10,	 TGF-β	 and	prostaglandin	E2,	
while	expression	of	IL-12	is	down-regulated	[37,	75].
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Figure 3: Tumour	associated	macrophages	promote	tumour	progression.	TAM are key play-
ers in the tumour stroma as sources of tumour growth supporting chemokines, cytokines, growth factors 
and matrix remodelling enzymes. Thus TAM mediate immunoediting and regulate the angiogenic switch 
to induce tumourangiogenesis. Furthermore, TAM promote tumour cell proliferation and direct tumour cell 
migration towards blood vessels to facilitate intravasation of tumour cells and the formation of metastasis. 
By secretion of matrix remodelling enzymes TAM support tumour cell invasion.
1.3.1 Tumour progression and angiogenesis
An	essential	event	during	the	conversion	from	benign	to	malignant	in	the	course	
of	 tumour	 progression	 is	 the	 development	 of	 a	 tumour	 vasculature.	 Tumour	
growth	beyond	a	critical	mass	requires	the	establishment	of	a	vascular	network	to	
warrant	sufficient	supply	with	nutrients,	oxygen	and	growth	factors.	In	addition,	
the	tumour	vessel	system	is	required	to	deposit	tumour	cell	meta	bolism	derived	
waste	products.	The	induction	of	tumour	mediated	angiogenesis	is	called	‘angio-
genic	switch’,	which	is	characterized	by	tilting	of	the	balance	between	pro-	and	
anti-	angiogenic	signals	in	favour	of	the	angiogenesis	promoting	mediators.	Under	
physio	logical	conditions,	angiogenesis	is	a	tightly	regulated	process	whereas	the	
deve	lop	ment	 of	 tumour	 vessels	 occurs	 in	 a	 rather	 deregulated	 manner	 hence	
resulting	in	malformed	leaky	vessels	[76,	77].	Different	cell	types	are	involved	in	
controlling	tumour	angiogenesis	amongst	which	macrophages	play	a	central	role.	
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Lin	and	colleagues	demonstrated	that	shortly	before	the	formation	of	a	tumour	ves-
sel	network	in	a	model	of	breast	cancer,	the	pre-malignant	lesion	is	infiltrated	by	
macro	phages.	Recruitment	of	monocytes	to	the	tumour	was	found	to	be	impaired	
in	CSF-1	null	mutant	mice,	which	in	turn	inhibited	the	formation	of	tumour	vessel	
system	and	tumour	growth,	respectively	[78].	In	a	similar		fashion	various	studies	
based	on	TAM	depletion	strategies	demonstrated	inhibition	of	angiogenesis	result-
ing	in	reduced	tumour	growth	[79,	80].	A	specific	subpopulation	of	TAM	marked	
by	the	expression	of	CD11	b	and	the	angiopoietin	receptor	TIE2	has	been	identified	
as	 angiogenic	macrophages	 [81].	By	 interaction	with	 the	TIE2	 ligand	angiopoie-
tin-2	(ANG-2)	on	the	endothelial	surface	these	macrophages	have	been	found	to	
be	aligned	to	the	abluminal	surface	of	blood	vessels.	The	majority	of	TIE2	express-
ing	macrophages	(TEM)	reside	in	viable,	highly	vascularized	areas	of	the	tumour	
and	 at	 the	 tumour	periphery	 [82].	 TIE2	 expressing	monocytes,	 the	progenitors	
of	TEM,	have	been	detected	 in	peripheral	blood	both	 from	healthy	donors	and	
cancer	patients,	whereas	TIE2+	macrophages	have	solely	been	found	in	tumours	
and	not	in	adjacent	healthy	tissues.	Furthermore,	co-injection	of	isolated	human	
CD14+	/	TIE2+	monocytes	and	a	glioblastoma	cell	line	resulted	in	enhanced	tumour	
vascularization	and	accordingly	increased	tumour	growth	[81].	Both	depletion	of	
the	TEM	subset	and	disruption	of	TIE2-ANG-2	based	interactions	between	endothe-
lial	cells	and	TAM	have	been	shown	to	inhibit	angiogenesis	and	tumour	progres-
sion	[83,	84].	Consequently,	recruited	macrophages	promote	the	development	of	a	
new	high-density	capillary	network	by	induction	of	sprouting	of	tumour	adjacent	
blood	vessels	which	facilitates	the	immense	expansion	of	proliferative	malignant	
cells	and	further	promote	the	progression	of	metastasis	by	establishing	the	routes	
for	tumour	cell	intravasation.
1.3.2 tam promote tumour growth
As	already	described	 above,	 the	majority	of	 tumours	benefits	 from	macrophage	
infiltration	 as	 TAM	 support	 tumour	 growth,	 angiogenesis	 and	 the	 formation	of	
metastasis.	TAM	secrete	a	broad	array	of	different	mediators	which	create	a	tumour	
promoting	microenvironment,	 like	e.	g.	 IL-10	and	TGF-β.	TAM	derived	 IL-10	pre-
vents	 the	 production	 of	 pro-inflammatory	 cytokines	 in	 an	 autocrine	 manner	
fostering	 an	 immunosuppressive	 microenvironment	 and	 promotes	 an	 alterna-
tive	 activation	 profile	 in	 TAM.	 In	 addition,	 IL-10	 is	 involved	 in	 the	 differentia-
tion	 of	monocytes	 to	macrophages,	 simultaneously	 preventing	 the	maturation	
of	dendritic	cells	[85].	Autocrine	IL-10	stimulation	leads	to	the	up-regulation	of	
programmed	death-ligand	1	(PD-L1)	expression	in	TAM	which	facilitates	efficient	
blockade	of	anti-tumour	response	mediated	by	cytotoxic	T cells	[86].	TGF-β	on	the	
other	hand	induces	differentiation	of	regulatory	T cells	(Treg)	which	are	potent	
immunosuppressive	cells	[87].	Chemokines	secreted	from	TAM	like	CCL13,	CCL18	
and	CCL22	are	further	involved	in	the	recruitment	of	Treg	cells	to	the	tumour	to	
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suppress	cytotoxic	T	cell	responses	[40].	While	CCL2	plays	a	crucial	role	in	macro-
phage	recruitment,	 the	chemokine	also	promotes	Th	2-responses	which	 in	 turn	
induce	M2-like	polarization	of	TAM	[88].	TAM	are	also	an	important	source	of	the	
growth	factors	PDGF	and	VEGF,	which	promote	tumour	growth	by	inducing	tumour	
cell	 proliferation	 and	 angiogenesis	 [78,	 89].	Matrix	 remodelling	 is	 required	 for	
both	tumour	angiogenesis	and	invasive	tumour	growth.	TAM	contribute	to	matrix	
de	gradation	by	the	secretion	of	various	MMPs.	Especially	expression	of	MMP-9	has	
been	linked	to	increased	angiogenesis	and	tumour	growth,	which	could	be	inhibi-
ted	in	a	MMP-9	knock	out	model	[90].	The	TAM	characteristic	up-regulation	of	
arginase-1	in	response	to	IL-4	and	IL-13	has	been	associated	with	impaired	T cell	
function	due	to	downregulation	of	CD3	ζ	expression	as	a	result	of	arginine	deple-
tion	[91].	Moreover,	TAM	have	been	identified	as	sources	of	cysteine	cathepsins.	
This	family	of	proteases	is	implicated	in	terminal	protein	degradation,	as	well	as	
activation	of	growth	factors	and	transcription	factors.	With	the	aid	of	 the	RIP1-
TAG2	 (RT2)	mouse	model	 of	 pancreatic	 islet	 cell	 cancer,	Gocheva	 et	 al.	 demon-
strated	 that	 IL-4	 induced	macrophage	derived	cathepsins	 substantially	 enhance	
tumour	growth,	invasiveness	and	angiogenesis	in vivo [92].	Diverse	cathepsins	are	
up-regulated	in	different	cancer	types,	which	is	associated	with	increased	tumour	
growth,	invasion,	angiogenesis	and	metastasis	[93].	
1.3.3 tam promote metastasis
Monocytes	and	macrophages	were	 found	to	direct	 tumour	cell	migration,	 intra-	
and	extravasation,	as	well	as	homing	to	metastatic	sites.	By	their	matrix	remodel-
ling	functions,	e.	g.	by	secretion	of	metalloproteinases	like	MMP-9,	TAM	have	been	
found	to	localize	at	the	invasive	front	of	aggressively	growing	tumours.	A	meta-	
analysis	revealed	that	high	expression	of	MMP-9	correlated	with	poor	patient	prog-
nosis	[94].	In	a	model	of	murine	breast	cancer,	Wyckoff	and	colleagues	combined	a	
chemotaxis-based	in vitro	invasion	assay	with	multiphoton-based	intra-vital	imag-
ing	which	allowed	them	to	observe	that	macrophages	and	tumour	cells	migrate	
side	by	side	in	response	to	chemotactic	factors.	Tumour	cells	produce	CSF-1	which	
attracts	TAM	and	 in	 turn	 stimulates	 the	myeloid	cells	 to	produce	EGF	 inducing	
tumour	cell	migration.	Hence	a	paracrine-loop	is	established	causing	tumour	cells	
and	macrophages	to	co-migrate	along	collagen	fibres	in	a	lock-step	fashion	[95].	
Macrophages	direct	tumour	cells	towards	blood	vessels	leading	to	the	formation	
of	so	a	called	tumour	microenvironment	for	metastasis	(TMEM),	which	serves	as	a	
prognostic	factor	for	the	formation	of	metastasis	in	breast	cancer	[96].	In	addition,	
the	number	of	perivascular	macrophages	correlates	with	the	number	of	circulat-
ing	tumour	cells	pointing	towards	the	pivotal	role	of	macrophages	for	tumour	cell	
migration	and	intravasation	[97].
Distinct	TAM	subsets	 are	 further	 involved	 in	 the	 formation	of	 the	pre-meta-
static	niche.	Already	in	1889,	Steve	Paget	formulated	the	hypothesis	of	‘seed	and	
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soil’	 in	which	he	 proposed	 that	 a	 pro-tumoural	microenvironment	 is	 requisite	
at	 the	site	of	metastasis.	The	primary	tumour	releases	soluble	 factors	 to	 induce	
the	formation	of	the	pre-metastatic	niche	at	distant	sites.	Myeloid	VEGFR+,	CD11	b+	
cells	are	recruited	to	these	sites	before	circulating	tumour	cells	arrive	and	create	
a	receptive	environment	to	promote	tumour	cell	engraftment	[98].	Upon	arrival	
at	 the	pre-metastatic	niche,	circulating	 tumour	cells	 aggregate	with	platelets	 to	
form	microclots	which	adhere	to	the	blood	vessel	adjacent	to	the	target	tissue.	The	
arrested	tumour	cells	recruit	monocytes	via	the	assembly	of	a	CCL2	chemoattrac-
tant	gradient.	The	monocytes	in	turn	express	VEGF	which	permeablises	the	blood	
vessels	facilitating	tumour	cell	extravasation	[56].	
1.3.4 tam as targets in cancer immunotherapy
Recent	research	and	substantiated	knowledge	of	tumour	immunology	have	high-
lighted	 the	 significant	contribution	of	 smouldering	 inflammation	and	 immune	
cells,	especially	of	TAM	to	tumour	initiation,	progression	and	metastasis,	thus	TAM	
have	evolved	to	interesting	new	targets	in	adjuvant	cancer	therapies.	TAM	directed	
anti-cancer	 therapies	 rely	 principally	 on	 TAM	depletion,	 blocking	 of	monocyte	
recruitment	and	strategies	to	re-educate	TAM	towards	a	tumouricidal,	pro-inflam-
matory	phenotype.	
A	promising	 strategy	 to	 target	 specific	 cell	 populations	 is	 the	 immunotoxin	
therapy	of	cancer.	The	directed	depletion	of	TAM	is	achieved	by	coupling	of	toxins	
to	monoclonal	 antibodies	which	bind	 to	macrophage	 specific	 surface	 receptors	
and	thus	are	able	to	induce	apoptosis	and	to	reduce	the	number	of	TAM.	In	human	
glioblastomas,	folate	receptor	β	has	been	identified	to	be	expressed	by	TAM	which	
could	be	targeted	by	a	monoclonal	antibody	coupled	to	Pseudomonas	exotoxin A.	
In	a	murine	in vivo	model,	glioma	tumour	growth	could	be	reduced	by	treatment	
with	the	immunotoxin	due	to	successful	depletion	of	TAM	[99].	Another	approach	
uses	bisphosphonates	such	as	clodronate	or	zoledronic	acid	(ZA)	to	achieve	TAM	
depletion.	Non-resorptive	ZA	 is	 actively	 taken	up	by	phagocytes	by	fluid-phase	
endocytosis	 eliciting	 reduced	migration	 and	 proliferation,	 whereas	 the	 apopto-
sis	rate	is	increased.	Interestingly,	ZA	treatment	also	impairs	MMP-9	secretion	by	
TAM	thus	inhibiting	angiogenesis	and	promoting	re-education	of	TAM	towards	a	
tumouricidal	M1-like	phenotype	[100].	Blocking	of	the	pro-survival	signal	M-CSF	
via	the	administration	of	a	monoclonal	antibody	(RG7155)	which	binds	to	the	cor-
responding	receptor	CSF-1R,	results	in	depletion	of	TAM	due	to	induced	cell	death.	
Moreover,	treatment	of	cancer	patients	with	RG7155	resulted	in	declined	infiltra-
tion	of	CSF-1R+CD163+	macrophages	in	tumour	tissues	[101].	
To	circumvent	monocyte	recruitment	to	the	tumour,	blocking	of	CCL2	signal-
ling	showed	encouraging	results	in	cancer	therapy,	as	administration	of	neutral-
izing	CCL2	antibodies	in	mice	reduced	tumour	growth	in	different	cancer	models	
[102].	A	humanized	monoclonoal	antibody	(MLN1202)	that	binds	to	CCR2	thereby	
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inhibiting	binding	of	CCL2	recently	went	through	a	phase II	clinical	trial	includ-
ing	patients	suffering	from	bone	metastasis	at	which	antibody	administration	elic-
ited	a	positive	effect	(NCT01015560).	Similarly,	CCL5	is	involved	in	chemoattraction	
of	monocytes,	as	well	as	Treg’s	and	myeloid	derived	suppressor	cells	(MDSC).	The	
interaction	with	its	respective	receptors	CCR1	and	CCR5	represents	a	potential	new	
target	in	adjuvant	therapy	of	breast	cancer.	CCR5	antagonist	are	already	used	for	
the	treatment	of	HIV	patients,	as	blocking	of	the	receptor	prevents	virus	intrusion	
into	the	host	cell	[103].	Treatment	of	mice	bearing	subcutaneous	tumours	with	the	
chemokine	antagonist	resulted	in	reduction	of	total	tumour	weight	and	volume	
accompanied	by	reduced	numbers	of	infiltrating	macrophages	[104].	
Induction	of	a	tumouricidal	macrophage	phenotype	has	been	achieved	by	acti-
vation	of	co-stimulatory	CD40	with	monoclonal	antibodies	(mAB).	In	a	murine	
model	of	pancreatic	 cancer	 treatment	with	 the	CD40	directed	mAB	 resulted	 in	
enhanced	 expression	of	MHC	 class  II	 in	macrophages	 and	 serum	 levels	 of	 pro-	
inflammatory	 cytokines	 IL-12,	 TNF-α	 and	 IFN-γ	were	 increased,	 subverting	 the	
immunosuppressive	 tumour	 microenvironment.	 Furthermore,	 therapeutic	 effi-
cacy	could	be	demonstrated	 in	patients	 suffering	 from	pancreatic	ductal	 adeno-
carcinoma	when	 the	 antibody	was	 administrated	 in	 combination	with	 gemcita-
bine	increasing	the	time	period	of	progression	free	survival	and	overall	survival	
rates	 [105].	 NFκB	 activation	 in	 macrophages	 induces	 a	 pro-inflammatory	 gene	
expression	profile.	Several	strategies	aim	at	TLR	mediated	activation	of	NFκB	in	
order	 to	 re-program	 TAM	 towards	 a	M1-like	 phenotype.	 In	macrophages,	 treat-
ment	with	the	TLR7	agonist	Imiquimod	stimulates	the	production	of	pro-inflam-
matory	cytokines	like	IFN-α,	TNF-α,	IL-6,	IL-8	and	IL-12	and	is	used	for	the	treat-
ment	of	non-melanoma	skin	cancers	such	as	basal	cell	carcinoma	[106].	Further	
TLR	agonists	are	under	current	evaluation.	Administration	of	TLR9	agonist	CpG-b	
also	induces	reprogramming	of	macrophages	and	thus	increased	innate	immune	
response	against	tumours	[107].	Intratumoural	injection	of	the	novel	TLR7	/	8	ago-
nist	 (3M-052)	has	been	 shown	 to	 raise	 a	 systemic	 anti-tumour	 response	 to	 the	
primary	tumour	as	well	as	growth	suppression	at	distant	sites	due	to	reprogram-
ming	of	TAM	towards	tumouricidal	phenotype	in	a	model	of	murine	melanoma	
[108].	Due	to	these	promising	effects	several	TLR	agonists	are	currently	in	Phase I	
and	 Phase  II	 clinical	 trials.	 The	 multikinase	 inhibitor	 Sorafenib,	 which	 is	 an	
approved	drug	for	renal	cell	carcinoma	and	hepatocellular	carcinoma,	acts	on	the	
RAF	/	MEK	/	ERK	 signalling	pathway.	 In vivo	 studies	 revealed	 that	 the	 inhibition	of	
this	pathway	leads	to	downregulation	of	IL-10	expression	in	murine	macrophages	
and	simultaneous	restoration	of	pro-inflammatory	 IL-12	reverting	 the	TAM	phe-
notype	towards	tumouricidal	[109].	Similar	results	were	obtained	when	IL-10	was	
targeted	with	CpG	oligonucleotides	which	were	administrated	 intravenously	 to	
tumour	bearing	mice	resulting	in	suppression	of	the	tumour	promoting	functions	
of	TAM	[110].
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In	 summary,	 lots	 of	 strategies	 to	 prevent	 tumour	 supporting	 functions	 and	
to	eliminate	TAM	have	been	successfully	developed.	The	relevance	of	these	adju-
vant	therapies	is	illustrated	by	the	findings	that	TAM	can	influence	the	response	
to	 chemotherapeutics	 by	 counteracting	 chemotherapy	 induced	 tumour	damage	
through	misdirected	 tissue	 repair	mechanisms	 thus	 supporting	 tumour	growth	
during	 treatments	 [111].	 Hence,	 targeting	 TAM	 might	 positively	 influence	 the	
responsiveness	to	classical	anti-cancer	therapies.
1.4 Lymphatic vessel endothelial hyalu- 
ronan receptor (Lyve-1)
1.4.1 Structure and Expression of Lyve-1
Lyve-1,	also	known	as	cell	surface	retention	sequence	binding	protein	1	(CRSBP-1),	
has	been	first	identified	as	a	lymphatic	vessel	specific	hyaluronic	acid	(HA)	recep-
tor	in	the	course	of	a	search	for	homologs	of	CD44,	which	aimed	at	the	identifica-
tion	of	further	receptors	for	HA.	Lyve-1	consists	of	322	amino	acids,	containing	a	
short	hydrophobic	leader	sequence,	followed	by	a	serine	and	threonine	rich	hydro-
philic	region	(212	amino	acids),	a	single	transmembrane	domain	and	a	short	C-ter-
minal	intracellular	cytoplasmic	tail	build	by	70	amino	acids.	The	greatest	sequence	
similarities	 between	 Lyve-1	 and	 CD44	were	 attributed	 to	 a	 single	 link	 domain	
which	is	located	in	the	N-terminal	extracellular	portion	of	the	receptors.	The	con-
sensus	sequence	of	the	link	domain	can	be	found	in	the	majority	of	HA-binding	
proteins.	The	hydrophobic	pocket,	which	is	responsible	for	interactions	with	HA,	
is	 formed	by	two	β-sheets	and	two	short	α	helices	stabilized	by	two	disulphide	
bridges	between	four	cysteine	residues.	Both	in	CD44	as	well	as	in	Lyve-1	the	link	
domain	is	extended	by	two	further	cysteine	residues	forming	a	third	disulphide	
bridge,	resulting	in	the	formation	of	four	additional	β-sheets	thus	enlarging	the	
pocket	for	HA-binding.	A	further	unpaired	cysteine	residue	is	located	in	the	trans-
membrane	domain	facilitating	the	formation	of	homodimers	by	disulphide	link-
age.	In	the	region	of	the	link-motif	of	Lyve-1,	two	sites	for	N-linked	glycosylation	
have	been	identified	while	O-linked	glycosylation	sites	were	found	in	the	trans-
membrane	proximal	 region	 [112-114].	Northern	 blot	 analysis	 and	 immunohisto-
logical	staining	revealed	abundant	Lyve-1	expression	in	spleen,	lymph	nodes,	heart,	
lung	and	fetal	liver,	as	well	as	moderate	expression	levels	in	appendix,	bone	mar-
row,	 placenta,	 muscle	 and	 adult	 liver.	 Initially,	 Lyve-1	 surface	 expression	 was	
assumed	to	be	exclusive	to	lymphatic	endothelial	cells,	equally	distributed	on	the	
luminal	and	the	basolateral	surface	of	the	vessels	with	the	exception	of	expression	
in	sinusoidal	endothelial	cells	in	the	kidney	and	syncytiotrophoblasts,	while	being	
absent	from	blood	vessels	[112].	However,	by	immunohistological	means	Lyve-1	
expression	could	also	be	demonstrated	 in	 liver	 sinusoidal	endothelial	cells	and	
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Kupffer	cells,	which	were	CD68+	/	Lyve-1+	double	positive	[115].	In	2006,	Schledze-
wski	et	al.	provided	further	evidence	for	extra-lymphatic	expression	of	Lyve-1.	In	
murine	 tumour	 and	wound	 healing	models	 a	 subpopulation	 of	 F4	/	80+,	 CD11	b+	
macrophages	had	been	discovered	to	express	Lyve-1.	In vitro,	Lyve-1	expression	was	
induced	in	murine	bone-marrow	derived	macrophages	(BMDM)	by	the	combined	
stimulation	with	B16F1	 tumour	 condition	medium,	 IL-4	 and	glucocorticoids	 in	
approximately	25-40	%	of	the	cells	[116].	
Figure 4: Structure	of	Lyve-1.	Lyve-1 is type I transmembrane glycoprotein. The N-terminal ecto-
domain contains an extended link domain which is stabilized by three disulphide bridges. In the region of 
the link domain two sites for N-linked glycosylation have been identified, while the membrane proximal 
domain is heavily O-glycosylated. In the transmembrane region an unpaired cysteine residue facilitates 
dimerization. ADAM17 and MT1-MMP mediate shedding of the Lyve-1 ectodomain (adapted from Jackson 
et al. [117]).
1.4.2 Binding properties of Lyve-1
The	functionality	of	the	link	domain	of	Lyve-1	was	examined	by	binding	assays	
using	a	recombinant	fusion	protein	composed	of	the	extracellular	soluble	domain	
of	Lyve-1	(1-232)	fused	to	human	Fc.	Highly	specific	interactions	of	Lyve-1	Fc	with	
both	soluble	and	immobilized	HA	were	shown	[112].	In	addition,	up-take	of	HA	by	
fibroblasts	which	were	genetically	engineered	to	express	murine	Lyve-1	was	demon-
strated,	pointing	towards	a	possible	role	of	Lyve-1	as	a	 lymphatic	specific	endo-
cytosis	receptor	for	HA	[118].	Further	biochemical	analyses	examining	the	nature	
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of	Lyve-1	/	HA	binding	revealed	that	the	binding	is	mediated	mainly	by	electrostatic	
interactions.	Moreover,	it	was	shown	that	the	monomeric	complete	ectodomain	
(amino	acids	1-232)	efficiently	bound	HA,	whereas	the	isolated	Lyve-1	link domain	
(amino	acids	 1-169)	was	not	competent	of	HA-binding	 indicating	 that	elements	
from	the	membrane	proximal	stalk	region	are	required	for	successful	interactions	
[119].	Yet,	binding	of	hyaluronic	acid	 to	endogenously	expressed	Lyve-1	 in	 lym-
phatic	vessels	and	cultured	lymphatic	endothelial	cells	could	not	be	proofed.	In	a	
cell	specific-manner	Lyve-1	encounters	glycosylation	dependent	masking	of	the	
HA-binding	site.	Enzymatic	treatment	with	neuroaminidase	of	Lyve-1	in	primary	
lymphatic	endothelial	cells	resulted	in	the	removal	of	sialylation	sites	and	thus	
reconstitution	of	 the	HA-binding	capacity	of	 the	 receptor.	Physiological	mecha-
nisms	leading	to	the	activation	of	Lyve-1	remained	elusive	[120].	Only	recently,	the	
importance	of	Lyve-1	density	on	the	cell	surface	of	lymphatic	endothelial	cells	for	
HA-binding	has	been	recognized.	A	critical	threshold	of	Lyve-1	molecules	on	the	
cell	surface	is	needed	to	enable	HA	binding,	which	could	be	achieved	in	human	
dermal	lymphatic	endothelial	cells	by	lentiviral	overexpression	of	Lyve-1.	Artifi-
cial	clustering	of	the	receptor	by	cross-linkage	with	antibodies	or	complexation	of	
HA	also	facilitated	ligand	interactions	with	the	endogenous	receptor	in	primary	
lymphatic	endothelial	cells	[121].	Contemporaneously,	CRSBP-1	/	Lyve-1	was	recog-
nized	to	be	involved	in	cell	surface	retention	of	growth	factors	and	cytokines,	thus	
identifying	cell	surface	retention	sequence	(CRS)	motif	carrying	proteins	PDGF-β,	
VEGF-α	and	insulin	like	growth	factor-binding	protein-3	(IGFBP-3)	as	further	lig-
ands	of	Lyve-1.	The	binding	site	for	the	growth	factors	does	not	coincide	with	the	
link	domain,	as	HA-binding	did	not	prevent	interaction	with	CRS	containing	pro-
teins	[122-124].	At	last,	high	affinity	interactions	between	FGF-2	and	Lyve-1	have	
been	demonstrated	in	solution	and	on	the	cell	surface	of	lymphatic	endothelial	
cells.	The	glycosylation	status	of	Lyve-1	played	a	critical	role	in	growth	factor	bind-
ing,	as	deglycosylation	of	Lyve-1	resulted	in	decreased	interactions.	Furthermore,	
FGF-2	stimulation	induced	LYVE-1	expression	in vitro	and	in vivo [125].
1.4.3 Processing of Lyve-1
In	an	attempt	to	determine	possible	Lyve-1	activation	stimuli	researchers	found	
that	 the	 surface	 expression	 of	 the	 receptor	 is	 impaired	 in	 response	 to	 the	 pro-	
inflammatory	stimuli	TNF-α	and	TNF-β	in	primary	lymphatic	endothelial	cells	as	
well	as	in	TNF-treated	mouse	ear	dermal	explants.	Under	inflammatory	conditions	
the	receptor	is	internalized	and	finally	degraded	in	phagolysosomes,	accompanied	
by	reversible	discontinuance	of	LYVE-1	gene	expression	[126].	In	analogy	to	CD44,	
which	undergoes	proteolytic	 cleavage,	 two	 recent	 studies	 supplied	evidence	 for	
ectodomain	shedding	of	Lyve-1.	Two	cleavage	sites	for	MT1-MMP	(membrane-type	
metalloproteinase,	also	known	as	MMP-14)	were	identified	in	the	ectodomain	of	
Lyve-1,	namely	G64-L	in	the	link domain	and	A235-L	in	the	stalk	region.	MMP-14	
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mediated	shedding	of	Lyve-1	negatively	regulates	Lyve-1	mediated	signalling	and	
lymphangiogenesis	 [127].	Almost	 simultaneously	 another	group	 showed	VEGF-A	
dependent	ectodomain	shedding	of	Lyve-1.	The	shedding	process	 is	dependent	
on	VEGFR2	mediated	phosphorylation	of	extracellular	signal	regulated	kinase	1	/	2	
(ERK1	/	2)	and	the	subsequent	activation	of	a	disintegrin	and	metalloproteinase	17	
(ADAM17)	which	cleaves	Lyve-1	between	the	amino	acid	sequence	226	–	229	[128].	
1.4.4 Lyve-1 signalling and functional implications
To	characterize	the	function	of	Lyve-1,	murine	knockout	models	have	been	gen-
erated.	Lyve-1-/- mice	display	a	normal	phenotype.	The	mice	develop	a	functional	
lymphoid	system	and	development	and	 trafficking	of	 the	 lymphocyte	subset	 is	
unperturbed	as	well.	Both	metabolism	and	levels	of	HA	in	blood	and	tissue	are	
not	 affected	by	 the	 ablation	of	Lyve-1	 from	 the	organism.	Furthermore,	 resolu-
tion	of	inflammation	is	comparable	to	wild	type	mice	and	no	differences	regard-
ing	growth	of	B16	and	Lewis	 lung	carcinoma	(LLC)	 tumours	have	been	noticed	
[129].	However,	in	a	second	study	morphological	changes	of	lymphatic	vessels	in	
the	 liver	and	intestine	of	Lyve-1-/-	mice	were	observed.	Enlargement	of	the	ves-
sels	 accelerated	 removal	of	 intradermal	 injected	macromolecular	dextran	point-
ing	toward	an	increased	interstitial	lymphatic	flow	[130].	A	possible	explanation	
for	this	observation	came	from	a	study	which	demonstrated	that	Lyve-1	receptor	
engagement	disassembles	a	complex	formed	by	Lyve-1,	PDGF-βR,	β-catenin	and	
VE-cadherin	resulting	in	the	internalization	of	VE-cadherin	and	thus	leading	to	the	
opening	of	lymphatic	endothelial	cells	(LEC)	intercellular	junctions	and	increased	
vascular	 permeability	 [131].	While	 no	 distinct	 function	 of	 Lyve-1	 on	 HA	meta-
bolism	has	been	noticed,	stimulation	with	low	molecular	weight	HA	(LMW-HA)	
promotes	 Lyve-1	 dependent	 lymphangiogenesis	 though	 the	 underlying	mecha-
nism	is	not	fully	understood	yet.	In	the	lymphatic	endothelial	cell	line	SVEC4-10,	
stimulation	with	LMW-HA	induced	Lyve-1	dependent	proliferation,	migration	and	
tube	formation	by	intracellular	activation	of	PKC	and	ERK1	/	2	[132].	A	second	study	
demonstrated	 that	LMW-HA	stimulation	 induced	co-localization	of	Lyve-1	with	
sphingosine	1	phosphate	3	receptor	(S1P3)	and	the	subsequent	phosphorylation	
of	the	downstream	targets	Src	and	ERK1	/	2	in	SVEC4-10	cells.	Silencing	either	S1P3	
or	Lyve-1	expression	attenuated	intracellular	downstream	signalling	[133].	FGF-2	
constitutes	an	additional	binding	partner	of	Lyve-1	known	to	induce	lymphangio-
genesis.	In vitro,	the	addition	of	the	soluble	Lyve-1	ectodomain	inhibited	migration,	
invasion	and	proliferation	of	FGF-2	stimulated	lymphatic	endothelial	cells,	while	
knockdown	of	Lyve-1	expression	of	LEC	also	reduced	FGF-2	induced	cell	prolifer-
ation	and	tubulogenesis.	Micropockets	containing	FGF-2	alone	or	in	combination	
with	Lyve-1,	which	were	implanted	in	the	cornea	of	mice,	substantiated	the	modu-
lating	 effect	 of	 Lyve-1	 on	 FGF-2	mediated	 lymphangiogenesis	 [125].	 Lyve-1	 has	
further	been	identified	to	be	involved	in	cell	surface	retention	of	growth	factors,	
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which	express	a	CRS	motif	like	PDGF,	VEGF	and	IGF-β.	In	cells,	which	expressing	
the	v-sis	gene	product,	overexpression	of	Lyve-1	was	associated	with	increased	cell	
proliferation	and	enhanced	tumourigenicity	in vivo	via	activation	of	PDGF	β-type	
receptor.	Hence,	Lyve-1	is	 involved	in	autocrine	growth	regulation	mediated	by	
growth	factors	carrying	the	CRS	motif	[124].
1.4.5 Lyve-1 expression in tam
In	 the	 past	 years,	 research	 in	 the	 field	 of	 tumour	 associated	macrophages	 has	
revealed	their	tumour	promoting	effects	making	them	interesting	new	targets	in	
adjuvant	cancer	therapy.	Though	it	became	apparent	that	TAM	constitute	a	highly	
heterogenic	 population	within	 the	 tumour	 stroma,	 as	 different	 subpopulations	
executing	different	functions	have	been	recognized.	Consequently,	a	need	for	fur-
ther	TAM-specific	marker	exists	to	identify	subpopulations	and	analyze	their	fea-
tures	in	more	detail.	Our	group	concentrated	on	the	identification	and	character-
ization	of	 such	macrophage	markers.	 In	murine	models	Ms4a8a,	 Stabilin-1	 and	
also	Lyve-1	have	been	discovered	by	our	group	to	be	expressed	by	TAM	in	different	
tumour	models. In vitro	 these	markers	 can	be	 induced	 in	BMDM	by	 stimulation	
with	a	combination	of	tumour-conditioned	medium,	glucocorticoids	and	IL-4	[116,	
134,	135].	In	2015,	Dr.	Kathrin	Schönhaar	published	her	doctoral	thesis	with	the	
title	‘Expression	analysis	of	murine	and	human	tumour	associated	macrophages’.	
The	aim	of	her	thesis	was	to	compare	similarities	and	differences	concerning	the	
expression	 of	 the	 three	mentioned	macrophages	markers	 between	 human	 and	
murine	 TAM.	 In	 addition,	 she	 conducted	 continuative	 experiments	 to	 examine	
the	nature	of	the	Lyve-1	expression	in	human	TAM.	Her	observations	are	the	basis	
of	this	work	and	the	results	concerning	Lyve-1	will	be	presented	in	the	following.	
Histopathological	 analyses	 of	 different	 human	 tumour	 entities	 revealed	 the	
presence	of	Lyve-1+	macrophages	in	colon	carcinoma,	ovarian	carcinoma	and	pri-
mary	melanoma.	In vitro, LYVE-1	was	induced	in	pBMC	after	7	days	of	stimulation	
with	M-CSF,	dexamethasone	and	 IL-4.	The	addition	of	 the	glucocorticoid	 recep-
tor	 (GR)	 antagonist	 mifepristone	 to	 the	 stimulation	 cocktail	 suppressed	 induc-
tion	of	 LYVE-1	 expression.	 In	pBMC,	 co-cultivation	with	 the	human	melanoma	
cell	line	WM115,	which	was	derived	from	a	primary	melanoma,	was	able	to	induce	
LYVE-1	expression	too,	whereas	co-incubation	with	the	metastatic	cell	line	WM266	
was	not.	By	immunoblotting	and	ELISA,	a	soluble	form	of	Lyve-1	was	detected	in	
the	cell	culture	supernatants	of	Lyve-1+	pBMC,	which	were	derived	either	 from	
M-CSF	/	dexa	/	IL-4	(MDI)	cytokine	stimulation	or	by	co-cultivation	with	WM115.	The	
murine	macrophage	 cell	 line	RAW	264.7	 and	a	human	analogous	 cell	 line	U937	
were	 genetically	 engineered	 to	 express	 Lyve-1	 to	 analyze	 protein	 processing	 of	
Lyve-1	 in	more	detail.	By	 immunoblot	 analysis	 a	 shorter	version	of	Lyve-1	was	
detected	with	a	molecular	weight	of	 approximately	 55	kDa	 in	 the	culture	 super-
natant	of	the	transgenic	cells,	while	full	length	Lyve-1	was	routinely	detected	at	
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around	70	kDa	in	the	cell	lysates.	Stimulation	of	the	transgenic	cell	lines	with	the	
shedding	 inducer	 APMA	 led	 to	 accumulation	 of	 the	 55	kDa	 Lyve-1	 form	 in	 the	
cell	culture	supernatant,	while	in	the	cell	lysates	the	amount	of	full	length	Lyve-1	
was	 reduced.	The	opposite	was	 true,	when	the	cells	were	 treated	with	different	
sheddase	inhibitors.	Hence,	the	macrophage	cell	lines	secreted	soluble	Lyve-1	by	
metallo	proteinase	mediated	shedding.
In	summary,	Schönhaar	outlined	the	existence	of	human	Lyve-1+	TAM	and	the	
dexamethasone	dependent	gene	induction	in	pBMC.	In	addition,	metalloprotein-
ase	mediated	ectodomain	shedding	has	been	observed	[136].
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We	 and	 others	 were	 able	 to	 demonstrate	 that	 Lyve-1	 expression	 is	 in	 fact	 not	
restricted	 to	 the	 lymphatic	 endothelium.	 Schönhaar	 provided	 evidence	 for	 the	
existence	of	Lyve-1+	tumour	infiltrating	macrophages	which	define	a	distinct	sub-
population	of	TAM.	In	order	to	develop	novel	cancer	treatment	strategies	involv-
ing	TAM,	it	is	essential	to	determine	the	net	effect	of	distinct	macrophage	subpop-
ulations.	Thus	this	study	focuses	on	the	following:
validation of lyve-1 as a marker of macroPhages Present in human melanoma
For	this	purpose,	serial	sections	of	human	melanoma	samples	will	be	prepared	for	
immunohistological	analyses	of	Lyve-1	and	macrophage	differentiation	markers.	
The	newly	established	method	of	sequential	staining	will	be	applied	on	human	
melanoma	 sections	 for	 the	 successive	 staining	 of	 Lyve-1	 in	 combination	 with	
macro	phage	markers	for	the	explicit	detection	of	Lyve-1+	macrophages.
characterization of pbmc as an in vitro model for lyve-1+ tam
After	prolonged	stimulation	of	pBMC	with	MDI	Lyve-1+	cells	were	detected	in vitro.	
Further	analyses	of	this	primary	cell	model	regarding	time	course	and	activated	
signalling	pathways	will	define	 the	basal	 requirements	 for	Lyve-1	 expression	 in 
vitro.	The	type	of	macrophage	differentiation	resulting	from	stimulation	of	pBMC	
with	MDI	will	be	characterized	by	macrophage	associated	markers	such	as	CD163	
and	CD206:
determination of the biological relevance of lyve-1+ in transgenic cells
For	functional	analyses	of	Lyve-1,	transgenic	human	and	murine	cell	models	will	
be	established.	These	will	be	used	to	get	first	hints	for	a	possible	role	of	Lyve-1	in	
macrophages	in	basal	cell	tests	like	proliferation	and	migration	assays.
Shedding	of	Lyve-1	will	be	examined	in	analogy	to	its	homolog	CD44,	which	is	
processed	by	metalloproteinases.	
effects of lyve-1 and gr signalling on tumour growth in animal models
Tumour	progression	will	be	monitored	in	Lyve-1-/-	mice	to	identify	the	net	effect	of	
Lyve-1+	cells	on	tumour	growth.	The	model	of	LysMcre;GRflox	mice	that	impairs	
GR	signalling	in	myeloid	cells	will	be	used	to	define	the	contribution	of	GR	signal-
ling	to	LYVE-1	induction	in	TAM	in vivo	and	for	the	analysis	of	TAM	differentiation	
in	general.
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2.1 Biochemical Methods
2.1.1 rna Isolation and cdna Synthesis
After	cultivation,	eukaryotic	cells	were	harvested	and	washed	once	in	phosphate	
buffered	saline	(PBS),	the	cell	suspension	was	spun	down	and	the	supernatant	was	
discarded.	The	cell	pellets	were	used	for	RNA	isolation	by	spin	column	based	puri-
fication	with	either	the	RNeasy	Kit	(Qiagen)	or	the	innuPREP	RNA	Mini	Kit	(Jena	
Analytik)	according	to	the	manufacturer’s	protocol.	In	both	cases	RNA	was	eluted	
in	a	volume	of	40	µL	RNase	free	water.	After	isolation	of	total	RNA	with	the	RNeasy	
kit,	removal	of	contaminating	genomic	DNA	was	achieved	by	a	digest	with	DNase	I	
(Fermentas)	for	1	h	at	37°C.	In	contrast	to	that,	genomic	DNA	was	removed	by	a	pre-
cleaner	column	when	the	innuPREP	RNA	Mini	Kit	was	used,	thus	an	additional	
DNA	digest	was	not	necessary.	RNA-concentration	of	the	samples	was	determined	
with	the	aid	of	the	photometer	Nanodrop	2000	(Thermo	Scientific).	The	RNA	was	
stored	at	-80°C.
Reverse	Transcription	(RT)	was	conducted	to	transcribe	single	stranded	mRNA	
into	double	stranded,	more	stable	cDNA.	In	contrast	to	genomic	DNA	of	eukaryotes,	
cDNA	is	characterized	by	the	lack	of	introns.	To	retranscribe	total	mRNA	of	a	sam-
ple	the	fact	that	a	poly-A-tail	is	attached	to	the	3'	end	of	eukaryotic	mRNA	as	a	pro-
tection	against	degradation	by	exoribonucleases	was	exploited	by	using	oligo(dT)	
primers.	For	reverse	transcription	1	µg	of	RNA	per	sample	was	used.	The	reaction	
was	performed	with	RevertAid	H	Minus	M-MuLV	Reverse	Transcriptase	(Fermen-
tas).	cDNA	was	produced	by	a	two-step	RT-PCR	protocol	as	follows.
Total	RNA 1	µg
Oligo(dT)	(100	µM) 0.5	µg
RNase	free	water To	12.5	µL
The	premix	was	mixed	gently	and	incubated	for	5	min	at	65°C	and	then	chilled	
on	ice	before	the	bellow	mentioned	components	were	added.
5	×	Reaction	Buffer	 4	μL	
RNase	Inhibitor	 0.5	μL	(20	U)	
dNTP	Mix,	10	mM	each	 2	μL	
RevertAid	H	Minus	Reverse	Transcriptase 1	μL	(200	U)	
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Reverse	 transcription	 was	 performed	 at	 42°C	 for	 60	min	 followed	 by	 heat	
induced	inactivation	of	the	enzyme	at	70°C	for	10	min.	cDNA	samples	were	stored	
at	-20°C.
2.1.2 Polymerase Chain Reaction (Pcr)
PCR	is	a	commonly	used	method	for	the	amplification	and	detection	of	specific	
DNA	/	cDNA	segments	of	up	to	6	kb.	Standard	PCR	occurs	generally	in	three	steps:	
denaturation,	annealing	and	elongation.	First	single	stranded	DNA	(ssDNA)	is	pro-
duced	by	heating	the	sample	to	95°C,	followed	by	a	temperature	reduction	which	
allows	the	annealing	of	oligonucleotide	primers	which	are	complementary	to	the	
flanking	sites	of	the	DNA	region	of	interest.	Thus	a	thermostable	DNA	polymerase	
can	bind	to	the	primer	/	ssDNA	hybrid	and	elongate	the	primer	according	to	the	
template	sequence	by	 incorporation	of	the	corresponding	dNTPs	[137].	For	PCR	
cDNA	was	diluted	1	:	10	in	ddH2O	and	the	DFS-TAQ	DNA	Polymerase	from	Bioron	
with	the	appendant	buffer	was	used	to	prepare	the	following	reaction	mixture:
10	×	complete	Buffer 1.2	µL
dNTP	(2	mM) 0.6	µL
Primer	forward	(10	µM) 0.5	µL
Primer	reverse	(10	µM) 0.5	µL
TAQ	DNA	Polymerase 0.1	µL
H2O 6.1	µL
cDNA	(1	:	10) 1.0	µL
Total 10	µL
The	general	cycling	conditions	were:
TEMPERATURE	[°C] TIME	 REPEATS
95 3	min 1	×
95 30	s
(60)	adaption	according	to	primer	pair 30	s
72 45	s
72 5	min 1	×
4 ∞ 1	×
For	analysis	the	PCR	products	were	loaded	on	1-2	%	agarose	gels	containing	10	%	
Nancy-520,	a	fluorescent	stain	for	dsDNA.	The	gels	were	run	in	a	chamber	filled	
with	TAE	and	electrophoresis	was	performed	at	130	V	for	30	min.	DNA	bands	were	
visualized	with	 the	aid	of	 Intas	UV	Systems	N-90	m	and	documented	by	photo-
graphing.
•
•
34	×
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2.1.3 Quantitative Real-Time Pcr (qrt-Pcr)
qRT-PCR	allows	the	simultaneous	amplification	and	detection	of	PCR	products.	By	
the	use	of	dsDNA	intercalating	dyes	a	fluorescent	signal	 is	generated,	which	en-	
ables	the	quantification	of	the	amount	of	PCR	product	during	each	PCR	cycle	in	
the	exponential	phase	of	DNA	amplification.	The	resulting	fluorescence	signal	is	
measured	and	plotted	as	a	function	of	the	cycle	number	by	a	sequence	detection	
system.	It	is	possible	to	extrapolate	back	in	order	to	calculate	the	amount	of	tem-
plate	prior	to	the	start	of	the	PCR	[138].	For	normalization	of	the	template	amount	
in	the	PCR,	it	is	necessary	to	include	an	internal	control,	at	which	housekeeping	
genes	are	used.	In	the	following	analyses	gene	expression	was	calculated	in	rela-
tion	to	β-Actin	[139].	
Prior	to	qRT-PCR,	template	cDNA	was	diluted	1	:	40	in	ddH2O,	mixed	with	for-
ward	and	reverse	primer	(2	µM)	of	the	gene	of	interest,	as	well	as	SyBRGreen	Mas-
ter	Mix	(Applied	Biosystems)	according	to	the	manufacturer’s	protocol.	Besides	
the	fluorescent	dye	 the	master	mix	 contains	buffer,	dNTPs	 and	 a	 thermostable	
hot-start	DNA	polymerase.	The	PCR	was	run	under	standard	conditions	with	an	
MX3000P	sequence	detection	system	(Stratagene).	
2.1.4 Protein isolation and modified Lowry assay
For	 protein	 isolation	 eukaryotic	 cells	 were	 harvested	 and	washed	 as	 described	
before	(compare	to	2.1.1	RNA	Isolation).	Cell	pellets	were	resuspended	in	cell	lysis	
buffer,	for	subsequent	immunoblot	analysis	RIPA	buffer	was	used,	whereas	DISC	
buffer	was	applied	in	the	case	of	sample	processing	for	immunoprecipitation	(IP).	
The	samples	were	incubated	on	ice	for	20	min	and	centrifuged	at	4°C	at	14	000	g	for	
10	min	to	remove	cellular	debris.	The	protein	containing	supernatant	was	 trans-
ferred	to	a	new	collection	tube.	
Colorimetric	quantification	of	protein	concentration	was	then	determined	by	
DC™	Protein	Assay	(Bio	Rad),	which	is	a	method	based	on	Lowry-Assay.	In	brief,	
in	an	alkaline	medium	copper-treated	proteins	reduce	Folin	reagent	resulting	in	
the	development	of	a	characteristic	blue	colour,	which	shows	strong	absorbance	
at	 λ	=	650	nm.	 In	 order	 to	 determine	 the	 protein	 concentration	with	 colorimet-
ric	means,	a	standard	curve	had	to	be	measured.	For	this	purpose,	a	seven-point	
standard	curve	was	prepared	using	bovine	serum	albumin	(BSA)	diluted	in	the	cor-
responding	lysis	buffer	with	a	range	from	10	mg	/	mL	to	0.16	mg	/	mL.	
2.1.5 sds Page
SDS	PAGE	facilitates	the	separation	of	proteins	according	to	their	molecular	weight.	
The	polyacrylamide	gels	were	casted	just	before	use.	First	the	resolving	gel	was	pre-
pared,	whereat	the	concentration	of	polyacrylamide	and	thus	the	resulting	pore	
size	 of	 the	 gel	was	 varied	 according	 to	 the	molecular	weight	 of	 the	protein	 of	
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interest.	During	polymerization	the	resolving	gel	was	covered	carefully	with	iso-
propanol	to	avoid	drying	up.
resolving gel
10	% 12	%
dH2O 5.9	mL 5.0	mL
30	%	Bisacrylamide 5.0	mL 6.0	mL
1.5	M	Tris,	pH	=	8.8 3.8	mL 3.8	mL
10	%	SDS 0.15	mL 0.15	mL
10	%	APS 0.15	mL 0.15	mL
TEMED 6	µL 6	µL
When	the	polymerization	of	the	resolving	gel	was	completed,	the	isopropanol	was	
demounted	and	the	stacking	gel	was	casted	on	top	of	the	resolving	gel	and	a	comb	
was	inserted.
stacking gel
dH2O 1.72	mL
30	%	Bisacrylamid 0.5	mL
0.5	M	Tris,	pH	=	6,8 0.76	mL
10	%	SDS 0.03	mL
10	%	APS 0.03	mL
TEMED 3	µL
Protein	samples	were	mixed	with	Laemmli	Buffer.	This	buffer	does	not	only	serve	
as	a	loading	dye,	but	it	also	contains	β-mercaptoethanol	and	SDS.	These	ingredi-
ents	crack	up	the	protein	tertiary	structure.	While	β-mercaptoethanol	splits	disul-
phide-bridges,	 SDS	 leads	 to	denaturation	of	 the	protein	and	a	constant	relation	
between	 negative	 charge	 and	molecular	 weight	 is	 achieved.	 The	 samples	 were	
boiled	in	Laemmli	at	95°C	for	5	min.	The	SDS-gels	were	placed	in	electrophoresis	
chambers	and	covered	with	TAE	buffer.	Equal	protein	amounts	were	loaded	on	the	
gels,	for	the	assignment	of	protein	size	PageRuler	plus	pre-stained	protein	ladder	
(Fermentas)	was	used.	The	samples	were	then	subjected	to	gel	electrophoresis	at	
20	mA	at	room	temperature.	The	proteins	migrated	from	cathode	to	anode	due	to	
their	negative	charge,	in	which	smaller	proteins	are	able	to	travel	the	gels	faster	
than	bigger	ones	hence	separation	occurred	according	to	protein	size	[140].
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2.1.6 Western Blot
Subsequently,	the	proteins	were	transferred	horizontally	to	nitrocellulose	or	PVDF	
membranes.	Blotting	was	performed	 either	 in	 a	wet	 chamber	overnight	 at	 4°C	
and	180	mA	or	in	a	semi-dry	manner	for	35	min	at	0.45	A	(limit	25	V)	in	the	Trans-
Blot	Turbo	device	(Bio	Rad).	After	blotting,	the	membranes	were	blocked	for	1	h	at	
room	temperature	in	PBS	containing	5	%	skimmed	milk	powder.	Then,	the	mem-
branes	were	 incubated	with	 the	desired	primary	antibodies	diluted	 in	5	%	milk	
either	 at	 room	 temperature	 for	 at	 least	 2	h	or	overnight	 at	 4°C.	Afterwards	 the	
blots	were	washed	thoroughly	three	times	with	PBS.	Meanwhile	a	suitable	horse-
raddish-	peroxidase	(HRP)-conjugated	secondary	antibody	was	diluted	in	PBS	+	5	%	
skimmed	milk	powder.	HRP	is	a	reporter	protein	that	catalyzes	the	oxidation	of	
luminol.	The	secondary	antibody	was	added	on	top	of	the	membrane	and	incu-
bated	for	1	h	at	room	temperature	on	a	shaker.	After	washing	again	thrice	for	10	min	
with	 PBS,	 the	membranes	were	 treated	with	Luminate	Forte	Western	HRP	 Sub-
strate	for	3	min.	The	luminescent	signal	was	then	detected	by	exposing	the	blots	
to	high	performance	chemiluminescence	films	(Amersham)	and	the	films	were	
developed	in	the	autoprocessor	Curx	60	(Agfa).	
2.1.7 Immunoprecipitation (iP)
This	method	allows	the	purification	of	specific	proteins	from	crude	protein	lysates	
as	well	as	from	cell	culture	supernatants.	For	this	purpose,	an	affinity	matrix	is	
used	which	is	composed	of	protein	G	cross	linked	to	agarose.	Protein	G	is	a	com-
ponent	of	the	bacterial	wall	capable	of	binding	the	Fc	domain	of	IgG	antibodies	
from	different	species.
One	day	prior	to	immunoprecipitation,	the	cells	were	washed	once	and	com-
plete	growth	medium	was	replaced	by	starvation	medium	(cell	culture	medium	
without	 FCS).	On	 the	 following	 day,	 the	 cells	were	 harvested	 as	 described	 pre-
viously.	The	cell	pellet	was	lysed	for	30	min	on	ice	using	DISC	lysis	buffer.	Cellu-
lar	debris	were	removed	by	centrifugation	at	14	000	g	for	5	min,	the	protein	con-
taining	supernatant	was	transferred	to	a	new	tube	and	the	protein	concentration	
was	determined	(see	also	2.1.4	Lowry	Assay).	Concentrations	of	the	samples	were	
adjusted	with	DISC	buffer	in	such	a	way	that	4	mg	/	mL	protein	per	sample	were	
obtained.	The	antibody	of	interest	was	added,	at	which	1-2	µg	antibody	per	4	mg	
protein	 sample	were	applied.	Meanwhile,	 the	affinity	matrix	Protein	G	agarose	
(Roche)	was	prepared.	For	this	purpose,	40	µL	of	the	matrix	stock	solution	were	
used	per	4	mg	protein	sample.	The	matrix	was	spun	down	for	1	min,	1500	g	and	4°C,	
the	supernatant	was	discarded	and	the	matrix	was	resuspended	in	1	mL	DISC	buffer.	
The	washing	procedure	was	repeated	three	times.	Finally,	the	matrix	was	diluted	in	
DISC	buffer	such	that	an	amount	of	100	µL	Protein G	agarose	per	4	mg	protein	sam-
ple	resulted.	The	combination	of	antibody,	protein	sample	and	Protein G	agarose	
was	incubated	overnight	at	4°C	on	a	rotor.	Subsequently,	the	matrix	was	washed	
32
2.  Methods
with	DISC	buffer	at	least	three	times	(400	g,	1	min,	4°C)	to	remove	unbound	pro-
teins.	Samples	were	boiled	for	10	min	at	95°C	in	1	×	Laemmli	buffer	and	loaded	to	
SDS-polyacrylamide	gels	and	subjected	to	analysis	by	western	blot	or	Coomassie	
staining.
2.1.8 Deglycosylation digest
As	the	protein	of	 interest,	Lyve-1,	 is	a	highly	glycosylated	protein	a	deglycosyla-
tion	digest	was	performed	in	order	to	remove	N-	and	O-linked	glycosylation	side	
chains	of	the	protein.	
For	 deglycosylation	 total	 cell	 lysates	were	 obtained	 from	Lyve-1+	 transgenic	
cells	lines.	The	digest	was	performed	with	the	EDEGLY	enzymatic	protein	degly-
cosylation	kit	(Sigma-Aldrich),	which	includes	the	following	proteins:	PNGase F,	
O-Glycosidase,	 α-(2 → 3,	6,	8,	9)-Neuraminidase	 (Sialidase	 A),	 β-(1 → 4)-Galactosi-
dase	and	β-N-Acetylglucosaminidase.	The	digest	was	performed	according	to	the	
manufacturer’s	instructions	at	37°C	for	3	h.
2.1.9 Enzyme-linked immunosorbent assay (elisa)
Prior	to	ELISA,	cell	culture	supernatants	were	centrifuged	to	obtain	cell-free	culture	
media.	After	collection	human	blood	samples	were	allowed	to	clot	at	room	tem-
perature	for	15	–	30	min.	The	precipitate	was	removed	by	centrifugation	at	1000	g.	
Immediately	after	the	centrifugation	step,	the	resulting	supernatant	or	plasma	was	
transferred	to	a	new	tube.	All	ELISAs	were	performed	according	to	the	manufac-
turer’s	instructions.
ELISA	is	a	robust	and	sensitive	method	that	facilitates	the	detection	and	quan-
tification	of	specific	soluble	antigens,	e.	g.	secreted	cytokines	or	proteins.	In	this	
case,	the	ELISA	method	was	used	for	the	analysis	and	characterization	of	cell	cul-
ture	supernatants	and	plasma	samples.	The	performed	ELISAs	were	based	on	the	
principal	 of	 sandwich	 ELISA.	 Shortly,	 a	 primary	 capture	 antibody	was	passively	
immobilized	onto	the	plastic	surface	of	96-well	plate.	Samples	were	added	in	the	
appropriate	dilutions,	so	the	antigen	of	interest	could	be	bound	whereas	unbound	
components	were	removed	by	washing.	A	second	primary	antibody,	the	so	called	
detection	antibody,	against	another	epitope	of	the	antigen	was	added.	Finally,	an	
enzyme-linked	antibody,	e.	g.	a	secondary	HRP-antibody,	was	applied	that	in	turn	
binds	 the	 detection	 antibody.	 The	 amount	 of	 antigen	was	 then	 determined	 by	
assessing	the	enzyme	activity	by	conversion	of	its	substrate	to	a	measurable	pro-
duct.	For	evaluation	of	the	experimental	outcome,	sample	values	had	to	be	corre-
lated	to	measurements	of	a	standard	curve.
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2.1.10 Fixation
For	 immunohistochemical	 analyses	 different	 samples	 types	were	 used	 and	 pre-
pared	in	different	ways	for	optimal	outcome.
Cells	were	either	grown	to	confluency	on	coverslips	or	centrifuged	onto	micro-
scopic	glass	slides	as	cytospins.	Dependent	on	the	desired	primary	antibody,	the	
cells	 were	 either	 fixed	 with	 ice-cold	 acetone	 for	 10	min	 or	 with	 PFA.	 For	 PFA-	
fixation,	the	cells	were	washed	first	with	PBS,	then	treated	with	2	%	PFA	for	10	min	
and	then	washed	with	0.5	%	Triton	X-100	in	PBS	for	15	min.	After	fixation	with	4	%	
PFA	for	10	min,	the	cells	were	again	washed	thoroughly	three	times	with	PBS.
After	cutting,	paraffin	sections	were	dried	overnight	at	37°C.	In	order	to	remove	
the	surrounding	paraffin,	 the	sections	were	rinsed	 twice	 in	xylene	and	then	re-	
hydrated	by	incubation	in	a	decreasing	alcohol	series	(100	%	–	70	%	EtOH)	and	finally	
the	sections	were	washed	with	water	twice.	For	antigen-retrieval	the	sections	were	
heated	to	95°C	for	20	min	either	in	EDTA	pH9	or	citrate	pH6	buffer	(Leica).	
Cryo-sections	 were	 air-dried	 overnight	 after	 preparation.	 Fixation	 was	 per-
formed	with	ice-cold	acetone	for	10	min	at	room	temperature.	
2.1.11 Immunohistochemistry
Fixed	samples	were	washed	twice	in	PBS	and	once	in	PBS	+	0.01	%	Tween	20	(PBST).	
To	block	intrinsic	peroxidase,	the	samples	were	treated	with	0.3	%	peroxide	in	PBS	
for	10	min.	Afterwards	the	samples	were	washed	as	before	and	protein	block	was	
performed	by	addition	of	2	%	BSA	in	PBS	for	30	min.	Next,	the	protein	block	was	
removed	 and	 the	 samples	were	 incubated	with	 the	desired	primary	 antibodies,	
which	were	diluted	in	Antibody	Diluent	(Dako)	for	2	h.	To	remove	unbound	anti-
bodies,	the	samples	were	again	washed	as	before	and	incubation	with	the	appro-
priate	HRP-coupled	secondary	antibody	(in	Antibody	Diluent)	was	performed	for	
45	min.	The	specimens	were	first	washed	as	previously	described,	before	AEC	chro-
mogen	(Dako)	was	used	for	the	visualization	of	the	HRP-labelled	target-molecules	
by	the	formation	of	an	insoluble	red	dye.	The	staining	was	stopped	by	rinsing	of	
the	samples	 in	water	and	counter-staining	was	conducted	with	Mayer’s	Haema-
laun	(Merck).	The	stained	samples	were	embedded	in	faramount	aqueous	mount-
ing	media	(dako).	Pictures	were	taken	with	the	Nikon	Eclipse	NI	microscope	with	
the	Clara	interline	CCD	camera	(Andor)	NIS-Elements	Advanced	software	(Nikon).	
Images	were	arranged	using	Adobe	Photoshop	6.0	software.	
2.1.12 Sequential staining
Paraffin	embedded	tissue	samples	were	dewaxed	as	described	before	with	the	aid	
of	a	xylene	/	alcohol	series.	For	antigen	retrieval	specimen	were	treated	with	pro-
teinase	K	(Dako)	for	5	min.	After	rinsing	once	in	water	and	TBS,	the	samples	were	
blocked	for	10	min	in	5	%	skimmed	milk	in	TBS.	Primary	antibodies	were	diluted	
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in	antibody	diluent	(Dako)	and	applied	for	1	h	at	37°C	or	overnight	at	4°C.	Surplus	
primary	antibodies	were	removed	by	washing	thrice	in	TBS	before	the	specimen	
were	incubated	with	peroxidase	blocking	solution	(Dako)	for	7	min.	The	samples	
were	washed	again	as	before	and	were	covered	with	HRP-labelled	secondary	anti-
body	for	30	min	at	room	temperature.	For	detection	of	HRP-labelled	cells	the	sub-
strate	VECTOR	NOVARED	Peroxidase	solution	(Vector	Laboratories)	was	used	for	
10	min	 at	 37°C.	After	 rinsing	 in	water	 for	 5	min	 counterstaining	was	performed	
with	10	%	Haemalaun-solution	for	6	min.	The	specimens	were	then	placed	succes-
sively	into	80	%,	96	%	and	100	%	ethanol	and	twice	in	xylene	for	2	min	each,	before	
they	were	mounted	with	eukitt.	After	documentation	of	the	staining	per	micro-
scopy,	the	cover	slips	and	mounting	medium	were	removed	by	placing	the	sam-
ples	into	xylene	overnight.	On	the	following	day	the	samples	were	re-hydrated	by	
the	descending	xylene	/	alcohol	series	and	de-stained	in	stripping	buffer	at	50°C	
for	 1	h.	 The	 samples	 were	 washed	 consecutively	 in	 water	 (5	min),	 95	%	 ethanol	
(2	min),	water	(2	min)	and	finally	in	TBS	(2	min).	Thus,	the	samples	were	completely	
de-stained	and	could	be	stained	for	another	antigen	of	interest.
2.1.13 Immunofluorescence
For	immunofluorescent	staining	the	samples	were	fixed	as	described	before.	The	
samples	were	washed	twice	in	PBS	and	once	in	PBST.	Blocking	was	performed	with	
2	%	BSA	in	PBS.	Primary	antibody	was	diluted	in	Antibody	Diluent	and	incubated	
with	the	specimens	for	at	least	2	h.	After	washing	as	before,	the	samples	were	treated	
with	the	corresponding	secondary	antibody	labelled	with	a	fluorochrome.	In	the	
case	of	double	staining,	primary	antibodies	were	mixed	and	incubated	simultane-
ously	with	the	samples.	Appropriate	secondary	antibodies	were	used	which	were	
labelled	with	different	fluorochromes.	Specimens	were	embedded	in	fluorescent	
mounting	media	(dako)	and	pictures	were	taken	with	the	Nikon	Eclipse	NI	micro-
scope	with	the	Clara	interline	CCD	camera	(Andor)	NIS-Elements	Advanced	soft-
ware	(Nikon).	Images	were	arranged	using	Adobe	Photoshop	6.0	software.
2.1.14 Fluorescent associated cell sorting (Facs) analysis
FACS	is	a	method	based	on	the	simultaneous	measurement	of	different	physical	
characteristics	of	cells.	For	this	purpose,	the	cells	are	transported	in	a	fluid	to	pass	
a	laser	beam	as	single	cells.	By	detection	of	the	emerging	scattered	and	transmit-
ted	 light	as	well	 as	emitted	fluorescence	 the	 relative	granularity	or	 intern	com-
plexity,	the	size	of	the	cell	and	the	fluorescence	intensity	can	be	determined.	Thus,	
the	method	allows	the	characterization	of	expression	levels	of	specific	proteins	
through	tagging	cells	with	fluorochrome	coupled	antibodies.	
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For	FACS	surface	staining	the	cells	were	prepared	as	a	single	cell	suspension.	The	
cells	were	washed	once	in	FACS	surface	buffer.	The	samples	were	then	treated	with	
1.5	µL	Fc	block	(BD	bioscience)	per	1	×	106	cells	for	10	min.	Next,	the	fluorochrome	
coupled	antibody	was	added	for	further	20	min	at	room	temperature.	After	wash-
ing	twice	with	FACS	surface	buffer,	the	cells	were	resuspended	in	approxi	mately	
300	µL	 FACS	 surface	 buffer	 and	 analyzed	with	 FACS-Canto™	II	 (BD	Biosciences)	
and	data	was	analyzed	using	FlowJo	V	10.1	software.
2.1.15 Detection of reactive oxygen species and nitric oxygen species
CD14+	 cells	 were	 stimulated	 for	 seven	 days	 either	 with	 M-CSF	 or	 M-CSF	/	dexa-	
methasone	/	IL-4	 and	washed	 once	 in	 PBS.	 The	 cells	 were	 incubated	 for	 30	min	
either	with	HPF	(Cell	Technology)	at	37°C	for	the	detection	of	ROS	or	with	DAF-
2DA	for	NOS	detection	(Cell	Technology)	at	4°C.	Both	reagents	are	non-fluorescent	
by	themselves.	In	the	presence	of	hROS	and	NOS	respectively	they	are	readily	con-
verted	to	emit	a	strong	dose-dependent	fluorescent	signal	(excitation	λ	=	488	nM	
and	emission	λ	=	515	nm).	After	cell	 loading,	excess	dyes	were	washed	away	with	
FACS	surface	buffer	and	the	cells	were	subjected	to	flow	cytometric	analysis	with	
FACS-Canto™	II	(BD	Biosciences)	and	data	was	analyzed	using	FlowJo	V	10.1	soft-
ware.
2.1.16 Expression Vectors
As	 a	vector	 construct	 the	previously	described	 lentiviral	 3	rd	generation	pHAGE	
vector	was	used.	This	vector	was	modified	by	Mostoslavsky	et	al.	by	insertion	of	
the	human	promoter	sequence	of	EF1	α	and	a	StemCCA	(stem	cell	cassette).	The	
StemCCA	was	then	replaced	by	a	multiple	cloning	site	(MCS),	also	called	ADR3,	an	
internal	ribosomal	entry	site	(IRES),	the	sequence	of	red	fluorescent	protein	(RFP)	
and	a	puromycin	resistance	gene	(Puro).	The	resulting	construct	constitutes	the	
empty	vector	(EV)	backbone,	which	will	be	called	ADR3	EV	in	the	following.
In	order	 to	generate	 a	DNA	 insert	which	can	be	cloned	 into	 the	vector	 con-
structs,	cDNA	of	mmLyve-1	(clone	IRAVp968E0743D,	Genome	CUBE)	and	hsLyve-1	
(clone	IRAUp969G0386D,	Genome	CUBE)	was	amplified	with	primers	that	add	the	
restriction	sites	for	the	endonucleases	Xba I	and	Mlu I	to	one	end	of	the	insert	
sequence	each.	The	PCR	amplification	was	performed	with	κ-HiFi	HotStart	PCR	
kit	(VWR /	formerly	Peqlab).	The	included	κ-DNA-polymerase	enables	high	fidelity	
PCR	amplification	while	proofreading	is	optimized	with	error	rates	approximately	
100	times	lower	than	commonly	used	wild-type	TAQ.	PCR	was	performed	accord-
ing	to	the	manufacturer’s	recommendations:
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COMPONENT	 50	μL	FINAL	VOLUME
PCR-grade	water	 Up	to	50	μL
5	×	κ-HiFi	Buffer 10.0	µL
10	mM	dNTP	Mix	 1.5	µL
10	μM	Forward	Primer	 1.5	µL
10	μM	Reverse	Primer	 1.5	µL
1	U	/	μL	κ-Polymerase 1	µL
Template	cDNA 1	ng
The	following	thermo	cycler	conditions	were	applied:
STEP TEMPERATURE TIME CYCLES
Hot	Start 95°C 3	min 1
Denaturation 98°C 20	s
18	or	22Annealing Tm	of	Primer	60-75°C 15	s
Extension	 72°C 60	s
Final	extension 72°C 5	min 1
The	 obtained	 PCR	 product	 was	 purified	 with	 the	 aid	 of	 purification	 kit	 omni-
pure-OLS	 (Omni	 life	 science).	Both	PCR	product	and	 the	vector	construct	were	
digested	in	parallel	with	the	restriction	enzymes	XbaI	and	Mlu	(Fermentas)	for	
at	least	3	h	at	37°C.	During	the	last	30	min	of	digest,	the	enzyme	CIAP	(Fermentas)	
was	added	to	the	vector	DNA.	CIAP	removes	the	5'-phosphate	group	of	the	DNA	
backbone,	thus	preventing	religation	of	the	linearized	vector.	After	the	digest,	DNA	
was	again	purified	as	before	(omnipure-OLS	Kit).	In	order	to	ligate	the	insert	with	
the	linearized	vector,	T4	DNA	ligase	(Thermo	Scientific)	was	used	in	the	follow-
ing	reaction	set	up.	Ligation	was	performed	either	for	1	h	at	room	temperature	or	
overnight	at	4°C.
COMPONENT 20	µL	FINAL	VOLUME
Linear	vector	DNA 20-100	ng
Insert	DNA molar	ratio	3	:	1	over	vector
10	×	T4	Ligase	Buffer 2	µL
T4	DNA	Ligase 1	U
nuclease-free	water to	20	µL
For	 transformation,	 the	 chemically	 competent	E.coli	 cloning	 strain	DH5	α	 (Invit-
rogen)	was	used.	50	µL	bacteria	culture	were	thawed	slowly	on	ice	and	3	µL	of	the	
ligation	mixture	was	added	and	mixed	thoroughly.	After	incubation	for	10	min	on	
ice,	the	plasmid	containing	bacteria	suspension	was	heat	shocked	at	42°C	for	45	s.	
The	mixture	was	cooled	on	ice	again	and	500	µL	SOC	medium	was	added.	The	bac-
•
•
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teria	solution	was	then	incubated	for	1	h	at	37°C	on	a	shaker	with	800	rpm.	A	part	of	
the	bacteria	solution	was	plated	on	LB	agar	plates	containing	100	µg	/	mL	ampicillin	
(Fluka)	 for	selection	of	positive	clones.	Bacterial	colonies	were	allowed	to	grow	
over	night	at	37°C	in	an	incubator.
After	transformation	single	colonies	were	picked	from	the	LB	agar	plates.	The	
colonies	were	used	to	inoculate	ampicillin	containing	LB-medium.	Bacteria	were	
allowed	to	grow	over	night	while	being	incubated	at	37°C	with	gentle	agitation.	On	
the	following	day	bacteria	were	harvested	by	centrifugation	and	plasmid	DNA	was	
purified	with	QIAGEN	Plasmid	Midi	Kit.	After	disruption	of	bacteria,	 the	 lysate	
was	cleared	by	centrifugation.	The	plasmid	DNA	was	purified	with	the	aid	of	a	DNA	
binding	column.	After	elution,	isopropanol	was	added	for	DNA	precipitation.	Iso-
propanol	was	removed	and	the	DNA	pellet	was	air-dried	before	being	resolved	in	
DNase-free	water.	The	DNA	concentration	was	determined	by	Nanodrop	and	the	
sequence	 identity	was	confirmed	by	sequencing	 (Sequencing	was	performed	by	
Source	Bioscience).
2.2 In vitro assays
2.2.1 Cell culture methods
For	 cell	 culture	 experiments	 different	 human	 and	murine	 cell	 lines	were	 used.	
Characteristics	and	culture	methods	of	the	individual	cell	lines	according	to	ATCC	
are	described	in	the	following.	All	cell	lines	were	cultured	at	37°C	in	an	atmosphere	
enriched	with	5	%	carbon	dioxide.	Assessment	of	cell	lines	was	accomplished	by	
observation	of	morphological	changes	and	growth	curve	analyses.	Both	cell	lines	
and	produced	transgenic	clones	were	tested	regularly	for	mycoplasma	infection	
by	PCR.
2.2.2 Human cell lines
1. u937 (atcc® crl-1593.2™)	 The	 monocytic	 cell	 line	 was	 established	 from	
malignant	cells	which	were	derived	from	a	caucasian	male	patient	suffering	from	
histiocytic	 lymphoma.	 The	 cells	 were	 cultured	 in	 RPMI-1640	 Medium	 supple-
mented	with	10	%	fetal	calf	 serum	(FCS),	 100	U	Penicillin,	as	well	as	 100	μg	/	mL	
Streptomycin	(Pen	/	Strep)	(RPMI	Complete).	As	the	cells	grow	in	suspension,	cul-
tures	were	maintained	either	by	 the	 addition	of	 fresh	medium	or	by	 complete	
replacement	of	medium.	The	latter	required	centrifugation	of	the	cell	suspension	
for	5	min	at	300	g,	the	supernatant	was	discarded	and	the	cell	pellet	resuspended	in	
PBS	for	a	washing	step.	Cells	were	seeded	at	approximately	1	×	105	cells	/	mL.
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2. ht144 (atcc® htb-63™)  The	cells	were	obtained	from	the	metastatic	site	of	
malignant	melanoma	from	a	male	caucasian	patient.	Morphologically	the	tumori-
genic	cells	resemble	fibroblasts.	The	adherent	cells	were	grown	in	RPMI	complete.	
For	subculturing,	the	medium	was	removed	and	the	cellular	monolayer	was	rinsed	
with	PBS	in	order	to	remove	residual	medium.	Cell	detachment	was	achieved	by	
incubation	with	Trypsin-EDTA	solution	for	several	minutes,	the	status	of	loosen-
ing	was	observed	with	an	inverted	microscope.	To	stop	trypsin	activity	complete	
growth	medium	was	added	and	the	cells	were	spun	down	at	300	g	for	at	least	5	min.	
The	 supernatant	was	 removed	 and	 the	 pellet	 resuspended	 in	 complete	 growth	
medium.	Cells	were	routinely	splitted	with	a	subcultivation	ratio	of	1	:	10.
3. a375 (atcc® crl-1619™)  The	cells	originate	from	malignant	melanoma	of	a	
female	patient.	Cultivation	procedures	were	performed	as	for	the	HT144	cell	line.
4. 293t/17 [hek 293t/17] (atcc® crl-11268™)  The	 cells	 originate	 from	 fetal	
kidney.	 The	 clone	 17	 is	 descended	 from	 the	highly	 transfectable	 293	T	 cell	 line,	
which	itself	is	a	derivative	of	the	cell	line	293.	For	transfection	experiments	293T	/	17	
cells	were	used	due	to	their	ability	to	produce	high	retrovirus	titers.	The	fast	grow-
ing	adherent	cells	were	cultivated	in	Dulbecco’s	Modified	Eagle’s	Medium	(DMEM)	
supplemented	with	10	%	fetal	calf	 serum	(FCS),	 100	U	Penicillin	and	100	μg	/	mL	
Streptomycin	(Pen	/	Strep)	(DMEM	complete)	in	combination	with	10	mM	sodium-	
pyruvate.	Subcultivation	was	achieved	by	 trypsin	 treatment,	 as	described	above.	
The	splitting	ratio	was	1	:	4	to	1	:	8.
5.  human  umbilical  vein  endothelial  cells  (huvec;  Promocell  heidelberg) 
Human	primary	cells	are	isolated	from	the	vein	in	the	umbilical	cord.	The	adher-
ent	 cells	were	 grown	 in	 endothelial	 growth	medium	 (EGM,	Promocell)	mix	 1	:	2	
with	Medium	199,	supplemented	with	10	%	FCS,	50	μg	/	mL	gentamycin,	50	μg	/	mL	
heparin	and	2.5	μg	/	mL	amphotericin B.	Cells	were	splitted	after	trypsin	treatment	
and	subcultured	with	a	ratio	of	1	:	3.
2.2.3 Murine cell lines
1. raw264.7 (atcc® tib-71™)	 The	adherent	macrophage	cell	 line	was	derived	
from	a	tumour	induced	by	Abelson	murine	leukaemia	virus	in	the	mouse	strain	
BALB	/	c.	The	cells	were	grown	in	DMEM	complete.	For	subcultivation,	medium	was	
removed	from	the	cellular	monolayer	and	the	cells	were	rinsed	with	DPBS.	New	
complete	growth	medium	was	added	and	cells	were	dislodged	from	the	culture	
vessel	surface	with	a	cell	scraper.	The	cell	suspension	was	aspirated	and	an	appro-
priate	amount	was	transferred	to	a	new	cell	culture	vessel.	The	cells	were	regularly	
subcultivated	at	1	:	6.
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2. b16-f1 (atcc® crl-6323™)	 B16-F1	is	a	melanoma	derived	cell	line	that	origi-
nates	from	the	mouse	strain	C57BL	/	6J.	In	a	syngeneic	mouse	model	the	cell	line	
is	tumorigenic.	As	growth	medium	DMEM	complete	was	used.	Subcultivation	was	
accomplished	by	trypsin	treatment	as	described	before.	Subcultivation	ratio	was	
at	least	1	:	10.
3. b16-f10 luc (bioware, caliPer)	 Like	B16F1,	B16F10	is	a	tumorigenic	cell	line	
derived	from	melanoma	bearing	C57BL	/	6J.	The	cells	were	stably	transfected	with	
the	North	American	firefly	luciferase	gene	under	the	control	of	the	SV40	promoter.	
The	cells	produce	a	bioluminescent	signal	when	the	substrate	luciferin	in	admin-
istrated.	The	cells	were	cultured	in	RPMI	complete.	For	subcultivation	(1	:	10),	the	
cells	were	loosened	by	trypsin	treatment.
2.2.4 Cryopreservation of cell lines
For	cryopreservation,	the	cells	were	prepared	as	single	cell	suspensions	in	freezing	
medium,	which	consisted	of	complete	growth	medium	supplemented	with	10	%	
anti-freezing	agent	DMSO	and	aliquoted	 into	cryo-vials.	To	avoid	the	 formation	
of	large	ice	crystals,	the	cells	were	frozen	slowly	at	1°C	/	min.	For	this	purpose,	the	
cryo-vials	were	put	 into	 isopropanol	 insulated	 freezing	 containers,	which	were	
placed	 into	 a	 -80°C	 freezer.	 For	 long-term	 storage,	 the	 frozen	 cells	 were	 then	
transferred	to	liquid	nitrogen	tanks.
The	frozen	cells	were	thawed	quickly	in	a	37°C	water	bath	until	only	a	small	ice	
crystal	was	left.	The	cell	suspension	was	diluted	rapidly	in	complete	growth	medium	
and	cells	were	spun	down	by	centrifugation	at	300	g	for	5	min.	The	DMSO-contain-
ing	supernatant	was	removed	and	the	cells	were	resuspended	and	seeded	in	com-
plete	growth	medium.	On	the	following	day,	the	medium	was	renewed.
2.2.5 Isolation of cd14+ cells from human peripheral blood
Buffy	coat	samples	from	healthy	donors	were	obtained	from	German	Red	Cross	
Blood	 Donation	 Service,	 Baden-Württemberg.	 By	 density	 gradient	 centrifuga-
tion	it	is	possible	to	separate	cellular	components	of	the	blood	according	to	their	
weight.	The	buffy	coats	were	diluted	1	:	1	with	sterile	PBS.	With	a	volume	ratio	of	2	:	1	
the	diluted	blood	samples	were	slowly	layered	over	biocoll	separation	solution.	For	
the	formation	of	the	density	gradient	the	samples	were	centrifuged	without	break	
at	1200	g	for	30	min.	Biocoll	solution	contains	polysucrose,	a	highly	branched	poly-
mer	of	approximately	400	kDa	and	a	density	of	1.077	g	/	mL.	During	the	gradient	
centrifugation	only	blood	cells	that	are	dense	enough	are	able	to	transmigrate	the	
biocoll	layer,	thus	after	centrifugation	layers	with	different	cell	types	are	formed.	
The	lowermost	layer	is	mainly	composed	of	erythrocytes,	which	aggregate	upon	
contact	with	the	polymer	component	of	the	separation	solution.	On	top	of	the	red	
blood	cells,	granulocytes	accumulate.	In	contrast	to	these	cell	types	mononuclear	
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cells	do	not	penetrate	 the	biocoll	 layer,	 so	 that	 a	 concentrated	band	consisting	
of	lymphocytes,	monocytes	and	thrombocytes	appears	right	between	the	biocoll	
layer	and	the	uppermost	layer	which	is	the	blood	plasma.
After	 formation	 of	 the	 density	 gradient	 the	 layer	 of	mononuclear	 cells	was	
transferred	to	a	new	collection	tube	using	a	sterile	Pasteur	pipette	and	the	tube	was	
filled	with	PBS.	The	cell	suspension	was	spun	down	at	300	g	for	10	min.	The	super-
natant	was	discarded	and	the	cell	pellet	was	again	resuspended	in	PBS,	the	washing	
step	was	repeated	twice.	A	second	density	gradient	centrifugation	was	performed,	
at	which	the	cell	suspension	was	 layered	over	a	continuous	gradient	formed	by	
silica	colloid	medium	Percoll©	to	achieve	improved	fractioning	of	lymphocytes	
and	monocytes.	Centrifugation	was	performed	at	1200	g	for	30	min	without	break.	
The	white	layer	consisting	of	monocytes	and	thrombocytes	was	transferred	to	a	
new	collection	tube	with	a	sterile	pipette.	The	cells	were	washed	three	times	with	
PBS	as	described	above.	After	the	last	washing	step,	the	cells	were	resuspended	in	
MACS	 (magnet	 associated	 cell	 sorting)	buffer	 and	 labelled	 for	 20	min	with	mag-
netic	 microbeads	 that	 are	 conjugated	 to	 monoclonal	 anti-human	 CD14	 antibo-
dies.	CD14	is	a	co-receptor	of	the	LPS	receptor	complex;	it	is	commonly	used	as	
a	marker	of	monocytes	and	macrophages.	After	washing	once	with	MACS	buffer,	
the	cell	suspension	was	loaded	onto	LS	MACS	Columns,	which	were	clipped	into	
the	MACS	Separator	Magnet.	The	columns	were	washed	thrice	with	MACS	buffer.	
Due	to	the	labelling	with	the	magnetic	beads,	CD14+	cells	were	restrained,	whereas	
the	negative	cell	 fraction	was	washed	out	of	 the	columns.	Finally,	 the	columns	
were	removed	from	the	magnetic	field	of	the	MACS	Separator	and	the	CD14+	cells	
were	eluted	in	MACS	buffer.	To	remove	MACS	buffer,	cells	were	washed	with	PBS	
and	resuspended	in	X-Vivo	medium.	The	cell	concentration	was	determined	and	
1	×	106 cells	/	mL	were	seeded	for	cultivation	and	stimulation	experiments.
STIMULUS CONCENTRATION
M-CSF 100	ng	/	mL
Dexamethasone 1	×	10-7	(1000	U	/	mL)
IL-4 10	ng	/	mL
TGF-β 100	ng	/	mL
SB203580 50	µM
NFκB	inhibitor 5	µM
Mifepristone 100	nM
APMA 50	µM
GM6001 50	µM
MMP-9	/	13	Inhibitor 50	µM
Tapi-1 50	µM
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2.2.6 Production of lenti virus for transduction of eukaryotic cells
Lenti	viruses	are	a	subset	of	retroviruses	which	are	derived	from	HIV-1.	The	advan-
tage	 of	 lentiviral	 vectors	 is	 their	 ability	 to	 transduce	 both	 dividing	 and	 non-	
dividing	cells.	Moreover,	the	transduction	of	cells	results	in	the	integration	of	the	
transgene	into	the	host	genome	and	thus	stable	expression	is	achieved.
To	produce	 lenti	 viruses	HEK293	/	T17	 cells	were	used.	The	 cells	were	 seeded	
and	grown	until	a	confluency	of	80	%	was	reached.	The	cells	were	transfected	with	
3	rd	generation	lentiviral	plasmids	(pMD2.G	L1,	pRSV	rev	L2,	pMDLg	/	pRRE	L3	and	
pCDNA3.1	/	p	35	E	71)	in	combination	with	the	transfer	vector	(ADR3)	carrying	the	
transgene	of	interest.	Transfection	was	achieved	with	X-tremeGENE	9	DNA	Trans-
fection	Reagent	(Roche),	a	non-liposomal	multicomponent	reagent.	In	order	to	
increase	efficacy	of	transfection,	100	mM	Na-pyruvate	was	added	to	the	complete	
growth	medium	 which	 supports	 plasmid	 uptake	 by	 HEK293	/	T17	 cells.	 On	 the	
following	day,	 the	 culture	medium	was	 supplemented	with	 10	mM	Na-butyrate.	
The	stimulation	for	8	h	with	Na-butyrate	increases	the	release	of	newly	produced	
viruses	by	the	producer	cells.	Subsequently,	the	medium	was	replaced	by	harvest-
ing	medium	(DMEM	+	1	%	Pen	/	Strep),	which	was	collected	and	filtered	after	8	h	of	
virus	production.	 To	obtain	 sufficient	 virus,	harvesting	procedure	was	 repeated	
three	further	times,	at	which	the	cells	were	cultured	in	the	harvesting	medium	for	
8-12	h	before	it	was	collected	and	filtered.	The	virus	containing	medium	was	con-
centrated	via	Vivaspin	Columns	(MWCO	=	100,000	PES),	the	suspension	was	stored	
in	aliquots	at	-80°C.
2.2.7 Production of transgenic cell lines
The	lentiviral	vector	system	was	used	for	production	of	eukaryotic	transgenic	cell	
lines.	 For	 this	 purpose,	 1	×	106	 cells	were	 seeded	 in	 10	 cm-dishes	 in	 10	mL	 com-
plete	growth	medium	and	100	µL	concentrated	virus	suspension	per	transduction	
was	added	dropwise.	After	two	days	the	virus	containing	medium	was	replaced	by	
selection	medium	(complete	growth	medium	+	2	µg	/	mL	puromycin).	As	a	control,	
virus	untreated	cells	were	cultured	in	selection	medium	as	well.	As	soon	as	these	
control	 cells	 died	due	 to	 the	 selection	pressure,	 the	 surviving	 transduced	 cells	
were	expanded	in	complete	growth	medium.	The	expression	of	the	transgene	was	
verified	by	western	blot	analysis,	qRT-PCR	and	fluorescence	microscopy.	
2.2.8 Proliferation-Assay
To	estimate	the	proliferative	capacity	of	cells,	a	5-bromo-2'-deoxy-uridine	(BrdU)	
based	assay	was	performed.	BrdU	is	a	pyrimidine	analogue	that	is	stably	integrated	
into	newly	synthesized	genomic	DNA	of	proliferating	cells	as	a	substitute	of	thy-
midine.	The	incorporated	BrdU	can	be	tracked	by	a	fluorochrome	labelled	mono-
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clonal	 antibody.	Thus	 the	 amount	of	BrdU	positive	 cells	 can	be	determined	by	
means	of	FACS	analyses	and	provides	information	about	the	proliferation	rate	of	
the	cell	lines.
For	the	proliferation-assay,	the	cells	were	seeded	at	low	concentrations	of	about	
1	×	105	cells	/	mL	in	10	cm	Petri-dishes.	On	the	following	day,	the	cells	were	pulsed	
with	25	µg	/	mL	BrdU	for	1	h.	The	labelling	medium	was	removed	and	the	cells	were	
harvested	and	washed	once	with	PBS.	Cell	suspensions	were	spun	down	at	300	g	
for	5	min.	The	cells	were	fixed	in	ice-cold	70	%	ethanol	(100	µL	/	1	×	106	cells),	which	
was	added	drop-wise	while	the	cells	were	vortexed.	After	20	min	incubation	at	RT,	
cells	were	washed	with	PBS	+	0.5	%	BSA	and	2 M	HCl	was	added	for	denaturation	for	
20	min.	The	cells	were	washed	again	as	before;	remaining	HCl	was	neutralized	by	
the	addition	of	0.1	M	sodiumborat	buffer.	For	the	detection	of	incorporated	BrdU,	
the	cells	were	then	incubated	with	mouse	anti-BrdU	or	a	mouse	IgG	isotype	con-
trol	antibody,	both	 labelled	with	fluorescein	 isothiocyanate	 (FITC).	The	amount	
of	BrdU+	cells	was	then	measured	by	flow	cytometry	(FACS-Canto™	II).	Data	was	
analyzed	using	FlowJo	V	10.1	software.
2.2.9 Scratch Assay
To	examine	 the	migratory	behaviour	of	different	cell	 lines,	 scratch	assays	or	 so	
called	wound	healing	experiments	were	performed.	The	cells	were	seeded	in	6-well	
culture	plates	with	a	concentration	of	2	×	105 cells	per	well.	The	cells	were	allowed	
to	grow	until	100	%	confluency	was	reached.	An	artificial	wound	was	caused	to	the	
monolayer	with	the	aid	of	a	10	µL	pipette	tip.	Floating	cells	were	washed	away	by	
several	medium	replacements.	Scratches	were	photographed	every	two	hours	in	a	
period	from	0-10	h	and	24	h	after	the	initial	scratch	with	Axio	Vert.A1	microscope	
from	Zeiss.	The	area	of	the	scratch	was	determined	with	the	aid	of	ImageJ	macro	
MRI	wound	healing	tool.
2.2.10 Apoptosis Assay
To	study	the	mortality	rate	of	cells,	a	hydrogen	peroxide	induced	apoptosis	assay	
was	performed.	Stimulating	cells	with	hydrogen	peroxide	leads	to	oxidative	stress	
which	 results	 in	 the	 intracellular	 accumulation	of	ROS.	Excessive	ROS	 are	detri-
mental	to	cellular	integrity	and	cause	cell	injury	like	e.	g.	DNA	damage.	High	doses	
of	hydrogen	peroxide	initiate	apoptosis	by	stimulating	the	release	of	cytochrome C	
from	mitochondria	and	the	activation	of	caspase	3	[141].
96-well	 culture	 plates	 were	 coated	 with	 0.2	%	 gelatine.	 In	 the	 following	
5	×	104 cells	/	well	were	seeded	in	complete	growth	medium.	The	cells	were	allowed	
to	grow	overnight	or	until	a	confluency	of	90	%	was	reached.	The	supernatant	was	
removed	and	the	cellular	monolayer	was	washed	once	with	PBS.	The	cells	were	
then	incubated	for	3	h	with	complete	growth	medium	containing	0-20	mM	hydro-
gen	peroxide.	Removal	of	dead	cells	was	achieved	by	washing	the	cells	carefully	
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with	water.	 The	 remaining	 attached	 cells	were	fixed	 and	 stained	with	 5	%	 crys-
tal	violet	and	20	%	methanol	in	H2O	for	15	min	at	room	temperature.	The	culture	
plates	were	rinsed	thoroughly	with	water	before	they	were	air	dried.	To	evaluate	
the	amount	of	survived	cells,	the	stained	cells	were	re-suspended	in	100	%	metha-
nol	and	photometrically	quantified	with	the	TECAN	Infinity	M200	Pro.
2.2.11 Adhesion Assay
To	study	cell	adhesion	to	components	of	the	ECM,	a	96-well	plate	was	coated	with	
either	1	µg	/	mL	fibronectin	or	0.2	%	gelatine.	After	24	h	at	37°C	the	plate	was	washed	
twice	with	PBS	and	2	×	104	cells	/	well	were	seeded	in	50	µL	culture	medium.	The	cells	
were	allowed	to	settle	for	30	min	at	37°C,	before	the	plate	was	shaken	for	10-15	s	at	
2000	rpm.	Non-adherent	cells	were	removed	by	careful	washing	with	H2O	twice.	
Adherent	cells	were	fixed	and	stained	with	crystal	violet	and	photometrically	quan-
tified	with	the	TECAN	infinity	M	2000	Pro	(see	also	2.2.10	Apoptosis	assay).	
2.3 In vivo experiments
2.3.1 Mouse Models
C57BL	/	6	wild	 type	mice	were	purchased	from	Elevisier	 Janvier,	Le	Genest	Saint	
Isle,	 France.	 B6.129P2-Lyz	2tm1(cre)Ifo/J	 (also	 known	 as	 LysMcre)	 and	 B6.129S1-	
Lyve-1tm1Lhua/J	(Lyve-1-/-)	were	purchased	from	the	Jackson	Laboratory.	GRflox	mice	
were	provided	by	Prof.	Dr.	Günther	Schütz	[199].	
All	 mice	 are	 housed	 under	 specific	 pathogen-free	 conditions	 at	 the	 animal	
facility	Mannheim.	All	animal	experiments	were	filed	at	the	local	authorities	Regi-
erungspräsidum	Karlsruhe	under	the	numbers	G213	/	12,	G42	/	14	and	G119	/	15.
2.3.2 Murine tumour models
For	 in vivo	 tumour	experiments	the	murine	melanoma	cell	 line	B16F1	or	B16F10	
LUC	were	used.	The	cells	were	loosened	from	the	culture	vessel	surface	by	treat-
ment	with	Trypsin	/	EDTA.	Afterwards	the	cells	were	washed	at	least	three	times	
with	PBS.	To	ensure	single	cell	suspension,	the	cells	were	run	through	a	70	µM	cell	
strainer.	The	cell	concentration	was	adjusted	to	10	×	106 cells	/	mL.	8-weeks	old	mice	
were	anesthetized	by	 intraperitoneal	 injection	of	 a	ketamine	/	xylazine	combina-
tion.	The	right	flanks	were	shaved	and	100	µL	of	the	cell	suspension	(1	×	106	cells)	
was	injected	sub-cutaneously.	Mice	were	sacrificed	after	at	least	ten	days	of	tumour	
growth.	The	tumours	were	weighed	and	shock	frosted	in	liquid	nitrogen.	The	tis-
sue	samples	were	stored	at	-80°C.	
44
2.  Methods
2.3.3 In vivo imaging
To	monitor	tumour	growth	in vivo	imaging	was	performed.	150	µL	of	D-Luciferin	
potassium	 salt	 30	mg	/	mL	 (Biovision)	 in	 PBS	were	 injected	 intraperitoneal	 into	
B16F10	 LUC	 tumour	 bearing	mice.	Mice	were	 anesthetized	 in	 an	 isoflurane	 gas	
chamber	and	luminescence	pictures	were	taken	three	min	after	substrate	injection	
with	IVIS	Lumina;	exposure	time	was	set	to	15	s	(PerkinElmer,	Living	Image	4.3).
2.3.4 Isolation of cd11+ from murine tumours
Tumor	bearing	mice	were	sacrificed	14	days	after	s.	c.	injection	of	tumour	cells.	The	
tumours	were	excised	and	rinsed	in	PBS,	before	being	homogenized	by	pressing	
through	a	100	µm	cell	strainer.	The	separated	tumour	cells	were	washed	with	pre-
cooled	PBS	and	centrifuged	for	10	min	at	300	g.	The	cell	pellet	was	resuspended	in	
10	mL	RPMI	supplemented	with	collagenase	IV	(190	U	/	mL,	Genaxxone)	and	DNAse	
I	(500	U	/	mL,	Sigma)	and	digested	at	37°C	for	at	least	one	hour.	The	samples	were	
washed	again	as	before	with	PBS.	The	cells	were	transferred	into	MACS	buffer	and	
after	determination	of	the	cell	number,	CD11	b	micro	beads	(Miltenyi)	were	added	
to	magnetically	 label	 tumour	associated	macrophages.	Following	20	min	 incuba-
tion	at	4°C	on	a	rotor	the	cells	were	washed	once	in	MACS	buffer	and	magnetic	
associated	cell	separation	was	performed	to	isolate	CD11	b+	cells	from	the	crude	cell	
mixture	(compare	to	2.2.5	isolation	of	CD14+	cells).
2.4 Statistics
Statistical	analyses	of	all	data	was	calculated	by	using	GraphPad	Prism 6.0	(Graph-
Pad	Software,	USA).	Statistical	 significance	was	examined	by	using	standard	Stu-
dent’s	t-test	or	by	one-way	ANOVA	and	Bonferroni	as	a	post-test.	The	level	of	signif-
icance	is	indicated	by	asterisks	(***	≤	0.001;	**	≤	0.01	and	*	≤	0.05).	Error	bars	depict	
SEM	of	each	experiment.	All	experiments	were	performed	at	least	in	triplicates.
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Table 1: Chemicals
CHEMICALS	AND	REAGENTS COMPANY
30	%	Acrylamide	mix Bio-Rad
4-Aminophenylmercuric	acetate	(APMA) Sigma
5-bromo-2'-deoxy-uridine	(BrdU) Sigma
Acetic	Acid Roth
Acetone Roth
Agarose Sigma
Ammonium	persulfate	(APS) Sigma
Ampicillin Fluka
Biocoll Biochrom
β-Mercaptoethanol Sigma-Aldrich
Bovine	Serum	Albumin	(BSA) Fitzgerald
CD14	Dynabeads Miltenyi
Hyperfilm	ECL	 Amersham
Coomassie	Brilliant	Blue Serva
Crystal	violet Roth
Dexamethasone Sigma
DMSO Sigma
DNA	Ladder Thermo	Scientific
dNTP Fermentas
Escherichia	coli Invitrogen
Ethanol Roth	
Ethylenediaminetetraacetic	acid	(EDTA) Sigma
Fc	Block BD	Biosciences
Fibroblast	growth	factor-2	(FGF-2) Peprotech
Fibronectin Sigma
Gelatine Sigma
High	molecular	weight	hyaluronic	acid R&D	Systems
Hydrogen-peroxide	(H2O2) Merck
Hydrochloric	acid	(HCl) Merck
Ilomastat,	MMP	Inh.,	Galardin	(GM6001) US	Biological
Immune-Blot	PVDF	Membrane BioRad
Interferon-γ	(IFN-γ) Peprotech
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CHEMICALS	AND	REAGENTS COMPANY
Interleukin-4 Peprotech
Isopropanol Roth
Ketamine	10	% Medistar
Lipopolysaccharide	(LPS) Invitrogen
Low	molecular	weight	hyaluronic	acid R&D	Systems
Luciferin BioVision
Lysogeny	broth	(LB)	Agar Roth
Lysogeny	broth	(LB)	Medium Roth
Macrophage	colony-stimulating	factor	(M-CSF) Peprotech
Methanol Sigma
Mifepristone Sigma
MMP-9	/	13	Inhibitor	I Merck
Nancy	520 Sgima
NFκB	Activation	inhibitor Calbiochem
NP	40 Fluka
Oligo	(dt)18	Primer Fermentas
PageRuler	Prestained	Protein	Ladder Fermentas
Paraformaldehyde Roth
Penicillin	/	Streptomycin Biochrom
Percoll GE	Healthcare
Protease	Inhibitor	Cocktail Roche
Protein	G	Agarose Roche	(Sigma)
Puromycin Invivogen
Ribolock	inhibitor Fermentas
Rompun	2	% Bayer
SB203580 Calbiochem
skim	milk	powder Roth
sLyve-1 R&D	Systems
Sodium	dodecyl	sulphate	(SDS) Bio-Rad
sodium	fluoride	(NaF) Sigma
Sodiumazide	(NaN3) Sigma
Sodium-borat	(Na2B4O7	×	10H2O) Fluka
Sodium-butyrate	(Na(C3H7COO)) Sigma-Aldrich
Sodium-chloride	(NaCl) Sigma
Sodiumdeoxychelat	(C24H39O4Na) Sigma	Aldrich
Sodiumpyruvate	(C3H3NaO3) Sigma
SyBRGreen	Master	Mix Applied	Biosystems
TAPI-1 Calbiochem
Tetramethylethylenediamine	(TEMED) GenAxxon
Transforming	growth	factor-β	(TGF-β) Peprotech
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CHEMICALS	AND	REAGENTS COMPANY
Tris	/	HCl Sigma
Triton	X-100 Sigma
Trypsin	/	EDTA Biochrom
Tumour	necrosis	factor-α	(TNF-α) Peprotech
Tween	20 Sigma
Vascular	endothelial	growth	factor-α	(VEGF-α165) Peprotech
Xylene Roth
Table 2: Enzymes
ENZYME COMPANY
CIAP Fermentas
Collagenase	IV Genaxxon
DFS	TAQ Bioron
DNase I Fermentas
Kappa	Polymerase Invitrogen
Mlu	I Thermo	Scientific
RevertAid	H	Minus	M-MuLV	Reverse	Transcriptase	 Thermo	Scientific
T4	DNA	Ligase Thermo	Scientific
Xba I Thermo	Scientific
Table 3: Kits
KIT COMPANY
VECTOR	NOVARED	Peroxidase	(HRP)	Substrate	Kit Vector	laboratories
Selective	Indicators	for	Highly	Reactive		
Oxygen	Species
Cell	technology
RNeasy	Kit	 Qiagen
Plasmid	Midi	Kit Qiagen
omnipure-OLS	 Omni	Life	Science
Nitric	Oxide	Synthase	(NOS)	Detection	Kit	 Cell	technology
κ-HiFi	HotStart	PCR	kit	 VWR	/	Peqlab
innuPREP	RNA	Mini	Kit Analytik	Jena
Human	Lyve-1	DuoSet	ELISA R&D
FITC	Mouse	Anti-BrdU	Set BD	Biosciences
DC™	Protein	Assay Bio	Rad
CD14	Microbeads Miltenyi
CD11	b	Microbeads Miltenyi
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Table 4: Instruments
INSTRUMENT COMPANY
Autoprocessor	Curx	60 Agfa
Axio	VER.A1	microscope Zeiss
Centrifuge	5417R Eppendorf
Centrifuge	5810R Eppendorf
Cryotome	CM3050S Leica
Cytospin	3 Shandon
DS-U3	Digital	Camera	Control	Unit	 Nikon
FACS-Canto™	II BD	Biosciences
Freezer	MDF	U743V Sanyo
HeraSafe	KS	Laminar	Flow Thermo	Scientific
Incubator	Heracell	L50	i Thermo	Scientific
infinite	M	200	Pro Tecan
Kelvitron	T Heraeus
Microtome	RM2065 Leica
Mupid-One	Electrophoresis	Chamber Biozym
Nanodrop	2000 Thermo	Scientific
pH	Meter	FG2	/	EL2 Mettler	Toledo
PowerPac	Basic BioRad
QuadroMACS™	Separator Miltenyi
Rotator	SB2 Stuart
Shaker	DRS12 Peqlab
TC20™	Automated	Cell	Counter BioRAd
Thermoblock	Thermomixer Eppendorf
Thermocycler	T100 BioRad
Trans-Blot	Turbo	Device BioRad
Upright	motorized	Microsope	Eclipse	Ni-E	 Nikon
UV	Systems	N-90	m	 Intas
Vortex	Genie-2 Scientific	Industries
Waterbath Memmet
Z2	Coulter	Particle	Count	&	Size	Analyzer Beckman	Coulter
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Table 5: Cell culture media
MEDIUM COMPANY
RPMI-1640 Gibco
Dulbeccos’s	Modified	Eagle	Medium	(DMEM) Gibco
Endothelial	Cell	Growth	Medium	(EGM) Lonza
Fetal	calf	serum	(FCS) Biochrom
Medium	199 Sigma
Minimum	Essential	Medium	Eagle Sigma
Non-Essential	Amino	Acid(NEAA) Biochrom
Opti-MEM	I	reduced	serum	media Gibco
SOC	Medium Invitrogen
Trypsin	/	EDTA Gibco
Vivaspin	Columns Sartorisus
X-treme	Gene	9	DNA	transfection	reagent Roche
X-Vivo Lonza
Table 6: Consumables
CONSUMABLE COMPANY
Immune-Blot	PVDF	Membrane BioRad
High	Performance	Chemiluminescence	Film	 Amersham
Cellculture	flask	25	cm2	(T25) Greiner	bio-one
Cellculture	flask	75	cm2	(T75) Greiner	bio-one
Cellculture	flask	175	cm2	(T175) Greiner	bio-one
6-well	plates	 Greiner	bio-one
12-well	plates Greiner	bio-one
24-well	plates	 Greiner	bio-one
96-well	plates	 Greiner	bio-one
Cell	scraper Greiner	bio-one
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Table 7: Software
Adobe	Photoshop	6.0	software
NIS-Elements	Advanced	software	(Nikon)
FlowCytomix	Pro	Software	(ebioscience)
GraphPad	Prism	6.00
Image	J
Zeiss	Software	System
FlowJo	V	10.1
Table 8: Primer
KLONIERUNG SEQUENCE
HS	LYVE-1	XbaI	Fw	 GAT	TCT	AGA	CAC	GAT	GGC	CAG	GTG	CTT
HS	LYVE-1	MluI	Rev	 GAT	ACG	CGT	CTA	AAC	TTC	AGC	TTC	CAG	GCA
MM	LYVE-1	XbaI	Fw TTA	TCT	AGA	GGG	ATC	TGC	ACA	ATG	CT
MM	LYVE-1	MluI	Rev	 AAT	ACG	CGT	TGC	ATC	TAA	ACT	TCA	GCT	T
qRT-PCR SEQUENCE
HS	CD163	Fw GCC	ACA	ACA	GGT	CGC	TCA	TCC
HS	CD163	Rev GTG	TGG	CTC	AGA	ATG	GCC	TCC
HS	CD206	Fw TGG	TTT	CCA	TTG	AAA	GTG	CTG	C
HS	CD206	Rev TTC	CTG	GGC	TTG	ACT	GAC	TGT	TA
HS	CD11B	Fw CCA	GGG	GGA	GGG	CTC	GGT
HS	CD11B	Rev CGT	GCC	CCT	GGG	CTC	CTA
HS	CD68	Fw ATG	ATG	AGA	GGC	AGC	AAF	ATG	G
HS	CD68	Rev GCT	ACA	TGG	CGG	TGG	AGT	ACA	A
HS	ARG-1	Fw CGG	AGA	CCA	CAG	TTT	GGC	A
HS	ARG-1	Rev TAC	AGG	GAG	TCA	CCC	AGG	AG
HS	ACTIN	Fw GGC	ACC	ACA	CCT	TCT	ACA	ATG	A
HS	ACTIN	Rev TCT	CCT	TAA	TGT	CAC	GCA	CGA	T
HS	LYVE-1	Fw CTT	GCA	GCT	ATG	GCT	GGG	TT
HS	LYVE-1	Rev TAA	GGG	GAT	GCC	ACC	GAG	TA
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Table 9: Antibodies
1st	ANTIBODY APPLICATION DILUTION COMPANY
PE	anti-hs	CD163 FACS 1	/	5
BD	Bioscience	
(#556018)
APC	anti-hs	CD11	b FACS 1	/	5
BD	Bioscience	
(#550019)
PE-Cy	5	anti-hs	CD206 FACS 1	/	5
BD	Bioscience	
(#551136)
APC-Cy	7	anti-hs	
HLA-DR
FACS 1	/	100
BD	Bioscience	
(#561358)
biotin	anti-hs	Lyve-1 Western	Blot	 0.08	µg	/	mL
R	&	D		
(BAF2089)
anti-hs	Lyve-1
IHC	(PFA	Fixation,	
Antigen	retrieval		
Proteinase	K)
10	µg	/	mL
Abcam	
(ab	36993)
anti-hs	CD68
IHC	(Antigen	retrieval	
Proteinase	K)
1	/	200
Dako	
(M087629-2)
anti-hs	CD163
IHC	(Antigen	retrieval	
Proteinase	K)
1	/	500
Abcam	
(ab111250)
anit-mm	/	hs	GAPDH Western	Blot 0.08	µg	/	mL
Santa	Cruz	
(SC25778)
anti-mm	CD68
IHC	/	IF	(Acetone		
Fixation)
2	µg	/	mL
ABD		
(MCS1957)
anti-mm	CD31
IHC	/	IF	(Acetone		
Fixation)
0.5	µg	/	mL
BD	Bioscience	
(#550274)
anti-mm	/	hs	Ki67 IHC	/	IF	(PFA	Fixation) 1	/	50
Abcam	
(ab16667)
2	nd	ANTIBODY APPLICATION DILUTION COMPANY
Strepta	HRP Western	Blot 1	/	10000
Dianova		
(016-030-084)
Strepta	FITC FACS 1	/	200
eBioscience	
(11-4317-87)
anti-rabbit	IgG	HRP IHC 1	/	200
Santa	Cruz	
(2031)
anti-rat	IgG	HRP IHC 1	/	200
Santa	Cruz	
(2956)
anti-rabbit	IgG	HRP Western	Blot 1	/	5000
GE	Healthcare	
(NA934V)
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2	nd	ANTIBODY APPLICATION DILUTION COMPANY
anti-rabbit	IgG	DL-488 IF 1	/	200
Dianova		
(711-486-152)
anti-rat	IgG	Cy	3 IF 1	/	200
Dianova		
(712-165-153)
Table 10: Buffers
BUFFER COMPANY
0.5	M	Tris	(pH	6,8) Bio-Rad
1.5	M	Tris	(pH	8,8) Bio-Rad
10	×	Tris	Glycine	Buffer	(TGS) Bio-Rad
AEC	Chromogen	Substrate Dako
AG	Retrieval	Solution	pH6 Leica
AG	Retrieval	Solution	pH9 Leica
Antibody	Diluent Dako
DPBS Gibco
Eukitt Kindler
Faramount	Aqueous	Mounting	Medium Dako
Fluorescent	Mounting	Medium Dako
Laemmli	Buffer Bio-Rad
Luminate	Forte	Western	HRP	Substrate Millipore
Mayer’s	Haematoxylin Merck
Peroxidase	Blocking	Solution Dako
Phosphate	buffered	saline Invitrogen
Proteinase	K Dako
Rotiophorese	Buffer	TAE Roth
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Table 11: Buffer recipes
RIPA-P	BUFFER
Sodium	chloride 150	mM
NP-40 1	%
Sodium	deoxychelate 0.50	%
SDS 0.10	%
Tris	/	HCl	(pH	8,0) 50	mM
Sodium	fluoride 10	mM
EDTA 2	mM
Protease	inhibitor	cocktail	(Roche) 4	%
BLOTTING	BUFFER	(WET	CHAMBER)
TGS 1	×
Methanol 20	%
BLOTTING	BUFFER	(SEMI-DRY)
TGS 2	×
Methanol 20	%
SDS 0.10	%
DISC
TrisHCl	pH07 30	mM
NaCl 120	mM
Glycerol 10	%
Triton	X-100 1	%
MACS	BUFFER
PBS 1	×
BSA 0.50	%
EDTA 2	mM
FACS	SURFACE	BUFFER
PBS 1	×
BSA 10	%
Sodium	azide 0.05	%
TBS
Tris 20	mM
NaCl 150	mM
pH	 7.6
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4. RESULTS
4.1 Lyve-1+ macrophages are present in human melanoma
Lyve-1	has	been	found	not	to	be	expressed	exclusively	by	lymphatic	endothelial	
cells	 as	 previously	 thought,	 but	 also	by	macrophages.	Our	 group	has	 identified	
Lyve-1+	TAM	in	murine	B16	melanoma	in vivo.	In	addition,	Lyve-1	expression	could	
be	induced	in vitro	in	bone	marrow	derived	macrophages	by	the	combined	stimula-
tion	with	B16	tumour	conditioned	medium	in	combination	with	dexamethasone	
(dexa)	and	IL-4	[116].
To	 determine	 if	 Lyve-1+	macrophages	 are	 also	 present	 in	human	melanoma,	
serial	sections	from	paraffin	embedded	specimens	were	prepared	and	stained	for	
Lyve-1,	the	pan-macrophage	marker	CD68	and	CD163,	which	is	a	marker	of	M2-like	
macrophages.	Histopathological	 analyses	 identified	 Lyve-1+	 cells	 as	 endothelial	
cells	and	macrophages.	Compared	 to	Lyve-1+ TAM	more	CD68+	 and	CD163+	TAM	
were	found	in	human	melanomas.	(Fig. 5	A).	
To	further	substantiate	the	existence	of	Lyve-1+	macrophages	in	human	mela-
noma	 samples,	 tissue	 microarrays	 with	 melanoma	 samples	 have	 been	 stained	
sequentially.	In	a	first	step,	the	samples	were	stained	with	anti-CD68	and	after	a	
destaining	procedure	the	same	samples	were	stained	with	an	anti-Lyve-1	antibody.	
Thus,	expression	of	Lyve-1	in	CD68+	cells	could	be	clearly	demonstrated.	However,	
Lyve-1	expression	has	been	observed	to	variable	extent	only	in	a	subpopulation	of	
CD68+	cells	(Fig. 5	B).
Figure 5: Identification	of	Lyve-1+	macrophages	is	human	melanoma. (A) Immunhistological 
stainings of serial sections of melanoma specimens derived from two different patients. The 1.5 µM sections 
were stained with antibodies against Lyve-1, CD68 and CD163. Whilst Lyve-1+ cells were visualized using 
AEC chromogen (red), CD68+ and CD163+ were stained with DAB (brown), scale bars = 100 µM. (B) Two 
tissue microarrays with 250 melanoma derived specimens were sequentially stained against CD68 with 
Nova Red for visualization first, after a destaining procedure the TMA were stained again with anti-Lyve-1 
(visualized with DAB in brown). Two representative specimen are depicted, scale bar = 100 µM.
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4.2 Characterization of the in vitro induction 
of Lyve-1 in pbmc
4.2.1 m-csF, dexamethasone and il-4 induce a  
         M2-like phenotype of pbmc in vitro
As	 already	 shown	 by	 Schönhaar,	 LYVE-1	 expression	 can	 be	 induced	 in vitro	 in	
pBMC	by	the	combined	stimulation	with	MDI	after	seven	days	of	stimulation.	The	
expression	of	a	combination	of	macrophage	markers	was	examined	to	describe	the	
phenotype	of	these	MDI	treated	cells	in	more	detail.	The	results	were	compared	
to	M-CSF	 (M)	 treated	pBMC.	Besides	analysis	of	 the	macrophage	differentiation	
marker	 CD11	b,	 expression	 levels	 of	 the	 scavenger	 receptor	 CD163	 and	mannose	
receptor	CD206	were	evaluated,	as	their	expression	is	associated	with	a	M2-like	
phenotype.	 In	 addition,	 human	 leukocyte	 antigen-antigen	 D	 related	 (HLA-DR)	
protein	surface	expression	was	studied.
Both	qRT-PCR	and	FACS	analysis	confirmed	the	significant	induction	of	LYVE-1	
in	pBMC	by	the	combined	stimulation	with	M-CSF	dexa	/	IL-4	after	seven	days	of	
stimulation	 (Fig. 6)	 In	general,	expression	analyses	on	protein	and	mRNA	 level	
showed	 similar	 trends	 for	MDI-induced	macrophage	markers.	 The	macrophage	
marker	expression	profile	revealed	significant	up-regulation	of	the	M2	associated	
markers	CD163	and	CD206	in	response	to	MDI	treatment,	likewise	on	mRNA	and	
protein	level,	whereas	changes	in	the	expression	level	of	CD11	b	were	not	signifi-
cant.	However,	 a	 slight	down-regulation	of	CD11	b	was	observed	 in	MDI-treated	
pBMC.	Finally,	examination	of	HLA-DR	expression	on	the	protein	 level	by	FACS	
analysis	showed	comparable	expression	levels	in	M	and	MDI	treated	pBMC	(Fig. 6).
Figure 6: Expression	analysis	of	macrophage	marker	in	M-CSF	and	MDI	stimulated	pBMC. 
pBMC were stimulated for seven days with M-CSF or M-CSF / dexa / IL4 (MDI) as indicted. (A) Expression 
of macrophage markers was analyzed by FACS, overlay histograms show a representative experiment; MCSF 
(silver) MDI (red). (B) To compare marker protein expression levels the median fluorescence intensities 
(MFI) of the FACS analyses were compared, n = 10, (C) qRT-PCR analysis determined mRNA expression 
relative to β-actin mRNA levels. MDI values are given as fold-induction over expression levels for M-CSF 
treated control, (n = 6).
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In	 addition,	 arginine	metabolism	 and	production	of	 ROS	 and	NOS	 in	M-CSF	
and	MDI	treated	pBMC	were	examined	by	means	of	FACS	and	qRT-PCR.	In	TAM	
and	M2-like	macrophages	arginase-1	is	up-regulated	promoting	the	hydrolysis	of	
	L-arginine	 to	 urea	 and	 ornithine,	whereas	 in	 pro-inflammatory	M1-like	macro-
phages	conversion	of	L-arginine	by	iNOS	to	NOS	is	prevailing	and	high	abundance	
of	ROS	is	characteristic.
In	MDI	 treated	 pBMC	 the	 number	 of	 NOS	 producing	 cells	 was	 significantly	
reduced	compared	to	MCSF	stimulated	control	cells	(Fig. 7	A).	These	findings	are	
in	line	with	the	observation	that	the	mRNA-expression	of	the	iNOS	counteracting	
enzyme	Arg-1	was	up-regulated	in	response	to	MDI	treatment	(Fig. 7	B).	More	over,	
it	was	 asserted	 that	 significantly	 fewer	MDI-treated	 cells	 contain	 ROS	 (Fig.  7	C).	
Taken	together	the	results	demonstrate	that	seven	days	of	MDI	stimulation	induce	
an	M2-like	phenotype	in	pBMC.
Figure 7: NOS	and	ROS	production	is	impaired	in	MDI	stimulated	pBMC. pBMC were stimu-
lated for seven days with M-CSF or MDI as indicted. (A) Presence of NOS was detected by loading cells 
with DAF-2 / DA, overlay histogram (left) shows a representative experiment; MCSF (black), MDI (red) 
and control (grey). The number of NOS producing cells was assessed by FACS analysis, (n = 3). (B) mRNA 
expression of ARG-1 relative to β-actin mRNA levels was determined by qRT-PCR. MDI values are given as 
fold- induction over expression levels for M-CSF treated controls, (n = 6). (C) Presence of ROS was detected 
by loading cells with HPF. Overlay histogram (left) shows a representative experiment, MCSF (black), MDI 
(red) and control (grey). The number of ROS producing cells was assessed by FACS analysis, (n = 3).
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4.2.2 Characterization of the Lyve-1+ pbmc subset
Only	a	subpopulation	of	pBMC	treated	with	MDI	express	Lyve-1.	By	FACS	analysis	
the	Lyve-1+	pBMC	subset	could	be	quantified	and	again	the	macrophage	marker	
expression	profile	was	analyzed	to	assess	the	differences	between	the	Lyve-1+	and	
Lyve-1-	MDI-stimulation	derived	cell	populations.
Figure 8: Expression	analysis	of	macrophage	marker	in	Lyve-1+	and	Lyve-1-	MDI	stimulat-
ed	pBMC. pBMC were stimulated for seven days with M or MDI as indicated. (A) Cytospins were fixed with 
PFA and stained with anti-Lyve-1, scale bars = 20 µM. (B) Flow cytometric quantification of Lyve-1 surface 
expression in M or MDI treated cells, (n = 8). (C) FACS analysis was performed to determine co-expression of 
Lyve-1 and diverse macrophage markers, representative experiments are shown. (D) Comparison of marker 
expression levels between Lyve-1+ and Lyve-1- MDI treated pBMC by evaluation of MFI, (n = 10).
60
4.  Results
Even	after	seven	days	of	treatment	with	MDI,	we	observed	Lyve-1	expression	
only	in	a	minor	subset	of	stimulated	pBMC	(Fig. 8	A).	With	regard	to	this	finding,	
flow	cytometric	analysis	revealed	that	Lyve-1	is	expressed	in	approximately	25	%	of	
the	MDI-treated	pBMC,	though	expression	levels	varied	between	different	donors	
(Fig. 8	B).	Furthermore,	Lyve-1	was	found	to	be	co-expressed	with	all	examined	
macrophage	markers.	In	the	Lyve-1+	pBMC	subpopulation	CD206	and	CD11	b	were	
significantly	up-regulated	and	CD163	showed	a	slight	up-regulation	too,	whereas	
HLA-DR	levels	were	comparable	to	the	Lyve-1-	subpopulation	(Fig. 8	C	+	D).
4.2.3 Dexamethasone is crucial for in vitro induction of LYVE-1 in pbmc
In vitro,	LYVE-1	could	already	be	induced	by	stimulation	of	pBMC	with	M-CSF	and	
dexa,	though	the	addition	of	IL-4	boosted	the	effect	and	yielded	higher	expression	
levels	of	LYVE-1.	Moreover,	 inhibition	of	the	glucocorticoid	receptor	(GR)	by	its	
antagonist	mifepristone	led	to	the	inhibition	of	LYVE-1	expression	in	pBMC	[136].
Yet,	it	remained	unknown	at	which	time	point	during	the	seven	day	lasting	MDI	
treatment	GR	activation	is	required	for	the	 induction	of	LYVE-1.	To	address	this	
question,	 time	course	experiments	with	dexamethasone	and	mifepristone	were	
performed.	For	this	purpose,	pBMC	were	stimulated	with	MDI	for	seven	days.	The	
first	sample	was	additionally	stimulated	with	100	nM	mifepristone	for	all	seven	
days,	 to	 the	 second	 sample	mifepristone	was	 added	on	 the	 second	day	 of	MDI	
stimulation,	to	the	third	sample	on	the	third	day	and	so	on.	In	a	similar	manner	a	
time	course	experiment	for	dexamethasone	stimulation	was	accomplished.	In	this	
case,	pBMC	were	stimulated	for	seven	days	with	M-CSF	in	combination	with	IL-4	
and	dexamethasone	was	added	on	consecutive	days	to	the	cell	culture	medium	for	
a	total	of	seven	days.
Immunohistological	 staining	 of	 PFA-fixed	 cytospins	 from	 MDI	 stimulated	
pBMC	showed	that	the	addition	of	100	nM	mifepristone	efficiently	blocked	Lyve-1	
expression	 in	 the	 cells,	whereas	 the	 expression	of	 Lyve-1	 in	 the	 control	 group	
(pBMC	treated	with	MDI	/	EtOH)	remained	unaffected	(Fig. 9	A).	
First,	LYVE-1	gene	expression	could	already	be	detected	after	five	days	of	MDI	
treatment	and	peaked	after	nine	days	of	stimulation	(Fig. 9	B).
Further	characterization	of	the	influence	of	GR-activation	on	Lyve-1	expression	
revealed	that	24	h	of	MF	treatment	prior	to	expiration	of	the	seven	days	lasting	MDI	
stimulation	was	sufficient	to	block	LYVE-1	gene	expression	completely	(Fig. 9	C).	
These	findings	brought	into	question	if	dexamethasone	stimulation	might	be	just	
required	during	the	last	days	of	the	stimulation.	However,	the	sequential	addition	
of	dexamethasone	to	M-CSF	/	IL-4	primed	cells	experiment	demonstrated	that	this	
was	not	the	case.	In	fact,	it	could	be	confirmed	that	dexamethasone	stimulation	
is	necessary	 for	 all	 seven	days	 in	 combination	with	M-CSF	/	IL-4	 to	 significantly	
induce	LYVE-1	expression	in	the	pBMC	model	(Fig. 9	D).
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Figure 9: Expression	of	LYVE-1	in	human	pBMC	is	dexamethasone	dependent. (A) Immu-
nohistological staining of Lyve-1 in pBMC following treatment with MDI in combination with GR antago-
nist mifepristone (MF) or ethanol (EtOH) as control, scale bars = 100 µM. (B) pBMC were stimulated for 
3, 5, 7 or 9 days with M or MDI, expression of LYVE-1 was examined on mRNA level by qRT-PCR, (n = 3). 
(C) qRT-PCR analysis of LYVE-1 expression after 100 nM MF was added to the MDI treated pBMC. The 
addition of MF was accomplished on consecutive days, at which the indicated time of MF stimulation is in 
relation to the experimental endpoint, (n = 4). (D) Time course experiment with dexamethasone being added 
at different time points to MCSF / IL-4 stimulated pBMC, (n = 4). All qRT-PCR values were normalized to an 
internal β-actin control and MDI values are given as fold-induction over expression levels for M-CSF treated 
control.
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4.2.4 Activation of p 38 maPk is relevant for LYVE-1 induction in pbmc
In	an	attempt	to	deepen	our	knowledge	about	the	in vitro	induction	of	LYVE-1,	we	
used	different	pathway	 inhibitors	of	major	 signalling	pathways	 involved	 in	 the	
generation	of	various	TAM	phenotypes	to	study	their	influence	on	LYVE-1	induc-
tion	in	MDI	stimulated	pBMC.	After	priming	of	the	pBMC	for	three	days	with	MCSF	
or	MDI,	the	stimulation	cocktail	was	supplemented	with	the	p	38	MAPK	inhibitor	
SB203580	for	the	remaining	stimulation	time.
The	 suppression	 of	 p	38	MAPK	 signalling	 resulted	 in	 the	 blockade	 of	 Lyve-1	
expression	in	MDI-stimulated	pBMC	on	the	protein	level	(Fig. 10	A	+	B).	To	deter-
mine	the	kinetics	of	this	inhibition	a	time	course	experiment	was	performed	by	
adding	the	p	38	inhibitor	to	the	MDI	treated	cells	on	day 3	(MDI	4	d	p	38	inhibition),	
4,	5	and	6	of	the	stimulation.	Evaluation	of	the	fold	induction	of	the	gene	expres-
sion	revealed	that	24	h	of	treatment	with	the	p	38	MAPK	inhibitor	were	sufficient	to	
block	LYVE-1	induction	significantly,	though	not	completely	(Fig. 10	C).	
Figure 10: p	38	inhibition	suppresses	MDI-mediated	LYVE-1	induction	in	pBMC. (A) Flow 
cytometric analysis, (n = 3) and (B) western blot of Lyve-1 expression in pBMC which were stimulated for 
seven days with M-CSF and MDI respectively; on the third day of the stimulation a p 38 inhibitor (50 µM) 
or DMSO (control) were added for the remaining stimulation time to MDI primed cells. (C) Gene expression 
of Lyve-1 was assessed via qRT-PCR in MCSF / MDI stimulated pBMC with subsequent addition of p 38 
inhibitor at different time points. Values were normalized to an internal β-actin control and MDI values are 
given as fold-induction over expression levels for M-CSF treated control, (n = 4).
Figure 11: Inhibition	of	NFκB	has	no	influence	on	
LYVE-1	expression	in	MDI	stimulated	pBMC. pBMC were 
stimulated for seven days with M-CSF and MDI respectively; 
on the third day of the stimulation a NFκB inhibitor (5 µM) 
or DMSO (control) were added for the remaining stimulation 
time to MDI primed cells. Flow cytometry was performed to 
determine the number of Lyve-1+ cells (n = 3).
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NFκB	 inhibition	 with	 a	 specific	 inhibitor	 did	 not	 significantly	 influence	
expression	of	Lyve-1	in	MDI-stimulated	pBMC	on	the	protein	level	(Fig. 11).	Thus,	
NFκB	signalling	is	not	required	for	the	regulation	of	LYVE-1	gene	transcription	in	
M2-like	differentiated	pBMC.
4.2.5 Activation of p 38 maPk signalling via tgF-β  
         does not induce LYVE-1 in pbmc
A	well-studied	activator	of	intracellular	p	38	MAPK	signalling	is	the	cytokine	TGF-β,	
which	is	also	involved	in	the	polarization	of	macrophages	towards	a	M2-like	phe-
notype.	To	study	the	role	of	p	38	MAPK	activation	for	Lyve-1	expression,	we	used	
different	cytokines	in	combination	with	TGF-β.
Figure 12: Stimulation	with	TGF-β	does	not	influence	LYVE-1	expression	in	pBMC.  
qRT-PCR analysis of Lyve-1 gene expression in stimulated pBMC. Values were normalized to an internal 
β-actin control and MDI values are given as fold-induction over expression levels for M-CSF treated controls, 
(n = 4). (A) Stimulation for 5 days as indicated. (B) Seven days of cytokine stimulation as indicated.
To	test	whether	the	addition	of	TGF-β	to	our	pBMC	model	might	lead	to	diffe-
rences	in	the	induction	of	LYVE-1	as	a	result	of	the	simultaneous	activation	of	the	
p	38	MAPK	signalling	cascade	and	GR	several	combinations	were	tested.	After	five	
days	of	stimulation	a	slight,	but	significant	induction	of	LYVE-1	could	be	observed	
by	exposure	to	MDI	as	seen	before.	The	addition	of	TGF-β	to	MDI	reduced	LYVE-1	
expression,	 thus	no	 synergistic	 effect	 of	 GR	 and	p	38	MAPK	 signalling	 could	 be	
observed	 to	 this	 point.	 Moreover,	 (M-CSF	+)	TGF-β	 alone,	 were	 not	 sufficient	
to	 induce	gene	expression	of	LYVE-1  (Fig.  12	A).	After	 seven	days	of	 stimulation,	
LYVE-1	expression	could	not	be	detected,	when	dexamethasone	was	removed	from	
the	 stimulation	mixture	 and	was	 substituted	by	TGF-β	 (Fig.  12	B).	Consequently,	
	activation	of	GR	is	crucial	for	induction	of	LYVE-1	and	stimulation	of	p	38	MAPK	
activity	via	TGF-β	does	not	contribute	to	the	induction	of	LYVE-1	expression.	Lyve-1	
expression	in	macrophages	seems	to	require	long	time	of	periods	of	stimulation	
indicating	more	fundamental	regulatory	mechanisms	as	for	example	chromatin	
modifications	rather	than	fast	direct	expression	switches.
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4.3 Functional analyses of Lyve-1 overexpression  
in U937 and B16F1
4.3.1 Highly glycosylated Lyve-1 in transgenic U937 binds the ligand ha
Previous	studies	have	shown	that	Lyve-1	has	got	various	sites	for	post-translational	
modifications	by	N-	and	O-linked	glycosylation.	Interestingly,	the	glycosylation	
status	of	the	protein	varies	depending	on	the	cell	type	in	which	Lyve-1	is	expressed.	
In	order	to	determine	the	glycosylation	status	of	Lyve-1	in	macrophages	and	to	
perform	functional	assays,	we	transduced	the	monocytic	cell	line	U937	with	the	
LYVE-1	containing	expression	vector	ADR3	and	the	empty	vector	(EV)	construct	as	
a	control.
Figure 13: U937	Lyve-1	express	glycosylated	Lyve-1	which	is	able	to	bind	HA. (A) Expres-
sion of Lyve-1 in transgenic U937 was verified on the protein level by Western blot and (B) flow cytometry. 
(C) Protein lysates derived from U937 Lyve-1 were digested for 3 h at 37°C with different degly cosylating 
enzymes as indicated and Lyve-1 was detected by immunoblot. (D) Overlay histogram of mock transduced 
U937 EV and U937 Lyve-1 stained for surface bound HA, representative experiment. (E) Ligand binding 
capability of U937 Lyve-1 was examined by incubation with biotinylated HA. Percentage of HA-binding 
cells was determined by flow cytometry using strepta-FITC to detect bound HA, (n = 3).
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The	U937	cell	line	was	transduced	with	pLenti-ADR3	EV	and	Lyve-1,	respectively.	
Expression	of	Lyve-1	was	verified	by	western	blot	and	flow	cytometry	(Fig. 13	A	+	B).	
U937	 derived	 Lyve-1	 had	 a	 protein	molecular	 weight	 of	 approximately	 70	kDa,	
whereas	the	322	AA	sequence	predicts	a	mass	of	35.2	kDa.	By	treatment	with	PNGase	
F	 and	 sialidase	A,	 post-translational	modifications	 in	 the	 form	of	 glycosylation	
could	be	removed	resulting	in	a	reduction	of	the	protein	weight	to	approximately	
65	kDa.	Digest	with	O-glycosilidase	did	not	show	any	effect	on	the	Lyve-1	protein	
weight,	 even	 though	O-glycosylation	 sites	have	been	described	 for	 the	protein.	
The	combined	digest	with	all	 three	enzymes	yielded	 in	a	deglycosylated	55	kDa	
protein	form,	indicating	that	removal	of	glycosylation	sites	could	not	be	achieved	
completely	(Fig. 13	C).	To	assess	the	functionality	of	transgenic	expressed	Lyve-1	in	
U937,	the	cells	were	incubated	with	biotinylated	HA,	which	could	be	detected	in	
FACS	by	streptavidin-FITC.	These	experiments	demonstrated	enhanced	binding	of	
HA	to	U937	Lyve-1	in	comparison	to	mock	transfected	U937	EV	cells	(Fig. 13	D	+	E).
4.3.2 Ligand binding does not influence proliferation rate of U937 Lyve-1
It	 has	 been	 described	 that	 in	 endothelial	 cells	 interactions	 of	 Lyve-1	with	 the	
ligands	FGF-2	and	 low	molecular	weight	hyaluronic	acid	 (LMW-HA)	 induce	cell	
proliferation,	whereas	 stimulation	with	 high	molecular	weight	 hyaluronic	 acid	
(HMW-HA)	has	an	anti-angiogenic	effect	on	endothelial	cells	[125,	132,	133,	151].	To	
assess	the	impact	of	Lyve-1	overexpression	and	ligand	interactions	on	the	prolifer-
ation	rate	of	macrophages,	U937	Lyve-1	and	U937	EV	were	seeded	in	RPMI	medium	
containing	0.2	%	FCS	and	allowed	to	adapt	to	the	culture	conditions	for	4	h.	In	the	
following	 the	U937	Lyve-1	were	 stimulated	with	20	ng	/	mL	FGF-2	 and	 10	µg	/	mL	
LMW-HA	or	HMW-HA	respectively.	24	h	later,	the	proliferation	rate	was	determined	
in	a	BrdU	based	proliferation	assay.	As	a	positive	control,	the	cells	were	incubated	
overnight	in	cell	culture	medium	supplemented	with	2	%	FCS.
Figure 14: The	proliferation	rate	
of	U937	Lyve-1	could	not	be	affec-
ted	by	FGF-2	or	HA	stimulation. 
(A) Proliferation rate of U937 EV and 
U937 Lyve-1 after culturing for 24 h in 
medium supplemented with 0.2 % FCS. 
(B) U937 EV and U937 Lyve-1 were stim- 
ulated overnight with ligands of Lyve-1 as 
indicated in culture medium containing 
0.2 % FCS and the proliferation rate was 
measured in a BrDU assay. To induce 
proliferation in U937, control cells were 
incubated simultaneously in RPMI + 2 % 
FCS (n = 5).
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Comparison	of	the	proliferation	rate	of	untreated	transgenic	U937	cells	revealed	
that	overexpression	of	Lyve-1	per se	did	not	affect	the	proliferation	rate	of	the	mono-
cytic	cell	line	(Fig. 14	A).	Furthermore,	stimulation	with	the	Lyve-1	ligands	FGF-2	
and	HA	did	not	induce	significant	changes	in	the	proliferation	rate	of	U937	Lyve-1.	
As	a	control,	U937	Lyve-1	were	incubated	in	medium	supplemented	with	2	%	FCS	
which	resulted	in	a	significantly	increased	proliferation	rate	by	12.18	±	2.308	%	com-
pared	to	cells	which	were	cultured	in	medium	with	0.2	%	FCS	(Fig. 14	B).	Hence,	in	
macrophages	ligand	binding	to	Lyve-1	does	not	influence	cell	proliferation.	
4.3.3 Overexpression of Lyve-1 in B16F1 increases adhesion  
          to fibronectin coated surfaces
For	further	 functional	analyses	 the	murine	melanoma	cell	 line	B16F1	was	trans-
duced	with	the	ADR3	expression	vector	containing	murine	LYVE-1	or	the	EV	con-
struct	as	a	control.	We	decided	to	use	this	model	for	two	reasons.	First,	in	contrast	
to	U937,	B16F1	 are	not	 suspension	cells	but	do	grow	adherently	 in	monolayers,	
which	 facilitates	 and	 simplifies	 the	 accomplishment	 of	 several	 basic	 assays	 to	
evaluate	the	impact	of	Lyve-1	overexpression	on	cellular	functions.	Secondly,	we	
planned	to	perform	in vivo	experiments	using	a	melanoma	mouse	model,	thus	evi-
dently	a	murine	melanoma	cell	line	was	selected,	as	experimental	outcomes	might	
provide	first	hints	for	the	possible	role	of	Lyve-1	in	a	tumour	environment.
It	has	already	been	demonstrated	that	Lyve-1	is	capable	of	binding	to	surfaces	
coated	with	 immobilized	HA,	so	 the	effect	of	Lyve-1	overexpression	on	cellular	
adhesion	was	examined	[112].
For	 this	 purpose,	 a	 96-well	 plate	 was	 coated	 either	 with	 0.2	%	 gelatine	 or	
fibronectin	 (1	μg	/	mL).	 B16F1	 EV	 and	 B16F1	 Lyve-1	 were	 seeded	 and	 allowed	 to	
adhere	 for	 30	min.	 Afterwards,	 the	 plates	 were	 shaken	 for	 10-15	s	 at	 2000	rpm.	
Non-adherent	cells	were	removed	by	washing	carefully,	while	adherent	cells	were	
stained	with	crystal	violet.	
Transgenic	surface	expression	of	Lyve-1	in	B16F1	was	confirmed	by	flow	cyto-
metric	 analysis	 (Fig.  15	A).	 In	 a	 simple	 adhesion	assay,	B16F1	 showed	 in	general	
stronger	connection	to	fibronectin	coated	surfaces	compared	to	gelatine	layered	
ones.	Furthermore,	the	overexpression	of	Lyve-1	in	B16F1	significantly	enhanced	
the	adhesion	specifically	 to	fibronectin,	whereas	adhesion	to	gelatine	remained	
comparable	between	B16F1	EV	and	B16F1	Lyve-1	(Fig. 15	B).
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4.3.4 Lyve-1 overexpression does not influence migratory behaviour  
          or cell death in B16F1
As	the	adhesion	quality	of	cells	also	influences	cellular	migration,	a	simple	wound	
healing	assay	was	performed	to	test	whether	overexpression	of	Lyve-1	has	an	influ-
ence	on	migration.	B16F1	EV	and	B16F1	Lyve-1	cells	were	grown	until	confluency	
was	reached	and	a	scratch	was	applied	to	the	cell	monolayer.	The	migration	rate	
of	 the	 cells	 into	 the	 scratch	was	 assessed	by	 regular	 two-hour	 scratch	measure-
ments	from	0	h-10	h	and	24	h	after	wounding.	To	determine	the	migration	rate,	the	
area	of	the	scratch	was	photographed	and	analyzed	with	the	MiToBo	(Microscope	
Image	Analysis	Tool	Box)	plug-in	for	ImageJ.	The	operator	‘scratch	assay	analyzer’	
was	used	for	the	segmentation	of	scratch	images	by	the	detection	of	the	scratch	
boundaries.	The	photographs	were	thus	converted	to	binary	images	facilitating	the	
computation	of	the	scratch	area.
By	measuring	the	area	of	the	wound,	it	could	be	demonstrated	that	B16F1	EV	
and	B16F1	Lyve-1	migrated	into	the	artificial	scratch	in	comparable	time.	After	24	h,	
complete	closure	of	 the	wound	was	neither	achieved	by	B16F1	EV	nor	by	B16F1	
Lyve-1	and	the	gaps	between	the	cell	boarders	remained	at	similar	magnitude.	Rep-
resentative	pictures	of	the	time	course	are	shown	from	the	starting	point	(0	h)	and	
during	the	closure	of	the	wound	after	4	h,	10	h	and	24	h,	indicating	no	differences	
in	the	amount	of	cells	populating	the	scratch	area	(Fig. 16).	Therefore,	migration	
rate	of	B16F1	was	not	influenced	by	Lyve-1	overexpression.
Figure 15: B16F1	Lyve-1	adhere	more	firmly	to	fibronectin	coated	surfaces. (A) Expression 
of murine Lyve-1 in B16F1 was verified by flow cytometry. (B) Cell culture vessels were coated either with 
fibronectin or with gelatine, after removal of non-adherent cells by subsequent shaking and washing, 
adherent cells were stained with crystal violet and colourimetrically quantified (n = 9).
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Moreover,	the	transgene	B16F1	cell	lines	were	exposed	to	different	concentra-
tions	of	peroxide	to	study	an	eventual	role	of	Lyve-1	in	cellular	response	to	apop-
totic	stimuli.
After	 three	 hours	 of	 peroxide	 stimulation,	 no	 differences	 in	 the	 amount	 of	
surviving	cells	between	the	lineages	B16F1	EV	and	Lyve-1	respectively	have	been	
asserted.	While	 2.5	mM	peroxide	were	not	 adequate	 to	 induce	 apoptosis,	 stimu-
lation	with	5	mM	peroxide	promoted	cell	death	in	3.1	%	of	B16F1	EV	and	6.8	%	of	
B16F1	Lyve-1,	however	the	difference	was	statistically	not	significant.	In	addition,	
exposure	to	10	nM	peroxide	led	to	cell	death	in	41.7	%	of	B16F1	EV	and	43.2	%	of	
B16F1	Lyve-1	and	in	the	case	of	stimulation	with	20	mM	in	both	cells	only	about	
24	%	of	the	cells	survived	the	treatment	(Fig. 17).	In	summary,	transgenic	expres-
sion	of	Lyve-1	did	not	affect	the	apoptosis	rate	of	B16F1.
Figure 16: Overexpression	of	Lyve-1	does	not	affect	motility	of	B16F1. An artificial wound 
was caused to a confluent monolayer of transgenic B16F1 cells allowing the indirect assessment of the 
migration rate by measurement of the reduction of the scratch area over time. (A) Results are shown as 
percentages of four independent experiments with 100 % indicating total scratch area. (B) Representative 
pictures of the scratch experiment are shown. The phase contrast microscopic pictures were converted by 
ImageJ in such a way, that the scratch area could be calculated.
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4.4 Functional implications of sLyve 
derived from macrophages
4.4.1 Identification of a soluble form of Lyve-1 in cell culture  
         supernatant of U937
Lyve-1	 is	 a	 structural	homolog	of	 the	hyaluronan	 receptor	CD44,	which	can	be	
secreted	by	metalloproteinase-mediated	shedding.	It	was	not	until	recently	that	
shedding	of	Lyve-1	has	been	reported	to	occur	in	lymphatic	endothelial	cells	cata-
lyzed	by	ADAM17	and	MT1-MMP	(MMP-14).	To	investigate	if	Lyve-1	is	secreted	from	
macrophages	in	a	similar	manner,	the	cell	culture	supernatant	of	U937	Lyve-1	cells	
was	used	for	immuno-precipitation	(IP).
Figure 17: Apoptosis	rate	of	B16F1	is	not	influenced	by	Lyve-1	overexpression. Transgenic B16F1 cells 
were stimulated with varying concentrations of peroxide for 3 h. Dead cells were removed by washing and surviving 
cells were quantified following crystal violet staining. The percentage of surviving B16F1 EV and B16F1 Lyve-1 is 
given in relation to untreated cells (0 mM H2O2). Results of three independent experiments are shown.
Figure 18: Confirmation	of	the	existence	of	macrophage	derived	soluble	Lyve-1.  
(A)  Lyve-1 was detected in western blot after Lyve-1 directed immunoprecipitation of lysates and culture 
supernatant (SN) derived from U937 Lyve-1. IP-samples were also stained with Coomassie brilliant blue, 
protein bands were excised and analyzed by mass spectrometry. (B) The amino acid sequence of Lyve-1 is 
depicted: signalling peptide – black, extracellular domain – red, transmembrane domain – green, intra-
cellular domain – violet. Lyve-1 was purified from U937 Lyve-1 SN and analyzed by mass spectrometry. 
Identified tryptic peptides are highlighted in yellow.
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Detection	of	Lyve-1	 after	 IP	 in	western	blot	 showed	 the	 full	 length	version	
(70	kDa)	of	the	protein	in	the	samples	derived	from	U937	Lyve-1	lysates,	whereas	a	
15	kDa	shorter	version	was	found	to	be	present	in	the	cell	culture	supernatant	(SN).	
After	purification	of	Lyve-1	from	the	lysate	and	the	SN	and	separation	by	SDS-PAGE,	
the	polyacryl-amide	gels	were	also	stained	by	Coomassie	brilliant	blue	(Fig. 18	A).	
The	protein	bands	of	Lyve-1	were	broadly	 excised	 from	 the	Coomassie	 gel	 and	
digested	 in-gel	with	 trypsin.	 Such	 generated	 tryptic	 peptides	were	 analyzed	by	
MALDI-TOF.	The	tryptic	peptides	identified	by	mass	spectrometry	confirmed	our	
assumption	that	the	55	kDa	protein	is	the	extracellular	Lyve-1	domain	(Fig. 18	B).
In	lymphatic	endothelial	cells	a	soluble	form	of	Lyve-1	is	produced	by	MMP-	
mediated	shedding.	In	order	to	examine	if	processing	of	Lyve-1	in	macrophages	
occurs	in	a	similar	way,	U937	Lyve-1	and	transgenic	HUVEC	Lyve-1	were	stimulated	
for	24	h	with	different	shedding	modulators.	U937	Lyve-1	were	stimulated	directly	
after	seeding,	whereas	HUVEC	Lyve-1	were	grown	until	a	confluency	of	70-80	%	
was	reached	before	stimulants	were	added.	
Stimulation	of	the	transgenic	cell	lines	U937	Lyve-1	and	HUVEC	Lyve-1	with	
the	shedding	activator	APMA	resulted	in	the	accumulation	of	sLyve-1	in	the	super-
natant,	whereas	reduced	amounts	of	full-length	Lyve-1	were	detected	in	the	cell	
lysates.	The	opposite	was	true	when	the	cells	were	stimulated	with	the	shedding	
Figure 19: sLyve-1	is	generated	by	metalloproteinase-mediated	shedding. U937 Lyve-1 and 
HUVEC Lyve-1 were stimulated with APMA, GM6001, MMP9 / 13 inhibitor, Tapi-1 and DMSO as a control 
(50 µM each) for 24 h. (A) Lyve-1 was detected by western blot, both in the cell lysates and in the super-
natants (SN). (B) SN of U937 Lyve-1 were analyzed by ELISA facilitating the quantification of sLyve-1  
after treatment with shedding modulators (n = 3).
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inhibitors	GM6001,	MMP-9	/	13	inhibitor	and	Tapi-1	resulting	in	reduction	of	Lyve-1	
shedding	 (Fig.  19	A).	Quantification	 of	 sLyve-1	 by	 ELISA	 in	 the	 supernatants	 of	
U937	Lyve-1	following	stimulation	with	the	shedding	modulators	confirmed	the	
western	blot	finding	revealing	that	MMP-9	/	13	inhibitor	has	the	strongest	inhibi-
tory	effect	(Fig. 19	B).	Besides	MMP-9	and	MMP-13,	this	small	molecule	inhibitor	
also	targets	metalloproteinases	1,	3	and	7.	Hence,	Lyve-1	secretion	in	macrophages	
occurs	via	a	shedding	process	that	is	orchestrated	by	metalloproteinases	similar,	
but	less	efficient	if	compared	to	shedding	in	endothelial	cells.
4.4.2 sLyve-1 reduces the proliferation rate of melanoma cell lines
We	hypothesized	that	the	shedded	ectodomain	of	Lyve-1	might	function	as	a	decoy	
receptor	for	the	respective	ligands	such	as	HA	and	FGF-2.	To	test	this	assumption	in	
the	connection	with	possible	implications	of	Lyve-1	shedding	for	tumour	growth,	
we	assessed	the	proliferation	rate	of	melanoma	cell	lines	after	exposure	to	soluble	
Lyve-1	 (sLyve-1)	 in vitro.	 1	×	106	U937	Lyve-1	or	EV	were	seeded	per	millilitre	FCS-
free	cell	culture	medium.	After	24	h	cells	were	removed	by	centrifugation	and	the	
conditioned	medium	was	again	centrifuged	to	remove	remaining	cellular	debris.	
HT144	were	seeded	in	the	conditioned	medium	mixed	with	fresh	FCS-free	culture	
medium	3	:	1.	The	melanoma	cell	line	was	cultured	for	24	h	and	the	proliferation	
rate	was	determined	in	a	BrdU	assay.	In	addition,	HT144	and	A375	were	seeded	in	a	
96-well	plate	and	stimulated	for	48	h	with	different	concentrations	of	synthesized	
sLyve-1	(amino	acids	24-238)	cell	growth	was	assessed	by	crystal	violet	staining.
Figure 20: sLyve-1	inhibits	growth	of	melanoma	cell	line	HT144. (A) Proliferation rate of 
HT144 cultured for 24 h in U937 EV / Lyve-1 conditioned FCS-free medium mixed 3 : 1 with fresh FCS-
free culture medium. (B) Different concentrations of sLyve-1 were added to HT144 and A375 cultured in 
medium supplemented with 2 % FCS, number of cells was determined by crystal violet staining in relation to 
untreated control cells, (n = 8). (C) Quantification of HA in supernatant of A375 and HT144 cells after 24 h 
of cultivation in FCS-free medium by ELISA, (n = 3).
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Cultivation	of	HT144	 in	U937	 conditioned	medium	 resulted	 in	 a	 significant	
inhibition	of	the	proliferation	of	the	cancer	cell	line	specifically	in	medium	derived	
from	U937	Lyve-1	(Fig. 20	A).	To	confirm	that	this	was	due	to	the	presence	of	sLyve-1	
in	the	culture	supernatant,	proliferation	of	HT144	and	additionally	A375	cells	was	
assessed	after	treatment	with	synthesized	sLyve-1.	Whereas	no	effect	of	sLyve-1	
was	observed	on	A375	cells,	500	ng	/	mL	sLyve-1	significantly	inhibited	cell	proli-
feration	of	HT144	cells	after	48	h	(Fig. 20	B).	Finally,	conditioned	FCS-free	medium	
from	A375	and	HT144	cells	was	examined	for	the	presence	of	HA	and	quantification	
by	ELISA	showed	enhanced	production	of	HA	by	the	HT144	(477.6	±	29.35	ng	/	mL)	
cell	 line	 compared	 to	A375	 cells	 (1352	±	168.2	ng	/	mL)	 (Fig.  20	C).	 Taken	 together,	
these	results	indicate	that	sLyve-1	interferes	with	melanoma	cell	proliferation	by	
interacting	with	autocrine	HA	stimulation.
4.4.3 sLyve-1 is significantly elevated in blood plasma  
         of psoriasis  patients
To	 test	whether	 circulating	Lyve-1	 exists	 in	human	blood	 and	may	qualify	 as	 a	
potential	prognostic	marker	in	human	diseases,	we	measured	levels	of	sLyve-1	in	
plasma	samples	derived	from	patients	suffering	from	skin	disorders.
Figure 21: sLyve-1	is	detectable	in	human	blood	plasma. The amount of sLyve-1 was deter-
mined by ELISA in blood plasma of healthy donors, (n = 20) compared to (A) plasma derived from psoriasis 
patients, (n = 42) and (B) patients suffering from melanoma, (n = 11) before and at different time points of 
PD-1 inhibitor treatment.
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sLyve-1	 could	 be	 detected	 in	 blood	 plasma	 samples	 derived	 from	 healthy	
donors	with	concentrations	of	158.8	±	18.67	ng	/	mL.	In	the	plasma	of	patients	suf-
fering	from	psoriasis,	which	is	Th	1	cytokine	dominated	skin	disease,	sLyve-1	levels	
were	found	to	be	significantly	elevated	(256.1	±	18.03	ng	/	mL)	(Fig. 21	A).	In	addition,	
the	concentration	of	sLyve-1	was	determined	in	plasma	from	melanoma	patients,	
which	were	 comparable	 to	 the	 control	 group	of	healthy	donors.	All	melanoma	
patients	 received	 a	 PD-1	 inhibitor	 treatment;	monitoring	 of	 sLyve-1	 levels	 dur-
ing	different	time	points	of	the	treatment	revealed	no	relevant	differences	in	the	
plasma	concentration	of	Lyve-1	(Fig. 21	B).	
4.5 Relevance of dexamethasone dependent proteins  
for tumour growth
4.5.1 In vivo Lyve-1 deficiency leads to increased tumour growth
As	already	shown	in	2006	by	Schledzweski	et	al.,	Lyve-1+	TAM	are	present	in	sub-
cutaneously	(s.	c.)	grown	B16F1	tumours	in	mice	[116].
We	examined	the	growth	of	melanoma	tumours	in	C57BL	/	6	Lyve-1-/-	knockout	
mice	and	compared	it	to	the	tumour	growth	in	wild	type	control	mice.	For	this	
purpose,	1	×	106	B16F1	cells	were	injected	s.	c.	into	the	flank	of	the	mice.
After	ten	days,	tumour	growth	of	B16F1	in	C57BL	/	6	Lyve-1-/-	and	wild	type	con-
trol	mice,	the	mice	were	sacrificed	and	the	tumours	were	harvested	and	analyzed.	
Immunohistological	staining	of	tumour	intersections	with	the	markers	for	macro-
phages	CD68	and	for	endothelial	cells	CD31	revealed	in	both	cases	a	minor,	not	sig-
nificant	reduction	of	positive	cells	in	the	tumours	derived	from	Lyve-1	knockout	
mice	(Fig. 22	A	+	B).	In	contrast,	significantly	more	cells	were	stained	positive	for	
the	proliferation	marker	Ki-67	in	tumours	grown	in	C57BL	/	6	Lyve-1-/-	(Fig. 22	C).	
The	higher	proliferation	rate	of	the	tumour	cells	also	correlated	with	the	finding	
that	the	tumour	end	weight	of	B16F1	tumours	was	increased	in	the	knockout	mice,	
thus	Lyve-1	deficiency	resulted	in	a	higher	tumour	end	weight	(Fig. 22	D).
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Figure 22: Tumour	growth	is	enhanced	in	Lyve-1-/-	mice. 1 × 106 B16F1 melanoma cells 
were injected s. c. into the flank of the mice and after ten days of growth, the mice were sacrificed and the 
tumours were harvested for analysis. (A) Immunohistological staining of 7 µm acetone-fixed cryosection 
of CD68 and (B) CD31. The number of positively stained cells was assessed in relation to the area of the 
tumour inter section, representative stainings are shown, (n = 7). (C) Staining of the cryosections with 
anti-Ki67, scale bars = 100 µm. The positive cells of five representative pictures per tumour sample were 
counted, (n = 7). (D) Tumour end weight after 10 days of growth (n = 8).
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Further	 in vivo	 tumour	 growth	 experiments	were	 accomplished	with	B16F10	
LUC	cells.	These	cells	express	luciferase	derived	from	the	North	American	firefly.	
This	cell	 line	was	used	for	the	 in vivo	monitoring	of	 tumour	growth	in	C57BL	/	6	
Lyve-1-/-	and	wild	type	control	mice	by	measuring	a	bioluminescence	signal	which	
is	produced	by	the	tumour	cells	after	the	administration	of	the	luciferase	substrate	
luciferin.	 150	µL	of	D-Luciferin	potassium	salt	 (30	mg	/	mL)	 in	PBS	were	 injected	
intraperitoneal	 into	 the	B16F10	LUC	 tumour	bearing	mice.	The	mice	were	anes-
thetized	 in	 an	 isoflurane	 gas	 chamber	 and	 luminescence	 pictures	 were	 taken	
three	minutes	 after	 substrate	 injection	with	 IVIS	 Lumina	 (PerkinElmer,	 Living	
Image 4.3).
By	 immunofluorescent	 double	 staining	 with	 anti-CD68	 and	 anti-Lyve-1	 of	
B16F10	LUC	tumours	derived	from	wild	type	mice	the	existence	of	Lyve-1+	macro-
phages	in	the	tumour	stroma	could	be	confirmed.	Lyve-1+	TAM	were	found	mainly	
in	the	tumour	periphery,	whereas	they	occurred	only	sporadically	in	the	tumour	
centre	(Fig. 23).
Figure 23: Lyve-1+	TAM	are	present	in	the	periphery	of	B16F10	tumours. 1 × 106 B16F10 
LUC melanoma cells were injected s. c. into the flank of the C57BL / 6 wild type mice. 11 days after tumour 
cell injec tion, mice were sacrificed and tumours were snap frozen in liquid nitrogen. Immunofluorescent 
staining of 7 µm acetone fixed cryosection with anti-CD68 (red) and anti-Lyve-1 (green) of tumours derived 
from wild type mice was accomplished, representative pictures are shown.
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Figure 24: Tumour	growth	is	accelerated	in	Lyve-1-/-	mice. 1 × 106 B16F10 LUC melanoma cells 
were injected s. c. into the flank of the C57BL / 6 Lyve-1-/- and wild type mice respectively. (A) Monitoring 
of tumour growth via luminescence measurement following luciferin injection after 7 days and 11 days of 
B16F10 LUC tumour growth following tumour cell injection; assessment of average photon flux and relative 
tumour growth, (n = 3). (B) Representative pictures of tumour bearing mice after luminescence injection at 
the indicated time points after tumour cell injection.
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Luminescence	measurement	on	day	7	 and	day	 11	 after	 tumour	cell	 injection	
facilitated	the	in vivo	monitoring	of	tumour	growth	in	Lyve-1	knockout	mice	and	
wild	type	controls.	The	average	photon	flux,	which	strongly	correlates	with	the	
tumour	volume,	was	assessed.	On	day	7	we	measured	an	enhanced	average	photon	
flux	in	the	knockout	mice,	while	on	day	11	differences	between	the	experimental	
groups	were	more	balanced.	Regarding	the	relative	tumour	volume	gain	between	
day	7	and	day	11,	tumours	in	the	knockout	mice	grew	faster	by	trend	(Fig. 24).	Over-
all	 these	analyses	reveal	that	Lyve-1	deficiency	accelerates	tumour	cell	prolifera-
tion	during	the	early	phases	of	tumour	growth.
4.5.2 Myeloid specific depletion of the glucocorticoid receptor  
         accelerates tumour growth
The	 in vitro	experiments	have	highlighted	the	central	role	of	glucocorticoids	for	
the	induction	of	Lyve-1.	To	define	the	role	of	glucocorticoids	for	Lyve-1	expres-
sion	and	 tumour	growth	 in vivo	 a	new	mouse	model	was	generated.	A	 strain	of	
mice	(LysMcre)	that	express	nuclear	localized-Cre	recombinase	under	the	control	
of	myeloid	specific,	endogenous	Lyz	2	promoter	/	enhancer	elements	was	crossed	
with	mice	(GR	fl)	having	loxP	sites	adjacent	to	exon 3	of	the	NR3C1	gene	which	
encodes	for	the	GR.	Descendants	of	this	breeding	strategy	show	a	myeloid	specific	
knockout	of	GR.	Recombination	of	NR3C1	was	confirmed	by	PCR-based	genotyp-
ing.	B16F10	LUC	cells	(1	×	106)	were	injected	s.	c.	 into	the	flank	of	female		GRLysMcre 
mice	and	 tumour	growth	was	documented	during	 12	days.	Tumour	growth	was	
monitored	by	luminescence	measurement	as	described	above	by	administration	
of	luciferin	to	the	tumour	bearing	mice.
Measurement	 of	 the	 average	 luminescent	 radiance	 of	 B16F10	 tumours	 of	
	GRLysMcre	and	wild	type	controls	showed	no	significant	differences	on	day	4	and	
day	8	after	the	injection	of	the	tumour	cells.	A	significant	greater	average	flux	was	
measured	on	day	12	in	the		GRLysMcre experimental	group	which	implied	increased	
tumour	volumes	(Fig. 25	B).	Furthermore,	relative	gain	of	tumour	volume	was	sig-
nificantly	increased	in	the		GRLysMcre	mice	between	day	8	and	day	12	(Fig. 25	B).	After	
two	weeks,	the	tumours	were	harvested	and	weighed	at	which	it	was	found	that	
the	 tumours	 from	 	GRLysMcre	were	 considerably	 bigger	 compared	 to	 the	 tumours	
which	grew	in	the	wild	type	controls	(Fig. 25	C).
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Figure 25: Tumour	growth	is	enhanced	in	GRLysMcre	mice. 1 × 106 B16F10 LUC melanoma 
cells were injected s. c. into the flank of the GRLysMcre and wild type mice, respectively. (A) Monitoring of 
tumour growth via luminescence measurement after luciferin injection at 4 d, 8 d and 12 d after tumour cell 
injection. (B) Assessment of average photon flux and relative gain of tumour area between day 8-12 (n = 5). 
(C) On day 14 of tumour growth mice were sacrificed and the tumour end weight was determined (n = 3).
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Cryosections	of	the	melanoma	tumours	grown	in	wild	type	and		GRLysMcre	mice	
were	analyzed	by	immunofluorescent	staining.	CD68	/	Lyve-1	double	positive	cells	
could	be	detected	in	the	periphery	of	B16	tumours	which	were	grown	in		GRLysMcre	
mice.	Therefore,	ablation	of	GR	expression	in	macrophages	did	not	suppress	Lyve-1	
expression	 in	 TAM.	 Evident	 differences	 regarding	 distribution	 and	 quantity	 of	
CD68+	/	Lyve-1+	 cells	 between	 tumours	 from	 control	mice	 and	 the	mutant	mice	
strain	were	not	observed	(Fig. 26).	Although,	GR	signalling	seems	to	be	a	key	reg-
ulator	of	Lyve-1	expression	in vitro,	during	tumour	growth	conditions	in vivo	other	
factors,	which	remain	 to	be	determined,	play	a	 role	 in	 the	regulation	of	Lyve-1	
expression.	 In	 summary,	 myeloid	 specific	 knockout	 of	 GR	 had	 an	 accelerating	
effect	on	tumour	growth,	but	had	no	effect	on	Lyve-1	expression	in	TAM.
Figure 26: Knockout	of	GR	in	macrophages	does	not	suppress	Lyve-1	expression	in	TAM. 
1 × 106 B16F10 LUC melanoma cells were injected s. c. into the flank of the GRLysMcre and wild type mice 
respectively after 12 days of growth, mice were sacrificed and tumours were snap frozen in liquid nitrogen. 
Immunofluorescent staining of 7 µm acetone fixed cryosection with anti-CD68 (red) and anti-Lyve-1 
(green) was performed, representative pictures are shown, scale bar = 100 µM.
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5.1 Characterization of Lyve-1+ macrophages  
in vivo and in vitro
Immunohistological	 staining	 of	 human	 primary	 melanoma	 revealed	 the	 exis-
tence	of	Lyve-1+	cells	within	the	tumour	stroma	which	were	identified	by	histo-
pathological	 analyses	 as	 endothelial	 cells	 and	 macrophages.	 The	 existence	 of	
Lyve-1+	macrophages	was	further	substantiated	by	the	observation	that	these	cells	
do	 also	 express	 the	macrophage	markers	 CD68	 and	 CD163.	 By	 sequential	 stain-
ing,	CD68+	/	Lyve-1+	cells	could	be	identified	for	the	first	time.	This	novel	staining	
method,	which	has	recently	been	established	in	our	lab,	allows	successive	staining	
of	the	same	slide	with	different	antibodies	and	therefore	is	really	helpful	to	study	
the	inflammatory	environment	of	tumours.	The	staining	revealed	that	these	dou-
ble	positive	cells	mainly	accumulate	in	the	periphery	of	the	tumours.
In vitro,	Lyve-1	expression	could	be	induced	in	murine	BMDM	by	the	stimulation	
with	tumour	conditioned	medium	(TCM)	/	dexa	/	IL-4.	To	transfer	this	to	a	human	
setting,	we	stimulated	pBMC	isolated	from	Buffy	coat	samples	and	detected	Lyve-1	
expression	after	seven	days	of	stimulation	with	MDI.	Besides	Lyve-1	the	combined	
stimulation	wit	MDI	induces	genes,	such	as	GLDN,	EPS8,	GPR91	and	CLEC10 a	which	
were	also	found	to	be	expressed	by	TAM	in vivo.	Hence,	this	stimulation	of	pBMC	
was	used	as	a	model	for	the	differentiation	of	human	TAM	in vitro	[136].	However,	
the	activation	status	and	phenotype	of	the	MDI-induced	macrophages	has	yet	not	
been	further	characterized.
Due	to	the	high	heterogeneity	of	macrophages	their	classification	represents	a	
serious	obstacle.	Diverse	models	exist	that	aim	at	the	classification	of	macrophage	
phenotypes.	 Most	 commonly	 macrophages	 were	 separated	 into	 pro-inflamma-
tory	M1	macrophages	induced	by	Th	1	derived	cytokines	such	as	IFN-γ	and	TNF-α,	
and	microbial	antigens	like	LPS	and	anti-inflammatory	M2	macrophages	shaped	
amongst	others	by	Th	2	cytokines	like	e.	g.	IL-4	or	IL-13,	IL-10	and	glucocorticoids.	
Still,	 this	division	only	represents	two	extremes	of	a	continuum	of	various	phe-
notypes	 lying	 in	 between.	 In  vivo,	macrophages	 are	 exposed	 to	 complex	micro-
environments	composed	of	a	mixture	of	pro-	and	anti-inflammatory	stimuli	and	
hence	develop	a	rather	mixed	M1	/	M2	phenotype.	Leading	researchers	in	the	field	
of	macrophages	recently	formulated	guidelines	to	describe	macrophage	activation	
and	polarization	more	specifically	 in	the	corresponding	experimental	set	up	by	
delineation	of	the	macrophage	source,	the	activators	used	for	macrophage	stimu-
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lation	and	marker	expression	profiling	to	describe	the	macrophage	activation	sta-
tus	[42].	Taking	this	into	account	expression	analyses	of	well-studied	macrophage	
markers	on	MDI-induced	macrophages	was	accomplished	and	compared	to	con-
trol	 cells	 which	 were	 stimulated	 by	 M-CSF	 only.	 The	 expression	 levels	 of	 pan-	
macrophage	marker	CD11	b,	mannose	 receptor	CD206,	 scavenger	 receptor	CD163	
and	MHC	class II	protein	were	examined.	The	analysis	revealed	up-regulation	of	
the	 scavenger	 receptors	 CD206	 and	CD163	 in	MDI-treated	pBMC,	 both	 are	 com-
monly	used	markers	for	M2-like	macrophages	and	TAM	[37].	Furthermore,	TAM	
are	characterized	by	impaired	antigen-presentation	abilities	as	a	result	of	reduced	
expression	of	MHC	molecules.	Yet,	an	influence	of	MDI	on	MHC	class II	expression	
was	not	observed	in	MDI	stimulated	pBMC.
Further	expression	analyses	of	the	MDI-induced	macrophages	indicated	a	shift	
of	the	arginine	metabolism	towards	the	production	of	ornithine	and	urea	accompa-
nied	by	decreased	production	of	NOS	and	ROS.	Enhanced	degradation	of	L-arginine	
as	a	result	of	arginase	up-regulation	in	myeloid	cells	constitutes	a	central	mecha-
nism	of	tumour	immunoescape.	Depletion	of	L-arginine	leads	to	the	suppression	
of	the	anti-tumour	response	mediated	by	T	cells	through	the	down-regulation	of	
TCR	ζ	chain.	In	different	neoplasms	such	as	prostate	cancer,	non-small	lung	cancer	
and	different	myelomas	involvement	of	arginase	mediated	immune	suppression	of	
tumour	 infiltrating	 leukocytes	has	been	shown	[142].	Immunosuppressive	quali-
ties	of	MDI-induced	macrophages	are	thus	conceivable.	Taken	together,	our	results	
clearly	demonstrate	that	the	combined	stimulation	of	MDI	induces	a	M2-like	phe-
notype	in	pBMC.	As	this	stimulation	induces	many	different	genes	which	also	been	
described	to	be	expressed	by	TAM	our	model	might	constitute	a	novel	in vitro	differ-
entiation	method	to	induce	a	TAM-like	phenotype	in	pBMC.
Stimulation	of	murine	BMDM	with	TCM,	dexa	and	IL-4	induced	Lyve-1	expres-
sion	in	approximately	40	%	of	the	treated	cells.	In	a	similar	manner,	cytokine	stimu-
lation	of	human	pBMC	resulted	in	the	formation	of	a	Lyve-1	expressing	subpopula-
tion	comprising	a	minor	fraction	of	25	%	of	the	stimulated	cells.	Protein	expression	
profiling	of	the	above	mentioned	macrophage	markers	was	repeated	to	determine	
specific	differences	between	the	Lyve-1+ and	Lyve-1-	MDI-derived	distinct	subsets.	
Lyve-1	expression	in	MDI-treated	pBMC	was	accompanied	by	increased	expression	
of	CD11	b	and	CD206.	A	similar	macrophage	marker	expression	profile	has	already	
been	 described	 in	 a	 subpopulation	 of	 TAM	derived	 from	 TS	/	A	 tumours.	 Lyve-1	
was	differentially	expressed	in	a	subpopulation	of	macrophages	displaying	high	
expression	of	ARG-1,	CD206,	CD163,	STAB-1	and	low	expression	of	MHC	class II	[73].	
In	connection	with	our	results,	we	assume	that	the	 in vitro	cytokine	stimulation	
with	MDI	induces	the	shaping	of	a	phenotype	mirroring	specific	characteristics	of	
Lyve-1+	TAM.	Moreover,	Lyve-1+	macrophages	are	a	distinct	subpopulation	which	
is	more	oriented	towards	a	M2-like	phenotype.
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MDI	treatment	induces	Lyve-1	expression	in	pBMC	in	a	time-dependent	manner	
showing	progressively	increasing	Lyve-1	expression	between	day	5	and	day	9	of	
MDI	stimulation.	This	raised	the	question	if	Lyve-1	is	a	direct	target	of	dexametha-
sone	induced	glucocorticoid	receptor	(GR)	activation.	Successive	addition	of	either	
GR	inhibitor	mifepristone	to	MDI	treated	cells	or	dexamethasone	to	M-CSF	/	IL-4	
stimulated	cells	demonstrated	the	crucial	dependency	of	Lyve-1	expression	on	GC	
during	the	complete	stimulation	time.	Impairment	of	dexamethasone	stimulation	
at	any	time	reduced	Lyve-1	expression	significantly.	The	GR	is	a	member	of	the	hor-
mone	receptor	transcription	factor	family,	which	is	expressed	almost	ubiquitously.	
Upon	ligand	binding	GR	is	liberated	from	a	multiprotein	complex	and	translocates	
from	the	cytoplasm	to	the	nucleus	to	modulate	gene	expression	via	binding	to	GR	
responsive	elements	(GRE)	in	the	regulatory	region	of	its	target	genes.	Transacti-
vation	of	genes	requires	the	dimerization	of	GR	whereas	transrepression	can	also	
be	mediated	by	monomers.	Anti-inflammatory	effects	of	GR	are	mediated	by	the	
transcription	of	anti-inflammatory	genes	like	IL-10	and	by	inhibiting	the	action	of	
key-regulators	of	inflammation	such	as	NFκB	and	AP-1	[143,	144].	In	macrophages,	
GC	 greatly	 influence	 gene	 expression.	On	 the	 one	 site	 immunomoldulators	 are	
downregulated	such	as	GM-CSF,	TNF-α,	IL-1,	 IL-6,	 iNOS	and	COX-2	[145].	On	the	
other	site,	a	recent	study	which	examined	gene	expression	during	monocyte	to	
macrophage	differentiation	under	the	influence	of	glucocorticoids	demonstrated	
activation	of	diverse	genes	associated	with	increased	cell	motility,	decreased	adhe-
sion	 and	 enhanced	 phagocytosis	 [146].	 In	 general,	 glucocorticoid	 receptor	 acti-
vation	in	macrophages	is	associated	with	the	formation	of	a	M2-like	phenotype.	
Such	macrophages	are	mainly	involved	in	homeostatic	processes,	wound	healing	
and	resolution	of	the	inflammatory	response.	TAM	resemble	M2-like	macrophages	
in	many	ways	 as	 they	 promote	 immunoescape,	 as	 well	 as	 tumour	 growth	 and	
progression.	Therefore,	it	is	tempting	to	speculate	that	the	dependency	on	GC	of	
Lyve-1	expression	is	suggestive	of	a	possible	pro-tumour	role	of	Lyve-1.	
In	the	course	of	expression	profiling	of	murine	Lyve-1+	BMDM	induced	by	the	
combined	 stimulation	 with	 TCM	/	dexa	/	IL-4,	 Ms4a8a	 was	 identified	 as	 a	 novel	
marker	 of	murine	M2	macrophages.	 Examination	of	 regulatory	mechanisms	of	
Ms4a8a	expression	 in vitro	 revealed	 that	 impairment	of	either	GR,	p	38	MAPK	or	
NFκB	 signalling	 inhibited	Ms4a8a	 expression.	 In	 analogy	 to	 these	observations	
the	eventual	contribution	of	these	signalling	pathways	on	Lyve-1	induction	was	
assessed.	While	Lyve-1	 expression	 in	MDI-treated	pBMC	 remained	unperturbed	
under	the	influence	of	a	NFκB	inhibitor,	treatment	with	the	p	38	MAPK	inhibitor	
SB203580	diminished	Lyve-1	induction	significantly.	The	physiological	role	of	p	38	
MAPK	activation	comprises	stress	and	immune	responses	as	well	as	regulation	of	
apoptosis	and	differentiation	[147].	TGF-β	is	a	well	characterized	inducer	of	the	p	38	
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MAPK	signalling	via	SMAD	independent	activation	of	a	MAPK	signalling	cascade	
involving	the	subsequent	activation	of	TRAF6,	TAK1,	as	well	as	MMK4	and	MKK3	/	6	
following	the	formation	of	a	TGF-β	receptor	complex	[148].	In	macrophages	TGF-β	
stimulation	is	involved	in	the	induction	of	M2-associated	genes.	Therefore,	TGF-β	
was	used	for	pBMC	stimulation	in	different	combinations	with	M-CSF,	dexa	and	
IL-4	to	examine	its	effect	on	Lyve-1	induction	in vitro,	at	which	TGF-β	showed	no	
influence	on	Lyve-1	induction.	
p	38	 MAPK	 signalling	 has	 also	 been	 identified	 to	 be	 involved	 in	 IL-4	 medi-
ated	differentiation	of	M2	macrophages.	The	first	stimuli	which	were	identified	
to	 induce	 alternative	 activation	 of	 macrophages	 were	 IL-4	 and	 IL-13	 inducing	
enhanced	expression	of	CD206	and	diminished	expression	of	pro-inflammatory	
cytokines.	 Classically,	 IL-4	 binding	 to	 its	 corresponding	 receptor	 activates	 the	
JAK	/	STAT6	pathway	or	PI3KC	downstream	signalling.	In	murine	peritoneal	macro-
phages,	activation	of	p	38	MAPK	signalling	in	response	to	IL-4	stimulation	has	been	
observed	and	was	related	 to	 the	expression	of	M2	marker	genes,	 such	as	ARG-1,	
YM-1	and	FIZZ-1	[149].	Further	evidence	for	this	connection	was	provided	by	the	
description	of	p	38	MAPK	dependency	of	APRIL	induction	in	murine	macrophages	
following	exposure	 to	 IL-4	 [150].	 In	human	pBMC,	 stimulation	with	M-CSF	and	
dexa	 suffices	 to	 induce	 Lyve-1	 expression,	 but	 the	 addition	 of	 IL-4	 boosts	 this	
effect	probably	through	indirect	mechanisms	mediated	by	the	activation	of	p	38	
MAPK.	This	is	also	in	line	with	the	observation	that	mifepristone	mediated	sup-
pression	of	Lyve-1	induction	proved	to	be	more	efficient	compared	to	treatment	
with	SB203580.	Considering	the	strong	dependency	of	Lyve-1	induction	on	dexa-
methasone	we	concluded	that	Lyve-1	induction	in	pBMC	is	subjected	to	GR	activa-
tion	by	direct	or	indirect	mechanisms	and	is	augmented	by	p	38	MAPK	signalling.
5.3 Functional implications of Lyve-1 expression
Both	MDI-induced	pBMC	and	 transgenic	U937	express	Lyve-1	 in	a	highly	glyco-
sylated	form.	In	the	area	of	the	link domain	two	sites	for	N-linked	glycosylation	
have	 been	 identified	which	 are	 involved	 in	 the	 HA-binding	 capacity	 of	 Lyve-1.	
Further	multiple	 sites	 for	O-linked	 glycosylation	 are	 located	 in	 the	membrane	
proxi	mal	 region	which	 is	characterized	by	numerous	serine	and	threonine	resi-
dues.	Lately,	it	was	demonstrated	that	HA-binding	to	Lyve-1	depends	on	the	sur-
face	density	of	the	receptor	and	cluster	formation	or	higher	order	complexation	
of	HA	accordingly.	Lyve-1	monomers	show	only	weak	affinity	to	HA	thus	it	is	con-
ceivable	that	several	receptors	are	required	for	stable	binding	of	HA	on	the	cellular	
surface	in	primary	lymphatic	endothelial	cells.	In	our	expression	model	of	lenti-
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viral	overexpression	Lyve-1	expression	levels	were	sufficient	to	bind	biotinylated	
HA	efficiently	on	the	cell	surface.	Interactions	of	endogenously	expressed	Lyve-1	
in	macrophages	with	HA	still	need	examination.	
HA	is	a	linear	non-sulphated	polymer	component	of	the	extracellular	matrix	
build	by	repetitive	assembly	of	 [β(1,	4)D-glucuronic	acid-β(1,	3)N-acetyl-D-gluco-
samine].	HA	is	subjected	to	constant	turn-over	which	is	mainly	accomplished	by	
local	uptake	and	degradation	by	macrophages	and	fibroblast	or	transport	via	the	
lymph	 to	 lymph	 nodes	 for	 final	 degradation.	 HA	 exerts	 a	wide	 range	 of	 differ-
ent	functions	which	are	mediated	by	diverse	receptors	with	distinct	properties,	at	
which	the	size	of	the	polymer	is	relevant,	too.	While	HMW-HA	exerts	anti-inflam-
matory	functions,	LMW-HA	promotes	inflammation	and	angiogenesis	[151].	Exces-
sive	production	of	HA	due	to	upregulated	expression	of	HA-synthases	is	associated	
with	the	formation	of	aggressive,	metastatic	tumours.	High	HA	levels	further	cor-
relate	with	tumour	progression	in	different	tumour	entities,	such	as	breast,	ovar-
ian,	prostate	and	colorectal	cancer	[152,	153].	In vivo,	inhibition	of	HA	synthesis	in	
prostate	cancer	cells	attenuated	tumour	growth	[154].	A	possible	explanation	for	
these	findings	was	provided	by	a	study	demonstrating	that	inhibition	of	HA	pro-
duction	within	the	tumour	stroma	resulted	in	decreased	recruitment	of	TAM	and	
thus	diminished	formation	of	a	tumour	vasculature.	Notably,	aggregation	of	HA	by	
versican,	a	member	of	the	HA-binding	chondroitin	sulphate	proteoglycan	family,	
was	found	to	be	necessary	for	successful	TAM	recruitment	and	enhanced	tumour	
growth	[155].	The	underlying	mechanism	of	the	interaction	of	TAM	with	stromal	
HA	has	not	been	examined	yet,	though	involvement	of	Lyve-1	is	conceivable.
Lyve-1	possesses	dual	ligand	binding	activity.	Besides	HA,	different	growth	fac-
tors	such	as	PDGF-bb,	VEGF-a	and	FGF-2	have	been	identified	as	ligands	of		Lyve-1.	
Their	binding	occurs	outside	of	the	HA-binding	link	domain.	Deglycosylation	of	
Lyve-1	impaired	interactions	with	FGF-2	demonstrating	the	importance	of	glyco-
sylation	for	growth	factor	interactions.	The	impact	of	receptor	density	on	growth	
factor	bindings	has	not	been	under	investigation	yet.	However,	it	seems	to	be	likely	
that	interactions	between	Lyve-1	and	its	growth	factor	ligands	occur	independently	
from	receptor	clustering,	as	interactions	between	Lyve-1	and	FGF-2	were	shown	in	
lymphatic	endothelial	cells	both	in vitro	and	in vivo.	In	lymphatic	endothelial	cells	
interactions	with	either	LMW-HA	or	FGF-2	with	Lyve-1	induced	proliferation	and	
migration.	Thus,	these	interactions	induce	lymphangiogenesis	[125,	132].	
While	 the	majority	 of	 TAM	 differentiate	 from	 chemokine	 recruited	 tumour	
infiltrating	monocytes,	 recent	findings	suggest	expansion	of	TAM	by	 local	proli-
feration	in	mammary	tumours	[156,	157].	In	this	context,	cell	surface	retention	of	
macrophage	produced	growth	factors	could	also	induce	proliferation	in	an	auto-
crine	manner	[124].	In	our	transgenic	macrophage	cell	line	however	neither	over-
expression	of	Lyve-1	per se	nor	stimulation	with	its	ligands	HA	or	FGF-2	induced	
cell	proliferation.
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Further	functional	analyses	were	performed	using	the	murine	melanoma	cell	
line	B16F1,	which	was	transduced	to	establish	lentiviral	overexpression	of	Lyve-1.	
We	used	this	artificial	model	to	gain	insights	into	principal	cellular	functions	of	
Lyve-1	expression	regarding	effects	on	cellular	adhesion	and	migration	as	well	as	
on	apoptosis.	As	it	is	well	established	that	Lyve-1	interacts	with	HA	and	thereby	
mediates	adhesion	to	HA	coated	surfaces	[112,	118],	we	examined	Lyve-1	mediated	
cellular	adhesion	to	fibronectin	and	gelatine.	 In	 fact,	Lyve-1	overexpression	sig-
nificantly	increased	adhesion	to	fibronectin,	whereas	no	such	effect	was	observed	
when	cellular	adhesion	to	gelatine	coated	surfaces	was	assessed.	CD44,	 the	clos-
est	homologue	of	Lyve-1,	shows	similar	adhesion	characteristics.	Besides	HA,	fur-
ther	 components	 of	 the	 extracellular	matrix	have	been	 identified	 as	 ligands	of	
CD44	such	as	laminin,	type I	collagen	fibrils	and	also	fibronectin,	while	binding	to	
gelatine	was	not	observed	[158].	In	this	context,	macrophages	direct	tumour	cell	
migration	in	a	lock-step	manner	towards	blood	vessels	by	moving	along	collagen	
fibres	and	thus	facilitate	intravasation	of	tumour	cells	and	promote	the	formation	
of	metastasis	at	distant	sites	[95].	Lyve-1	might	therefore	play	a	role	in	mediating	
adhesion	and	migration	of	tumour	associated	macrophages	along	components	of	
the	extracellular	matrix	and	directing	tumour	cell	migration.	To	evaluate	a	possi-
ble	role	of	Lyve-1	for	cell	migration	a	simple	wound	healing	assay	was	performed.	
Closure	of	an	artificial	wound	introduced	to	a	cellular	monolayer	in	the	form	of	a	
scratch	occurred	at	comparable	velocity	between	Lyve-1	overexpressing	and	mock	
transfected	 control	 cells.	Hence,	 cell	migration	was	 not	 influenced	 directly	 by	
Lyve-1	overexpression.	However,	a	possible	role	of	Lyve-1	in	chemotaxis	induced	
migration	should	not	be	disregarded	and	needs	further	evaluation.	
Both	 signalling	 pathways	 identified	 to	 be	 relevant	 for	 the	 in vitro	 induction	
of	Lyve-1	are	regulators	of	cell	survival.	Glucocorticoids	are	widely	used	 in	can-
cer	therapies	based	on	their	apoptosis	promoting	effect	on	cancer	cells.	However,	
GR	 signalling	 regulates	 the	expression	of	both	pro-	 and	anti-apoptotic	proteins	
and	induction	of	apoptosis	occurs	in	a	cancer	type	specific	way	[159].	p	38	MAPK	
signalling	too	is	involved	in	regulation	of	cell	death	in	a	cell-type	and	stimulus	
dependent	manner	[160].	Hence,	functional	relevance	of	Lyve-1	was	examined	in	
the	context	of	cell	survival.	Transgenic	expression	of	Lyve-1	did	not	influence	the	
apoptosis	rate	of	cells	which	were	challenged	with	increasing	concentrations	of	
cytotoxic	peroxide.
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The	high	sequence	homology	of	Lyve-1	and	CD44	imply	possible	functional	sim-
ilarities	between	the	HA-receptors	at	least	to	some	extent.	CD44	is	a	type	I	trans-
membrane	 protein	 which	 is	 expressed	 almost	 ubiquitously	 in	 malignant	 and	
benign	cells	with	diverse	 functions	mediating	proliferation,	differentiation	and	
migration.	 Interactions	with	HA	and	 further	 ligands	 such	as	osteopontin,	 colla-
gens,	 fibronectin	 and	matrix	metalloproteinases	 (MMP)	 influence	 cell-cell	 and	
cell-matrix	adhesion.	Various	different	splicing	variants	plus	extensive	post-trans-
lational	modifications	by	glycosylation	determine	cell-type	specific	functions	of	
CD44.	The	protein	is	encoded	by	a	single	gene	consisting	of	20	exons.	While	the	
constant	N-terminal	 link domain	 is	 the	 region	of	highest	homology	 to	Lyve-1,	
differential	splicing	results	in	a	variable	membrane	proximal	stalk	region.	On	the	
other	site,	the	transmembrane	and	intracellular	domains	are	conserved	amongst	
CD44	isoforms.	Binding	motifs	in	the	intracellular	tail	mediate	interactions	with	
proteins	 like	 ankyrin	 and	 ERM	 (for	 ezrin,	 radixin	 and	moesin)	 proteins	which	
brace	CD44	to	the	cytoskeleton	and	influence	cellular	shape	and	motility	[161,	162].	
A	soluble	form	of	CD44	is	produced	by	shedding	of	the	ectodomain.	Proteolytic	
cleavage	in	the	membrane	proximal	stalk	region	is	regulated	by	the	activation	of	
several	membrane	associated	metalloproteinases.	CD44	has	been	 identified	as	 a	
substrate	of	ADAM10	which	is	activated	as	a	consequence	of	cellular	Ca2+	influx.	In	
addition,	activation	of	PKC	or	of	the	GTPase	family	members	Rac	and	Ras	induce	
ADAM17	activity	which	in	turn	cleaves	CD44.	MT1-MMP	and	MT3-MMP	are	addi-
tional	proteases	 involved	 in	 shedding	of	CD44.	The	 residual	C-terminal	part	of	
CD44	 experiences	 further	 proteolytic	 processing.	 Intramembranous	 cleavage	 by	
presenilin	 (PS)-dependent	 γ-secretase	 liberates	 the	 C-terminal	 fragment	 (CTF)	
from	the	membrane	anchor.	The	CD44-CTF	readily	translocates	to	the	nucleus	and	
induces	gene	expression	via	interaction	with	TPA-responsive	elements,	amongst	
others	inducing	expression	of	CD44	by	self-regulation	[163,	164].	
In	analogy	to	CD44	shedding,	we	examined	cell	culture	supernatants	of	geneti-
cally	engineered	U937	Lyve-1	for	the	presence	of	a	soluble	form	of	Lyve-1.	Western	
blot	analysis	 facilitated	the	 identification	of	an	approximately	55	kDa	version	of	
Lyve-1.	The	molecular	weight	and	the	identified	tryptic	peptides	in	mass	spectro-
metry	allowed	the	conclusion	that	we	detected	the	soluble	ectodomain	of	Lyve-1	
in	the	cell	culture	supernatant.	Stimulation	with	a	sheddase	activator	and	different	
protease	inhibitors	revealed	that	sLyve-1	is	produced	by	metalloprotease	mediated	
shedding	in	macrophages	and	in	HUVEC	in	a	comparable	fashion.	
Independent	from	our	observations	evidence	for	Lyve-1	shedding	in	lymphatic	
endothelial	cells	came	from	two	further	studies	published	in	March	2016.	VEGF-A	
binding	 to	 its	 corresponding	 receptor	 VEGFR-2	 induced	 ERK-dependent	 activa-
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tion	 of	 ADAM17	which	 in	 turn	 cleaved	 Lyve-1.	 In	 a	migration	 assay	 it	 was	 fur-
ther	demonstrated	that	VEGF-A	induced	shedding	of	Lyve-1	promoted	migration	
of	LEC	across	HA-coated	membranes	[128].	The	second	study	demonstrated	MT1-
MMP	 (also	known	 as	MMP-14)	mediated	 shedding	of	Lyve-1	 in	 LEC	 and	macro-
phages.	In	MMP-14	deficient	mice	spontaneous	lymphangiogenesis	occurred	as	a	
result	of	augmented	Lyve-1	surface	expression	on	lymphatic	endothelial	cells	in	
combination	with	increased	expression	of	lymphangiogenic	growth	factor	VEGF-C	
in	 pro-angiogenic	 macrophages.	 Loss	 of	 MMP-14	 expression	 and	 thus	 reduced	
Lyve-1	shedding	increased	the	proliferation	and	migration	of	LEC	in	response	to	
FGF-2	and	HA	stimulation.	A	functional	analysis	on	MMP-14	dependent	cleavage	of	
Lyve-1	expressed	in	macrophages	has	not	been	performed	[127].	In	humans,	MMPs	
comprise	a	 family	of	 23	different	zinc	dependent	endonucleases.	Under	physio-
logical	conditions	these	enzymes	are	mainly	involved	in	organ	development	and	
tissue	remodelling.	MMPs	were	found	to	be	up-regulated	in	various	cancer	types,	
which	 often	 correlated	 with	 shortened	 patient	 survival	 due	 to	 increased	 inva-
siveness	of	the	tumour.	Substrates	of	MMPs	are	ECM	components	and	cell	surface	
proteins	mediating	cellular	adhesion,	growth	and	growth	factor	surface	retention.	
Hence,	increased	expression	of	MMPs	by	cancer	cells	and	cancer	associated	stro-
mal	cells	like	e.	g.	macrophages	promotes	cancer	progression	by	numerous	mech-
anisms	affecting	cell	proliferation	and	migration,	angiogenesis,	as	well	as	tumour	
invasion	and	the	development	of	metastasis	[165,	166].	Mammary	gland	specific	
overexpression	of	MMP-14	led	e.	g.	to	extensive	matrix	remodelling	and	tumour	
development	 in	 transgenic	mice	 [167].	Overexpression	of	MMP-14	 in	 an	 adeno-
carcinoma	cell	line	increased	tumour	cell	proliferation	in vitro	and	in	a	transplant	
tumour	model	elevated	MMP-14	expression	promoted	the	development	of	highly	
vascularized	invasive	tumours	accompanied	by	elevated	levels	of	VEGF	[168].	In	
human	breast	cancer	patients,	high	expression	 levels	of	MMP-14	and	of	VEGF-C	
correlated	with	 increased	 lymphatic	 vessel	 density	 and	 lymph	node	metastasis	
resulting	in	decreased	overall	survival	[169].	Closely	related	to	MMPs	is	the	family	
of	21	different	ADAMs,	which	are	also	commonly	up-regulated	in	cancers.	These	
zinc	dependent	sheddases	act	during	fertilization	and	development,	but	also	pro-
mote	cancer.	By	shedding,	ADAMs	regulate	the	autocrine	and	paracrine	signalling	
activity	of	chemokines,	cytokines	which	can	be	expressed	 in	membrane	bound	
forms.	ADAMs	also	 influence	motility	of	cells	by	mediating	proteolysis	of	adhe-
sion	proteins.	ADAM	induced	shedding	plays	also	an	important	role	in	the	regu-
lation	intramembrane	proteolysis,	which	liberates	the	intracellular	domain	from	
the	membrane	following	ectodomain	shedding	of	transmembrane	proteins	[170].	
ADAM17	has	first	been	identified	as	tumour	necrosis	factor-α	converting	enzyme	
(TACE)	as	it	regulates	paracrine	TNF-α	signalling	by	cleaving	the	membrane	bound	
pro-form	 of	 the	 cytokine.	 Besides	 different	 cytokines,	 adhesion	 proteins	 and	
growth	factors	are	substrates	of	ADAM17,	which	hence	mediates	a	broad	array	of	
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cellular	functions.	In	breast	cancer	ADAM17	overexpression	is	for	example	associ-
ated	with	elevated	levels	of	TGF-α,	tumour	progression,	metastasis	and	poor	prog-
nosis	[171].	Thus	expression	of	Lyve-1	converting	enzymes	has	closely	been	linked	
to	cancer	and	tumour	progression.	Extensive	shedding	of	Lyve-1	 in	the	tumour	
microenvironment	is	therefore	imaginable.	
In	 this	 context,	 our	 results	 demonstrated	 that	macrophage	 derived	 sLyve-1	
inhibited	 the	proliferation	of	 tumour	 cells	 probably	by	 acting	 as	 a	 competitive	
inhibitor	or	decoy	receptor	for	membrane-bound	HA-receptors.	By	decreasing	the	
interactions	to	HA,	sLyve-1	might	also	influence	migration	of	macrophages	and	
by	paracrine	 stimulation	also	migration	and	proliferation	of	 tumour	cells.	Like-
wise,	interactions	between	HA	and	CD44	have	a	major	impact	on	cell	adhesion	and	
migration	in	physiological	and	pathological	processes,	like	mediation	of	leukocyte	
adhesion	to	the	endothelium	and	subsequent	extravasation,	but	also	on	tumour	
cell	migration	and	tumour	growth.	On	the	one	site,	co-expression	studies	of	MT1-
MMP	and	its	substrate	CD44	in	tumour	cells	revealed	that	tumour	cell	migration	
required	shedding	of	CD44	[172].	Another	study	demonstrated	that	in	a	malignant	
melanoma	 cell	 line	 transgenic	 expression	 of	 soluble	 CD44	 resulted	 in	 reduced	
tumour	cell	proliferation	and	HA	sequestration	on	the	cell	surface	was	inhibited.	
Using	these	cells	in	a	tumour	transplant	model	resulted	in	a	significant	reduction	
of	the	tumour	volume	due	to	forced	expression	of	the	soluble	form	of	CD44	[173].	
These	opposing	findings	led	to	the	formulation	of	the	following	model	of	CD44	
mediated	cell	migration.	Ectodomain	shedding	at	the	leading	edge	of	motile	cells	
enables	detachment	from	HA	components	of	the	ECM	and	the	formation	of	lamel-
lipodia.	Stretching	of	the	cell	opens	mechanosensitive	Ca2+	channels.	Subsequently,	
ADAM10	is	activated	by	the	resulting	Ca2+	influx	and	cleaves	CD44	at	the	rear	end	
of	 the	 crawling	 cell.	 Simultaneously,	 the	 CD44-CTF	 domain	 translocates	 to	 the	
nucleus	and	induces	CD44	expression,	thus	promoting	adhesion	to	HA	via	newly	
synthesized	CD44.	Shifting	of	this	balance	of	shedding	mediated	CD44	turnover	
impairs	cell	migration	[164].	Potentially,	processing	of	Lyve-1	mediates	migration	
of	macrophages	in	a	similar	way.
Under	 physiological	 conditions	 soluble	 CD44	 (sCD44)	 has	 been	 detected	 in	
the	 lymph,	 synovial	 fluid,	 branchoalveolar	 lavage	 and	 serum.	 Examination	 of	
plasma	levels	of	sCD44	were	found	to	be	increased	in	mice	during	an	inflamma-
tory	response	and	tumour	growth,	while	immunodeficiency	was	associated	with	
reduced	plasma	concentrations	of	sCD44	[174,	175].	In	highly	metastatic	melanoma	
cell	 lines	 increased	motility	was	 associated	with	 elevated	CD44	 expression	 and	
turnover	[176].	By	detection	of	the	25	kDa	CD44-CTF	protein	by	immunoblotting,	
evaluation	of	CD44	shedding	in	malignant	cells	derived	from	different	cancer	tis-
sues	was	facilitated,	thus	sCD44	could	be	detected	frequently	in	brain,	breast,	lung,	
colon	and	ovarian	cancers	[177].
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We	were	able	to	detect	sLyve-1	in	plasma	samples	derived	from	healthy	donors	
and	found	significantly	increased	levels	of	sLyve-1	in	plasma	from	patients	suffering	
from	Psoriasis.	Our	observations	were	in	line	with	the	findings	of	Nishida-	Fukuda	
et	 al.	who	demonstrated	Lyve-1	 shedding	 in	human	psoriatic	 lesion	 by	 double	
staining	of	the	intracellular	and	extracellular	portion	of	the	protein	[128].	Psoria-
sis	is	a	frequent	chronic	inflammatory	skin	disease	affecting	1-3	%	of	the	popula-
tion	in	the	United	States	and	Europe.	Psoriasis	vulgaris	is	the	most	common	form	
of	the	disease	which	is	characterized	by	the	development	of	red	coloured,	scaly	
plaques	with	clear	boarders	occurring	mainly	in	elbows,	knees,	scalp	and	the	lum-
bosacral	area.	A	histologic	hallmark	of	psoriasis	is	a	greatly	thickened	epidermis	
(acanthosis),	which	is	caused	by	increased	proliferation	and	accelerated	movement	
of	keratinocytes	through	the	epidermis.	Thus	differentiation	is	impaired	leading	
to	 hyperkeratosis	 and	 parakeratosis.	 In	 psoriatic	 lesions	 the	 number	 of	 mono-
nuclear	leukocytes	is	significantly	increased	and	abnormal	vascularization	leads	to	
the	development	of	numerous	dilated	dermal	blood	vessels	resulting	in	erythema.	
Mechanistically,	 psoriasis	 is	 a	 T  cell	mediated	 disease.	 Langerhans	 cells	 secrete	
IL-12	and	IL-23	to	activate	the	T cell	subsets	Th	1,	Th	17	and	Th	22	which	in	turn	pro-
duce	the	pro-inflammatory	cytokines	IL-17,	IFN-γ,	TNF	and	IL-22.	The	inflamma-
tory	milieu	stimulates	keratinocytes	to	sustain	T cell	activation	and	recruitment	by	
inducing	the	expression	of	further	inflammatory	cytokines	and	chemokines	[178].	
Elevated	plasma	levels	of	Lyve-1	therefore	imply	that	shedding	could	be	induced	
under	inflammatory	conditions.	
We	further	examined	levels	of	sLyve-1	in	plasma	of	melanoma	patients	before	
and	during	the	treatment	with	the	PD-1	inhibitor	pembrolizumab.	sLyve-1	levels	
in	the	plasma	from	melanoma	patients	were	not	increased	and	cancer	immuno-
therapy	did	not	influence	the	levels	of	Lyve-1.	Yet,	continuously	increasing	MT1-
MMP	 expression	 has	 been	 associated	 with	 melanoma	 progression	 [179].	 There-
fore,	it	is	also	conceivable	that	extensive	shedding	indeed	occurs	during	tumour	
growth,	but	consequently	 results	 in	higher	concentrations	of	 sLyve-1	 locally	 in	
interstitial	fluid	and	the	tumour	draining	lymph	vessels,	considering	the	predomi-
nant	expression	of	Lyve-1	in	lymphatic	vessels.	Examination	of	the	composition	
of	the	tumour	interstitial	fluid	(TIF)	has	gained	more	interest	in	the	recent	years	
as	the	TIF	represents	the	microenvironment	to	which	tumour	cells	are	exposed.	
Extraction	of	the	TIF	 is	still	an	obstacle,	 though	a	centrifugation	based	method	
allowed	TIF	collection	from	excised	solid	 tumour	samples	 from	animal	models	
and	from	human	ovarian	cancer	[180,	181].	Malignant	melanoma	is	a	highly	aggres-
sive	skin	cancer	occurring	with	increasing	incidence.	Approximately	1.7	%	of	the	
population	 in	 the	United	 States	will	 be	 diagnosed	with	melanoma	 throughout	
their	 lifetime.	Melanoma	arises	 from	transformed	melanocytes	which	are	mela-
nin	producing	cells	predominantly	located	in	the	skin	but	can	also	be	found	in	
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the	uveal	tract	of	the	eye,	as	well	as	in	the	meninges	and	the	angogenital	tract	[182,	
183].	In	the	course	of	malignant	transformation	mutations	lead	to	the	expression	
of	tumour-associated	antigens	which	can	elicit	an	anti-tumour	immune	response.	
Though,	immuoescape	mechanisms	of	the	tumours	lead	to	resistance	against	such	
host	defence	programs.	Human	melanoma	cells	frequently	express	ligands	of	PD-1	
(programmed	death	receptor-1),	which	is	expressed	on	activated	T cells.	Ligand	
binding	limits	T cell	functions	by	inhibiting	down-stream	signalling	of	the	TCR.	
By	blockade	of	this	so	called	immune-checkpoint	antitumour	effector	functions	
of	T cells	in	the	tumour	microenvironment	are	augmented	and	tumour	regression	
can	be	achieved	[184].
5.5 Lyve-1 deficiency promotes tumour growth
Our	 in vivo	 experiments	demonstrated	 that	 in	 subcutaneously	grown	B16F1	 and	
B16F10	melanoma	Lyve-1+	TAM	were	located	in	the	marginal	zone	of	the	tumour	
whereas	macrophages	within	the	tumour	mass	did	not	express	Lyve-1.	In	ortho-
topically	grown	mammary	tumours	similar	observations	were	made	revealing	the	
expression	of	Lyve-1	in	TAM	which	were	located	in	the	tumour	periphery	while	
this	 subpopulation	was	 absent	 in	 tumour	 infiltrating	macrophages	 [185].	 These	
findings	sustain	the	view	that	diverse	TAM	subpopulations	with	distinct	functions	
exist.	Expression	profiling	of	TAM	subsets	derived	from	murine	mammary	TS	/	A	
tumours	showed	strong	correlation	between	 low	expression	of	MHC II	and	ele-
vated	expression	LYVE-1.	Further	analyses	of	the	MHC II low	TAM	subset	revealed	
localization	in	hypoxic	areas	with	potent	pro-angiogenic	functions	[73].	A	pro-an-
giogenic	role	of	Lyve-1+	TAM	has	also	been	demonstrated	in	adipose	tissue,	where	
Lyve-1+	infiltrating	macrophages	orchestrate	the	formation	of	vascular	networks	in	
hypoxic	regions	[186].
Surprisingly,	 we	 detected	 enhanced	 tumour	 growth	 of	 B16	 transplanted	
tumours	in	Lyve-1	knockout	mice.	As	we	and	others	identified	a	soluble	form	of	
Lyve-1	which	can	be	secreted	by	endothelial	cells	and	macrophages,	we	speculate	
that	excessive	production	of	sLyve-1	 impairs	 tumour	growth	 in	wild	 type	mice.	
Shedding	 of	 the	 ectodomain	 of	 cell	 surface	 receptors	 can	 have	 diverse	 effects.	
Lyve-1	 possesses	 dual	 functionality	 as	 a	 surface	 protein	mediating	 interactions	
with	HA	and	as	a	growth	factor	binding	protein.	Processing	of	Lyve-1	might	there-
fore	decrease	adhesion	to	the	ECM	and	inhibit	growth	factor	induced	proliferation.	
Furthermore,	Lyve-1	mediates	cell	surface	retention	of	growth	factors,	therefore	
shedding	also	impairs	autocrine	growth	stimulation.	The	shedded	ectodomain	of	
Lyve-1	could	also	act	as	a	decoy	receptor	for	the	respective	ligands.	In	a	paracrine	
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manner	sLyve-1	could	also	influence	growth	and	migration	of	tumour	cells.	Our	
in vitro	experiments	support	this	hypothesis	demonstrating	reduced	proliferation	
of	melanoma	cells	in	the	presence	of	macrophage	derived	and	synthesized	soluble	
Lyve-1.	The	regulatory	mechanism	of	Lyve-1	processing	is	not	known	so	far.	To	
gain	a	better	understanding	of	 the	distinct	 functions	of	 full	 length	and	soluble	
Lyve-1	for	tumour	growth,	differential	expression	of	the	protein	forms	in	a	tumour	
model	would	be	necessary.	
Therefore,	 it	 should	not	be	disregarded	 that	our	Lyve-1-/-	model	 results	 in	 a	
global	knockout	of	Lyve-1	expression	such	that	obstruction	of	Lyve-1	expression	
is	not	restricted	to	macrophages	but	affects	the	whole	organism	and	hence	also	
lymphatic	 endothelial	 cells.	Characterization	of	Lyve-1	null	mice	 revealed	mor-
phological	and	functional	changes	 in	the	lymphatic	vessels	marked	by	constitu-
tive	 increased	 interstitial	 fluid	flow	 [130].	Various	 studies	highlight	 the	 critical	
involvement	of	the	lymphatics	in	tumour	growth	and	progression,	not	only	as	a	
possible	 route	 for	 tumour	 dissemination.	 The	 lymphatic	 vessel	 network	 consti-
tutes	 the	 second	 circulatory	 system	which	 collects	 interstitial	 fluid	 and	macro-
molecules,	 which	 constantly	 leak	 from	 blood	 vessels,	 and	 transport	 it	 back	 to	
the	blood	vasculature.	Under	physiological	 conditions,	 the	 lymphatic	 system	 is	
involved	in	tissue	fluid	homeostasis,	immune	surveillance	and	fat	absorption.	Spa-
tial	 restriction	 during	 the	 expansion	 of	 the	 tumour	mass	 leads	 to	 the	 develop-
ment	of	high	intratumoural	pressure.	Simultaneously	the	amount	of	 interstitial	
fluid	 in	 tumours	 is	 elevated	due	 to	 increased	 leakage	of	permeable,	malformed	
tumour	blood	vessels.	Therefore,	fluid	flow	especially	in	the	tumour	stroma	and	
the	peritumoural	lymph	vessels	is	enhanced.	Elevated	interstitial	fluids	flow	(IF)	
and	lymph	flow	have	been	associated	with	increased	invasiveness	of	tumours	in	
diverse	in vitro	and	in vivo	studies	[187,	188].	In	a	model	of	xenografted	breast	cancer	
for	example	invasiveness	of	the	tumours	correlated	with	increased	extravascular	
drainage	 [189].	Moreover,	 it	was	 shown	 that	 interstitial	 fluid	flow	directed	 the	
migration	of	tumour	cells	towards	the	tumour	draining	lymph	nodes	by	homing	
of	autologous	chemotaxis	[190].	Interstitial	flow	activates	mechanosensitive	can-
cer	associated	fibroblasts	mediating	stiffening	of	the	extracellular	matrix	which	in	
turn	promotes	tumour	progression	and	invasion	[191].	Besides	fluid	flow	has	been	
shown	to	be	critical	for	the	formation	of	both	blood	and	lymphatic	vessels	and	IF	
precedes	directed	lymphangiogenesis	[192,	193].	Changes	in	the	interstitial	fluid	
flow	rate	in	Lyve-1	knockout	mice	might	therefore	contribute	to	enhanced	tumour	
growth	of	the	B16	melanoma.
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By	establishment	of	the	in vitro	differentiation	model	of	monocytes	derived	TAM	by	
stimulation	with	MDI	several	genes	were	found	to	be	up-regulated	which	were	also	
expressed	by	TAM	in vivo.	In	general	glucocorticoids	greatly	influence	gene	expres-
sion	in	macrophages	by	mediating	the	down-regulation	of	pro-inflammatory	genes,	
while	simultaneously	inducing	expression	of	immunosuppressive	mediators.	Our	
in vitro	data	indicate	a	central	role	of	GC	for	the	induction	of	Lyve-1	expression	and	
probably	for	further	M2	associated	marker	proteins.	To	examine	the	role	of	GC	for	
the	shaping	of	TAM	phenotypes	in vivo	we	bred	a	mouse	strain	with	specific	dele-
tion	of	functional	glucocorticoid	receptor	in	myeloid	cells.	For	this	purpose,	we	
crossed	mice	carrying	loxP	sites	flanking	the	third	exon	of	the	NR3C1	gene,	which	
codes	for	the	first	zinc-finger	of	the	GR	DNA	binding	domain,	with	mice	expressing	
the	cre-recombinase	under	the	control	of	the	LysM	promoter.	The	progeny	of	this	
breeding	strategy	shows	efficient	GR	excision	in	macrophages	and	granulocytes,	as	
well	as	partial	deletion	of	the	functional	receptor	in	splenic	dendritic	cells	[194,	
195].	 In	spite	of	myeloid	specific	GR	deletion,	Lyve-1+	TAM	were	still	present	 in	
the	periphery	of	subcutaneously	grown	B16	tumours	in		GRLysMcre	mice.	Therefore,	
Lyve-1	gene	induction	in vivo	might	be	regulated	differently	by	a	yet	unknown	sig-
nalling	pathway.	In	addition,	we	observed	that	the	tumour	growth	was	enhanced	
in		GRLysMcre.	The	myeloid	specific	GR	deletion	model	has	previously	been	used	to	
study	 the	particular	effect	of	GR	signalling	on	macrophage	polarization.	Due	 to	
impaired	 resolution	of	 the	 inflammatory	 innate	 immune	 response	 the	 	GRLysMcre	
mouse	showed	greater	mortality	when	being	challenged	with	LPS.	Mechanistically,	
GR	deficiency	led	to	impaired	inhibition	of	MAPK	signalling	following	LPS	medi-
ated	 activation	of	 TLR-4	 and	hence	 sustained	 the	pro-inflammatory	 expression	
profile	of	LPS-exposed	macrophages	[196].	Similar	observations	were	made	in	a	
study	examining	the	role	of	GC	mediated	anti-inflammatory	effects	in	a	murine	
model	of	skin	contact	allergy.	Myeloid	specific	knockout	of	GR	abrogated	the	cura-
tive	effect	of	GC	treatment	by	maintaining	a	pro-inflammatory	macrophage	phe-
notype	[197].	Based	on	their	anti-inflammatory	effects	glucocorticoids	have	been	
used	as	therapeutics	in	chronic	and	acute	inflammations,	like	rheumatoid	arthri-
tis,	multiple	sclerosis,	psoriasis	and	as	immunosuppressive	agents	following	organ	
transplantation.	Furthermore,	GC	are	administrated	as	adjuvants	in	chemotherapy	
to	treat	lymphoid	malignancies	as	GR	signalling	induces	cell	death	in	cells	of	the	
lymphoid	lineage	[143,	198].	It	has	yet	not	been	understood	by	which	mechanism	
the	ablation	of	GR	signalling	 in	myeloid	cells	 in	our	murine	tumour	transplant	
model	promotes	tumour	growth	and	needs	further	characterizations	of	the	phe-
notype	of	GR -	TAM	besides	Lyve-1	expression.
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5.7 Concluding remarks
In	conclusion,	we	demonstrated	the	existence	of	Lyve-1+	macrophage	subset	in	
murine	and	human	melanoma.	
A	human	pBMC	model	was	established	to	study	Lyve-1+	macrophages	 in vitro	
and	expression	profiling	of	the	MDI	induced	macrophages	demonstrated	M2-pola-
rization	of	the	Lyve-1+	subset.	
While	 in vitro	Lyve-1	 induction	was	crucially	dependent	on	GR	signalling	we	
found	Lyve-1+ TAM	 in	B16	 tumours	 derived	 from	 	GRLysMcre	mice,	which	 lack	 GR	
specifically	in	myeloid	cells.	Further	characterization	of	the	phenotype	of	these	
Lyve-1+	TAM	by	gene	expression	profiling	will	help	to	functionally	range	their	phe-
notype	and	will	bring	new	insights	into	the	regulation	of	Lyve-1	induction	in vivo.	
Moreover,	this	model	can	be	used	to	gain	a	better	understanding	of	the	in vivo	rele-
vance	of	GR	activation	for	tumour	growth.	
In	macrophages	Lyve-1	is	subjected	to	processing	by	metalloproteinases	which	
results	in	shedding	of	the	ectodomain	of	the	protein.	Macrophage	derived	sLyve-1	
diminishes	the	proliferation	rate	of	melanoma	cells	in vitro;	therefore,	we	speculate	
that	sLyve-1	acts	as	decoy	receptor.	
The	exact	role	of	Lyve-1+	macrophages	for	tumour	growth	could	not	be	resolved	
completely	 within	 the	 Lyve-1	 knockout	 model,	 as	 the	 global	 knockout	 affects	
expression	of	Lyve-1	also	in	the	lymphatic	vasculature	and	thus	our	findings	can-
not	 be	 attributed	 explicitly	 to	macrophages.	 Therefore,	 it	 will	 be	 necessary	 to	
develop	a	mouse	model	with	macrophage	specific	ablation	of	Lyve-1	expression	to	
determine	the	particular	net	effect	of	Lyve-1+	TAM.	
Our	in vitro	findings	and	evidence	from	current	literature	links	expression	of	
Lyve-1	to	motile	pro-angiogenic	macrophages,	thus	implications	of	Lyve-1+	mac-
rophages	regarding	tumour	angiogenesis	and	formation	of	metastasis	should	be	
taken	into	consideration.
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7.  ABBREVIATIONS
ADAM a	disintegrin	and	metalloproteinase
ANG-2 angiopoietin
APC antigen-presenting	cell
APS ammonium	persulphate
APS ammonium	persulfate
BCG bovis	bacillus	Calmette-Guerin
BMDM bone-marrow	derived	macrophages
BrdU 5-bromo-2′-deoxy-uridine	
BSA bovine	serum	albumin
BSA bovine	serum	albumin
CD cluster	of	differentiation
CEBP CCAAT	/	enhancer-binding	protein
COX cyclooxygenase
CRSBP-1 cell	surface	retention	sequence	binding	protein-1
CRS cell	surface	retention	sequence
CTF C-terminal	fragment
DAF2-DA 4,5-Diaminofluorescein
DC dendritic	cell
dexa dexamethasone
ECM extracellular	matrix
EGF epidermal	growth	factor
ELISA enzyme-linked	immunosorbent	assay	
EMP erythromyeloid	progenitor
ERK extracellular	signal	regulated	kinase	
EtOH ethanol
EV empty	vector
FACS fluorescence	associated	cell	sorting
FcR Fc	receptor
FCS fetal	calf	serum
FGF fibroblast	growth	factor
Fig. Figure
FITC fluorescein	isothiocyanate
GC glucocorticoid	
GM-CSF granulocyte-macrophage	colony	stimulating	factor
GRE GR	responsive	elements
xvi
7.  Abbreviations
GR glucocorticoid	receptor
GTP guanosine	triphosphate
HA hyaluronic	acid
HGF hepatocyte	growth	factor
HLA-DR Human	leucocyte	antigen-antigen	D	related
HMW high	molecular	weight
HRP horse	raddish	peroxidase
HSC hematopoietic	stem	cell
ICAM intercellular	adhesion	molecule
IFN interferon
IGFBP insulin-like	growth	factor	binding	protein
Ig immunoglobulin
IKKb inhibitor	of	nuclear	factor	kappa-B	kinase	subunit	beta
IL interleukin
iNOS inducible	nitric	oxide	synthase
IP immunoprecipitation
IRES internal	ribosomal	entry	site
LEC lymphatic	endothelial	cells
LLC Lewis	lung	carcinoma
LMW low	molecular	weight
LPS lipopolysaccharide
Ly6C lymphocyte	Antigen	6	C
Lyve-1 lymphatic	vessel	endothelial	hyaluronan	receptor
M-CSF macrophage-colony	stimulating	factor
MACS magnet	associated	cell	sorting
MAPK mitogen	activated	protein	kinase
MCP-1 monocyte	chemoattracting	protein-1
MCS multiple	cloning	site
MDI M-CSF	/	dexamethasone	/	IL-4
MDSC myeloid	derived	supressor	cell
MHC major	histocompability	complex
MMP metalloproteinase
MPS mononuclear	phagocyte	system
MR mannose	receptor
MT-MMP membrane-type	metalloproteinase
NADPH	oxidase nicotinamide	adenine	dinucleotide	phosphate	oxidase	
NFκB nuclear	factor	κ-light-chain-enhancer	of	activated	B	cells
NK	cell natural	killer	cell
NOD nucleotide	binding	oligomerization	domain
NOS reactive	nitrogen	species
NRL leucine-riche	repeat-containing	receptors
xvi i
7.  Abbreviations
NSAID non-steroidal	anti-inflammatory	drugs
PAGE polyacrylamide	gelelectrophoresis
PAMP pathogen	associated	molecular	patterns
pBMC peripheral	blood	monocytes
PBS phosphate	buffered	saline
PCR polymerase	chain	reaction
PD-L1 programmed	cell	death-ligand	1
PDGF platelet	derived	growth	factor
PKC protein	kinase	C
PPAR	γ peroxisome	proliferator-activated	receptor	γ	
PRR pattern	recognition	receptor
qRT-PCR quantitative	real-time	PCR
ROS reactive	oxygen	species
RT reverse	transcription
s.	c. subcutan
S1P3 sphingosine	1	phosphate	3	receptor
sCD44 soluble	CD44
SCS subcapsular	sinus	
SDS sodium	dodecyl	sulphate
SDS sodium	dodecyl	sulphate
sLyve-1 soluble	Lyve-1
SN supernatant
STAT signal	transducer	and	activator	of	transcription
STREPTA streptavidin
TACE TNF-α	converting	enzyme
TAM tumour	associated	macrophage
TCM tumour	conditioned	medium
TCR T	cell	receptor
TEMED tetramethylethylenediamine
TEM TIE2	expressing	macrophages
TGF transforming	growth	factor
Th	1	/	2 T	helper	1	/	2
TIF tumour	interstitial	fluid
TLR toll-like	receptor
TMEM tumour	microenvironment	for	metastasis
TNF tumour	necrosis	factor
Treg regulatory	T	cell
VEGF vascular	endothelial	growth	factor
YS yolk	sac
ZA zoledronic	acid
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